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Tryptophan C-mannosylation involves the covalent and irreversible attachment of α-D-
mannose onto the C2 carbon of the indole ring of tryptophan forming an unusual C-glycosidic 
bond that is far more stable than an N- or O-glycosidic bond. C-mannosylation was first 
discovered on RNaseII in humans in 1994 and there are now over twenty human proteins for 
which there is evidence confirming the presence of this modification. It is found predominantly 
on thrombospondin type-1 repeat domains and type-I cytokine receptors. The glycosylation 
consensus sequence for C-mannosylation is WXXW.  
 
Despite being conserved on many important proteins, the function and biological significance 
of C-mannosylation remains unknown. Addressing this problem was hampered by the fact that 
the genetic basis for C-mannosylation was unknown for a long time and because there are 
limited tools available for installing and detecting this protein modification. This has been 
remedied to some degree by the discovery that the dpy19 gene in C. elegans encodes a 
tryptophan C-mannosyltransferase. There are four homologues of dpy19 in humans and recent 
studies have found that at least two of these encode functional tryptophan C-
mannosyltransferases.  
 
I have embarked on the creation of a suite of tools for studying the roles of tryptophan 
mannosylation to progress this field. A simple Pichia pastoris protein production system was 
created to produce natively C-mannosylated proteins, with both C2-α-D-mannosyl-tryptophan 
and without the modification. This was accomplished by integrating C. elegans dpy19 under 
the strong constitutive GAPDH promoter. This yeast strain enabled the production of a wide 
variety of recombinant proteins with and without C2-α-D-mannosyl-tryptophan. Two to five-
fold improvements in protein production were observed when the protein was C-mannosylated, 
implying that the modification may play a role in protein folding, trafficking and/or stability. 
Differential scanning fluorimetry subsequently revealed that C-mannosylation of proteins 
stabilises them against thermal denaturation. This same yeast system provided a convenient 
means to explore the substrate specificities of the DPY19 enzyme and probe what enzyme 
residues were important for enzyme activity.  
 
I have also generated the first monoclonal antibodies for detecting C2-α-D-mannosyl-
tryptophan. Using a C-mannosylated peptide derived from recombinant proteins produced in 
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my engineered yeast, I was able to generate five novel monoclonal antibodies that only 
recognised proteins with the modification. These monoclonal antibodies were validated for use 
in Western blots and ELISAs and biophysically characterised using surface plasmon resonance 
techniques. Sequencing the hybridomas that made these antibodies revealed a case of 
immunoconvergence, where two mice converged on essentially the same solutions for 
recognising C2-α-D-mannosyl-tryptophan. I was able to crystallise a complex of one antibody’s 
Fab with the C-mannosylated peptide and determine its structure using X-ray diffraction 
techniques to reveal the key interactions used to recognise C2-α-D-mannosyl-tryptophan. 
 
Using the engineered yeast, monoclonal antibodies and substrate mimics of C-mannosylation, 
we were able to discover the first chemical inhibitors of C-mannosylation that can be used to 
probe C-mannosylation biology. 
 
Lastly, I genetically disrupted the dpy19 homologues in human cells and performed some 
comparative cell surface proteomic experiments to provide the first insights into how loss of 
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An introduction to tryptophan C-mannosylation 
 
1.1 - Protein glycosylation 
Protein modifications (PMs), which can occur during or after translation, enable the cell to 
expand and diversify its proteome, augmenting protein function and regulation beyond what is 
directly encoded by the genome. PMs involve the covalent chemical modification of proteins 
and are accompanied with changes in protein physical and chemical properties that influence 
its folding, trafficking, localisation, turnover, functional activity, and conformational dynamics 
[1]. Some of the most common PMs are glycosylation, phosphorylation, ubiquitination, 
acetylation and methylation [2]. Among the different types of PMs, protein glycosylation is the 
most diverse and abundant [3] [4]. It is estimated that around 65% of all proteins in humans 
undergo some form of protein glycosylation and more than 90% of cell surface proteins are 
glycosylated [3] [1]. Protein glycosylation can occur co- and post-translationally and involves 
the attachment of carbohydrate molecules to a protein. 
 
In eukaryotes, all glycosylation occurs in either the endoplasmic reticulum (ER) or Golgi 
compartments, with the exception of the addition of O-GlcNAc moieties, which occurs in the 
cytoplasm [5]. As such, most glycoproteins transit through the secretory pathway and are either 
secreted, displayed on the cell surface or reside within the organelles of the cell [5]. The most 
common types of protein glycosylation in eukaryotes are N-glycosylation and O-glycosylation, 
with C-glycosylation being somewhat rarer [4]. N-glycosylation involves the attachment of a 
carbohydrate molecule to the side-chain nitrogen of an asparagine or, in the case of some 
bacteria, arginine [6]. O-glycosylation, involves the attachment of a sugar moiety onto the 
oxygen of a hydroxyl group of a serine, threonine, tyrosine, hydroxylysine or hydroxyproline 
residue [7]. The last and most unusual type of glycosylation is C-glycosylation, whereby a 
mannose is attached to the side-chain of a tryptophan residue forming a carbon-carbon bond 
[8].   
 
1.2 - Tryptophan C-mannosylation 
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Tryptophan C-mannosylation involves the attachment of an α-D-mannopyranosyl unit onto the 
C2 carbon of the indole ring of tryptophan to form an unusual C-glycosidic bond (Figure 1.1A), 
which, in chemical terms, is radically different and far more stable than an N- or O-glycosidic 
bond [9] [8]. C-mannosylation was first discovered on RNaseII in humans in 1994, and there 
are now over twenty human proteins for which there is direct evidence of this modification [8]. 
Tryptophan C-mannosylation is predominantly found on proteins possessing a thrombospondin 
type-1 repeat (TSR) domain and on the ectodomains of the type-I cytokine receptors [10-12]. 
 
The glycosylation consensus sequence (sequon) for C-mannosylation is WXXW, with the 
modification occurring predominantly on the first tryptophan in the consensus sequence [13]. 
This sequon was established soon after the modification’s discovery on RNaseII. This 
consensus sequence for C-mannosylation was established using alanine scanning across the 
first 13 residues of mature RNaseII. This experiment revealed that the only essential residues 
for C-mannosylation were W7 and W10, thereby establishing the WXXW motif of RNaseII as 
the minimum requirement for C-mannosylation. Identifying the WXXW sequon for C-
mannosylation enabled the identification of over 350 human proteins as candidates for C-
mannosylation [13].  
 
Figure 1. 1: The biochemistry of tryptophan C-mannosylation 
a) Chemical structure of C2-α-D-mannosyl-tryptophan 
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b) Biochemical reaction that takes place in the ER when a C-mannosyltransferase (CMT) 
transfers a mannose from a Dol-P-Man onto a tryptophan molecule of a target protein.  
 
In 1998, several years after C-mannosylation was discovered on RNaseII, Doucey and 
colleagues discovered that C-mannosylation occurs in the ER, that it was catalysed by a 
specific unidentified C-mannosyltransferase (CMT), and that this enzyme utilised dolichol 
phosphate mannose (Dol-P-Man) as the sugar donor substrate (Figure 1.1B)  [14]. Dol-P-Man 
is used in the ER as a sugar donor substrate for O-glycosylation, to assemble the lipid-bound 
oligosaccharide utilised by oligosaccharyltransferases (OST) in N-glycosylation, and in GPI 
anchor biosynthesis, making it a highly important metabolite for cellular glycosylation 
pathways [15]. Dol-P-Man is, in turn, biosynthesised on the cytoplasmic side of the ER 
membrane from dolichol phosphate (Dol-P) and GDP-D-mannose (GDP-Man), which is tied 
to the tightly regulated metabolism of mannose within the cell. Figure 1.2 illustrates the 
biosynthetic pathway for Dol-P-Man and mannose metabolism in the cell [15].  
 
 
Figure 1. 2: Mannose metabolism and utilisation in eukaryotic cells. 
 Man, D-mannose; Glc, D-glucose; HK, hexokinase; MPI, phosphomannose isomerase; 
PMM2, phosphomannomutase; GMPPA/B, GDP-mannose pyrophosphorylase (A/B); PGI, 
phosphoglucose isomerase; KPS, KDN-9-phosphate synthase; Man-6-P, mannose-6-
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phosphate; Fru-6-P, fructose-6- phosphate, Glc-6-P, glucose-6-phosphate; GDP-Man, GDP-
mannose; Dol-P-Man, dolichol phosphate mannose; DPM1/2/3, Dol-P-Man synthase.  
 
Most of what is known about the biosynthetic pathway of C-mannosylation is extrapolated 
from other well-studied glycosylation pathways such as O-mannosylation, N-glycosylation and 
GPI-anchor synthesis because they all share Dol-P-Man as the sugar donor substrate [16]. The 
biosynthetic pathway for C-mannosylation begins on the cytosolic surface of the ER membrane 
where a phosphate molecule from ATP is transferred to the membrane bound dolichol molecule 
by dolichol kinase (Figure 1.3) [16]. A mannose molecule is then transferred from GDP-Man 
onto the dolichol-phosphate molecule by dolichol phosphate mannose synthase to give Dol-P-
Man. The Dol-P-Man molecule is then flipped from the cytosolic surface of the ER membrane 
into the ER lumen by a flippase [16]. From there, a C-mannosyltransferase transfers the 
mannose moiety from the Dol-P-Man onto the tryptophan of the WXXW motif of a nascent, 




Figure 1. 3: Biosynthetic pathway of C-mannosylation in mammalian cells. 
The pathway is initiated at the cytosolic surface of the ER membrane, and is terminated in the 
lumen of the ER.  ADP, Adenosine diphosphate; ATP, Adenosine triphosphate; GDP, 





1.3 - The tryptophan ladder and putative roles for tryptophan C-mannosylation 
As mentioned above, proteins with TSRs and type-I cytokine receptors are commonly C-
mannosylated. The WXXW motif of both of these proteins is involved in a unique structural 
element known as a tryptophan ladder, which is characterised by π-cation interactions between 
two or more tryptophan residues and one or more intercalating arginine residues [17] [18]. The 
planar stacking arrangement of the guanidinium moiety of arginine side chains over the centre 
of the aromatic rings of tryptophan stabilises protein tertiary structure [19]. 
 
The similarity of these structure can be best appreciated when the Fibronectin Type III (FNIII) 
module of the extracellular domain of the prolactin receptor (PRLR) is superimposed on the 
TSR domain of thrombospondin-1 (Figure 1.4) [17]. The root-mean-square deviation (RMSD) 
of the carbon-backbone in these overlaid structures is only 0.39 Å [17]. These strikingly similar 
features from very dissimilar proteins serve as an elegant example of convergent evolution at 
a protein structure level. A recently-developed 19-amino acid miniature protein consisting only 
of a tryptophan ladder revealed the structural and biophysical dynamics of the structural motif 
[20]. Structural characterization of the miniature protein revealed a novel topology composed 
of a β-strand:loop:PPII-helix [20]. Through mutagenesis studies, the authors concluded that the 
structure is stabilized by π-cation interactions and that each π-cation interaction can stabilise 
the miniature protein by up to -5.5 kcal/mol [20]. This value is on par with the Gibbs free 
energy of hydrogen bond formation and even protein folding, suggesting that formation of the 













Figure 1. 4: Superposition of tryptophan ladders from cytokine receptors and TSRs.  
a) TSR domain of Thrombospondin-1.  
b) FNIII domain of the type I cytokine receptor, prolactin receptor (PRLR).  
c) Superposition of the TSR and the type I cytokine receptor FNIII domains. (Adapted from 
Olsen and Kragelund) [17]. 
 
The roles of tryptophan C-mannosylation on these, or any other, protein remains to be 
definitely established. It is conceivable that C-mannosylation of the tryptophan residues in the 
WXXW motif help to assemble or stabilize the tryptophan ladder by pre-arranging the aromatic 
ring of tryptophan to encourage a π-cation interaction with the arginine side chain and shielding 
this hydrophobic amino acid from the bulk solvent [17]. Mutagenesis studies on Arg202 and 
Trp215 of the tryptophan ladder in the ϒc receptor (a type-I cytokine receptor) resulted in 
accumulation of the receptor in the ER: its failure to be exported to the plasma membrane 
suggests it was misfolded [21]. Another type-I cytokine receptor,  IL21R, had the same 
phenotype when the key W and R residues in the tryptophan ladder were mutated [21]. While 
these studies speak to the importance of the tryptophan ladder, they cannot be used to infer a 
role for C-mannosylation. To examine the effects of C-mannosylation on the folding and 
stability of proteins with a tryptophan ladder, one must either produce the wild-type candidate 
proteins with and without C-mannosylation or examine their trafficking in cells with and 
without the tryptophan C-mannosyltransferase. 
 
Another hypothesis for the role of C-mannosylation is that it plays a role in the function of 
proteins with tryptophan ladders, many of which bind sulphated glycosaminoglycans (GAGs), 
sulphatide, lipopolysaccharide (LPS) and phosphatidylserine. For example, the TSR domains 
of thrombospondin-1 are known to bind to heparin and heparin sulphate [22] and the tryptophan 
ladder formed by its KRFKQDGGWSHWSPWSS peptide mediates this interaction. However, 
when this TSR domain is expressed in E. coli, which does not produce C-mannosylated 
proteins [22], the heparin and heparin sulfate binding is ameliorated. The idea that C-
mannosylation play a role in protein function is not mutually exclusive with the proposal that 
it also aids in protein folding and stabilisation. 
 
1.4 - All of the human proteins with a predicted C-mannosylation sequon 
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Although the majority of the proteins discovered to date with a C2-α-D-mannosyl-tryptophan 
have fallen in the type I cytokine receptor and thrombospondin type 1 repeat (TSR) domain 
families, there are many more protein families with the WXXW motif that are likely to bear 
the modification. Julenius constructed NetCGlyc, an online tool that predicts C-mannosylation 
sites in proteins based on the presence of a signal peptide and WXXW motif in their sequence 
[23]. A ScanProsite search using the WXXW motif indicates that there are >2000 proteins in 
the human proteome that contain this consensus sequence for C-mannosylation [24]. Further 
analysis of these proteins with TargetP and SignalP, which predict the sub-cellular location of 
these proteins, predicts if these sequences pass through the secretory pathway [25]. 
Approximately 500 of these proteins pass through the secretory pathway and are thus 
potentially C-mannosylated.  
 
Gene ontology software can be used to predict what biological pathways these putatively C-
mannosylated proteins are involved in [26] [27]. The heat map in Figure 1.5A shows the 
prevalence of these putatively modified proteins in different biological pathways. The most 
enriched pathway is the bone morphogenetic protein (BMP) signalling pathway, which senses 
a number of pleiotropic growth factors in different organs, not just bone [28]. BMPs have roles 
in osteogenesis and skeletogenesis, as well as embryogenesis and organogenesis [28]. There is 
also evidence that BMP signalling is involved in cellular differentiation and apoptosis [28].  
Putatively C-mannosylated proteins are also highly enriched and may play a pivotal role in the 
immunity, particularly in: T-cell proliferation, the adaptive immune response and leukocyte 
cell-cell adhesion. This suggests that C-mannosylation plays a more important role in human 
biology than presently appreciated  
 
These putatively C-mannosylated proteins belong to many different protein classes: not just 
TSR domains and type-I cytokine receptors (Figure 1.5B). The majority are cell surface 
receptors or enzymes, though some transporters, signalling molecules and secreted proteins 
also made the list. Of the receptors, only 19% were type-I cytokine receptors: the remaining 
81% belonged to diverse receptor families that have not yet been definitely linked to C-
mannosylation (Figure 1.6). G-protein coupled receptors account for 16% of these receptors 
and many of these receptors belong to the adhesion G-protein couple receptor sub-family 
(Figure 1.6). G-protein coupled receptors have a wide variety of molecular functions and 
transduced there downstream signalling either through cAMP or the phosphatidylinositol 
signal pathway [29]. An example is Adhesion G protein-coupled receptor B1(ADGRB1) which 
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is a cellular receptor that recognises phosphatidylserine and enhances the engulfment of 
apoptotic cells [30].  
 
	
Figure 1. 5: Pathways and protein classes for putatively C-mannosylated human 
proteins. 
a) Biological pathways replete with putatively C-mannosylated proteins. 






Figure 1. 6: Sub-classification of receptors with putative C-mannosylation sites.  
 
Olfactory receptors also made the list. These receptors bind to odorant molecules in the nose 
to trigger a neuronal response which gives rise to the perception of smell (Figure 1.6) [31]. 
Taste receptors comprise 5% of the putative C-mannosylated receptor class, and one example 
is the TAS2R16 receptor which mediates the bitter taste response [32]. Approximately half of 
the receptors are a mixture of different family of proteins and examples include: LDLR, which 
is involved in the engulfment of cholesterol-rich LDL [33]; L1CAM, which is a receptor 
involved in cell adhesion and migration [34]; and the netrin receptors UNC5A, UNC5B, 
UNC5C and UNC5D, which contain a TSR domain and are involved in axon guidance, cell 
repulsion/attraction and apoptosis [35].  
 
The majority of the enzymes with a putative C-mannosylation motif are hydrolases (57%) 
(Figure 1.7). Examples include: furin, an endoprotease that activates TGF-beta [36]; 
acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE), two enzymes that break 
down the neurotransmitters acetylcholine and butyrylcholine [37]; and angiotensin-converting 
enzyme 1 (ACE) and angiotensin-converting enzyme 2 (ACE2), which are involved in the 
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renin–angiotensin–aldosterone system (RAAS) and targets of commonly used ant-
hypertension medications [38]. The other major class of enzymes that are putatively C-
mannosylated are the transferases, which account for 30% of total enzymes (Figure 1.7). Many 
of these enzymes are glycosyltransferases such as: GPI mannosyltransferase 4 (PIGZ), which 
is an enzyme involved in glycosylphosphatidylinositol-anchor biosynthesis [39]; and protein 
O-glucosyltransferase 1 (POGLUT1), which transfers glucose and xylose from UDP-glucose 
and UDP-xylose, respectively, to a serine residue  [40]. Oxidoreductases, kinases, ligases and 
isomerases are also represented in this list (Figure 1.7).  
 
	
Figure 1. 7: Sub-classification of enzymes with putative C-mannosylation sites. 
 
Of the signalling molecules with a putative C-mannosylation site, ≈60% are growth factors 
(Figure 1.8A). An overwhelming majority of these growth factors are bone morphogenetic 
proteins (BMP) (including all the GDF genes in the list). These BMPs a part of the transforming 
growth factor-beta (TGF-beta) protein family and are involved in a variety of different roles in 
the human body [28]. Other interesting growth factors include: vascular endothelial growth 
factor A (VEGFA) and vascular endothelial growth factor D (VEGFD) (Figure 1.8A), which 
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are  glycoproteins involved in angiogenesis [41, 42]; and left-right determination factors 1 and 
2 (LEFTY1/2), which are also members of the TGF-beta protein family and involved in left-
right asymmetry determination [43]. The other signalling molecules are a mixed bag and 
include proteins like fibrinogen gamma chain (FGG), fibrinogen beta chain (FGB) and 
coagulation factor V (F5), which are all part of the blood coagulation system (Figure 1.8A). 
Other putative C-mannosylated proteins include enzyme modulators, calcium binding proteins 




Figure 1. 8: Sub-classification of (a) signalling molecules and (b) other proteins with 




Secreted proteins account for around 13% of all of the putatively C-mannosylated proteins 
identified in humans (Figure 1.9A). Within this group, ≈80% are classified as extracellular 
matrix proteins. Proteins in this class include the RSPON1-4 genes as well as SBSPON, which 
are all a part of the F-spondin family of proteins that regulate Wnt signalling in adult stem cells 
during development [44]. Another family of proteins is the ADAMTSL1-3 genes which are 
extracellular proteins involved cell-matrix interactions [45]. About 20% of the secreted 
proteins are cell adhesion molecules, such as transmembrane glycoprotein NMB (GPNMB), 
which plays a role in osteoblast differentiation and function (Figure 1.9A) [46].  
	
	
Figure 1. 9: Sub-classification of (a) secreted proteins, (b) transporters and (c) 




The transporter class of proteins account for 8% of all of the putatively C-mannosylated 
proteins (Figure 1.9B) and includes the aquaporin gene family (AQP1-2, AQP4-6), which are 
integral membrane proteins that transport water in and out of cells [47]. The remaining 11% of 
the putatively C-mannosylated proteins did not have any assigned function (Figure 1.9B). 
 
1.5 - Proteins for which there is direct empirical evidence of C-mannosylation 
Table 1.1 lists a wide variety of proteins which have been proven to be C-mannosylated, mostly 
through mass spectrometry evidence. These proteins will be discussed in further detail in this 
chapter. 
 
1.5.1 - Type-I cytokine receptors  
Type-I cytokine receptors were initially identified and grouped together because they 
possessed a highly conserved WSXWS motif. This motif is consistent with the consensus 
sequence for C-mannosylation, WXXW, and so one might expect all of these proteins to be C-
mannosylated. Type I cytokine receptors have similar structural features: they all contain an 
extracellular domain comprised of FNIII modules, a transmembrane domain and cytoplasmic 
signalling domain [48]. The extracellular domain always contains a cytokine receptor 
homology domain (CHD), which is composed of two FNIII modules [49]. One of the FNIII 
modules contains two pairs of conserved cysteine residues in the following configuration: CX-
(9–10)-CXWX-(26–32)-CX-(10–15)-C [49]. The second FNIII module contains the conserved 
WSXWS motif [50, 51]. The type I cytokine receptors can be characterised into five groups 
based on their structural homology, topology and evolutionary history (Figure 1.10) [48]. 
Group 1 receptor ectodomains consist solely of CHDs and form homodimers. They include the 
thrombopoietin receptor (TPOR, also known as c-mpl), prolactin receptor (PRLR), 
erythropoietin receptor (EPOR), CLF-3 receptor and the growth hormone receptor (GHR) [48]. 
Group 2 and group 3 receptors both contain a N-terminal Ig-domain on their extracellular 
domain but group 3 has a shortened intracellular domain [52] [53]. Group 2 and group 3 
collectively comprise the IL6R family of receptor complexes. Group 4 receptors contain only 
an extracellular CHD domain and long intracellular domains [54] (Figure 1.10), whereas, group 
5 receptors contain an Ig-like domain and short intracellular domains [54]. Group 4 and 5 chain 
receptors associate to form receptor complexes of the IL2R and IL3R receptor families (Figure 
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1.10). All of these possess the C-mannosylation WXXW sequon, with the exception of the 
growth hormone receptor (GHR). 
 






Figure 1. 10: Topological arrangement of type-I cytokine receptors.   
Structural and topological arrangement of type-I cytokine receptors into five main groups.  
 
1.5.1.1 - C-mannosylation of Interleukin 21 receptor 
The Interleukin-21 receptor (IL-21R) is a type I cytokine receptor that is activated through the 
binding of Interleukin-21, which is a pleiotropic cytokine [55]. IL-21R is a heterodimeric 
receptor that is composed of an IL-21R α chain and a γc chain. Recently, the structure of the 
extracellular domain of the IL21-R bound to IL21 was determined and C2-α-D-mannosyl-
tryptophan identified on the protein’s tryptophan ladder [12]. In this structure, the C-mannose 
appeared to play a role in multiple intra- and -inter molecular interactions through a hydrogen-
bonding network between the arginine residues in the tryptophan ladder and a remote N-glycan 
from another FNIII domain of IL21R [12]. This supports the hypothesis that C-mannosylation 
may play a role in stabilising the π-cation network of the tryptophan ladder and the idea that 
mannosylated tryptophan can facilitate interactions between the tryptophan ladder and ligands. 
 A follow-up study by Siupka et al. has demonstrated that C-mannosylation is not only 
important for the structure of IL21R, but also important for the folding and trafficking of Il-
21R to the plasma membrane [21]. HA-tagged WT-IL21R and R182A, N54A, and W195A 
mutants of IL21R were heterologously expressed in HEK293T and HeLa cells. Using 
immunofluorescence confocal microscopy, they found that the WT-IL21R was expressed on 
the cell surface while the W195A and R182A mutants accumulated in the ER with no cell 




1.5.1.2 - C-mannosylation of the thrombopoietin receptor 
The thrombopoietin receptor (TPOR) is involved in the proliferation of multipotent 
hematopoietic bone marrow stem cells, their differentiation into mature megakaryocytes, and 
the production of platelets [56]. TPOR is a homodimeric receptor and signalling through the 
TPOR is initiated by the binding of its ligand, thrombopoietin (TPO), which then initiates the 
JAK/STAT and MAPK signalling cascade [56]. TPOR is interesting because it contains two 
WSXWS motifs. Recently, work by Sasazawa et al. revealed through mass spectrometry that 
TPOR is C-mannosylated at five tryptophan residues [57]. On the first WSXWS motif, Trp269 
and Trp272 are C-mannosylated while on the second WSXWS motif Trp474 and Trp477 are C-
mannosylated [57]. The fifth residue to be C-mannosylated is Trp416, which is not part of any 
WSXWS motif [57]. These cryptic C-mannosylation sites may mean that there may be more 
C-mannosylated proteins in the human proteome than predicted in above (see 1.4).  
 Sasazawa et al. examined if C-mannosylation impacts the downstream signalling 
function of TPOR. They expressed recombinant flag-tagged TPOR in CHO cells together with 
the following mutants: W269F, W272F, W474F, W477F and W416F [57]. Using flow 
cytometry, the authors observed a decrease in expression of these mutant receptors on the 
surface of the cells, suggesting that C-mannosylation plays a role in protein folding and 
trafficking. These cell lines were stimulated with TPO and examined for the production of 
phosphorylated-STAT3, STAT3, phosphorylated-ERK, and ERK2, which are all downstream 
signalling proteins involved in TPO signal transduction [57]. There was no expression of 
phosphorylated-STAT3 and phosphorylated-ERK in the W269F, W272F, W474F, and W477F 
mutants as compared to wild-type TPOR [57]. This suggested that JAK/STAT and MAPK 
signalling was not initiated by these mutants. Notably, the W416F mutant, which is not located 
in any WXXW tryptophan ladder motif, did generate phosphorylated-STAT3 and 
phosphorylated-ERK, which suggests that it was functionally competent [57]. 
 
1.5.1.3 - C-mannosylation of the Erythropoietin receptor 
The erythropoietin receptor (EPOR) was the first type I cytokine receptor proven to be C-
mannosylated [10]. It is a homodimeric type I cytokine receptor responsible for erythropoiesis, 
which is the production of red blood cells, and also involved in the terminal differentiation of 
erythroid progenitors [58]. When its ligand, Erythropoietin (EPO), binds to EPOR it initiates a 
downstream JAK/STAT signalling cascade [58]. Like other type I cytokine receptors, it 
contains a highly conserved WSXWS motif. Hilton et al.  carried out mutagenesis studies on 
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the WSXWS motif of EPOR [59]. All the residues in this motif were systematically mutated 
and examined for receptor export to the plasma membrane and ligand binding to receptor [59]. 
When the authors mutated Trp232 and Ser233, there was a 300-fold decrease in receptor cell 
surface expression and EPOR was instead retained in the ER [59]. The Trp232 mutant also 
bound EPO 100-fold less than the wild type [59]. When overexpressed in HEK-EBNA, EPOR 
was found by mass spectrometry to be C-mannosylated on Trp232 with an occupancy of 50% 
[10]. Collectively, this alludes to possible roles for C-mannosylation in the trafficking of EPOR 
and in EPO binding. 
 
1.5.1.4 - C-mannosylation of Interleukin-12 
Interleukin-12 (IL-12) is a pro-inflammatory heterodimeric type-I cytokine that is composed 
of a β (p40) subunit and α (p35) subunit [60]. In actual fact, the p40 subunit is a homologue of 
the type-I cytokine receptors and is perhaps better described as a soluble type-I-cytokine 
receptor. It possesses the conserved WXXW motif within a FNIII domain that is characteristic 
of the type-I cytokine receptors. Doucey et al. expressed recombinant IL-12 β (p40) in Chinese 
hamster ovary (CHO) cells and showed by mass spectrometry that it was C-mannosylated on 
Trp319 [61]. IL-12 is expressed in minute amounts in IL-12 secreting cells, making it 
challenging to obtain enough material for mass spectrometry on endogenous samples. As yet, 
there is no information available on the possible function of C-mannosylation in IL-12 
expression or activity.		
 
1.5.2 - Thrombospondin type I repeats 
The thrombospondin type I repeats (TSRs) are small domains approximately 60 amino acids 
in length with six conserved cysteine residues that hold the protein together through the 
formation of disulphide bonds [62]. The disulphide bonds can be found in two different 
configurations [62]. Group 1 TSR domains have a bonding configuration of C1–C5, C2–C6, 
C3–C4, while group 2 TSR domains have a configuration of C1–C4, C2–C5, C3–C6 [62]. The 
crystal structure of the TSR domains from thrombospondin-1 revealed that TSRs are composed 
of three antiparallel strands (Figure 1.11A). Strand A is irregular, but strand B and C form a β-
sheet. Strand A of TSRs contain a conserved stretch of tryptophan residues arranged as 
WXXW(XXW), where X equals any amino acid, which is of course the consensus sequence 
for C-mannosylation. Most TSR domains also contain a YXRXZ motif (where, Y and Z are 
usually, R, K or Q) on strand B, with the lysine side chain interdigitating the aromatic 
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tryptophan side chains from strand A to form a tryptophan ladder with stabilising π-cation 
interactions [19] [18] (Figure 1.11B). These features are obvious at an amino acid sequence 




Figure 1. 11: (a) Structure and (b) configuration of TSR domains.  
(Adapted from Olsen and Kragelund) [17]. 
  
 
[3], which is a challenge to structure–function studies by
mutational analysis. However, atomic resolution NMR spectro-
scopic analysis of the prolactin receptor D2-domain, containing the
Trp-ladder, has shown that Wj shifts from p-cation stacking with
arginine Ri+2 in the hormone bound state to an edge-to-face (or T-
stack) configuration with Wj+3 in the unbound receptor state [4].
3. In the thrombospondin type I repeat
The TSR-1 domain is found in a wide range of animal proteins
including the group A thrombospondins, properdin (complement
pathway regulator), the Plasmodium hepatocyte binding protein
TRAP [5], the ADAMTS family [6], hemicentin [7], F-spondin [8],
semaphorins [9], SRPX2 [10] and many others. Often, TSR-1
domains occur in two or more consecutive copies, with properdin
perhaps being the most prominent example with six consecutive
TSR-1 modules [11]. Most, if not all proteins harbouring the TSR-1
domain, are associated with the extracellular matrix, and are
mostly involved in cell–cell communication, differentiation and
morphogenesis.
The TSR-1 domain is a 50-odd residues flat, elongated structure
with up–down–up topology (Fig. 1). Of the three strands, the two
C-terminal ones form a small b-sheet whereas the N-terminal
strand is mainly connected to the second strand via side-chain
hydrogen bonds and Trp-ladder interactions. The Trp-ladder is
capped in both ends by a disulphide bridge. The N-terminal strand
contains the tryptophans and the second strand contains the
intercalating arginine residues. Like the CHR modules, the TSR-1
domains occasionally have other residues substituting for Arg and
Trp.
4. A case of convergent evolution
The FNIII Trp-ladders are composed of residues from four
strands, representing one face of the FNIII b-sandwich, whereas
the TRS-1 ladders are composed of residues from only two,
Fig. 1. The tryptophan-ladder. TSR-1 (left) and CHR FNIII (right) domain Trp-ladder structures. The TSR-1 example is domain 3 of thrombospondin; the FNIII structure is
domain 2 of the prolactin receptor. The topology diagrams emphasize the reversed distribution of ladder residues.
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A" B"
Str nd"A" Strand"B" Str nd"C"
TSR1-Properdin|     ---SPRWSLWSTWAPCSV-T------CSEGS----QLRYRRCVGWNGQ--CS-----GKVAPGTL-E-- 
TSR2-Properdin|     ---MGGWSGWGPWEPCSV-T------CSKGT----RTRRRACNHPAPK--CG-----G-HCPGQA---- 
TSR3-Properdin|     ---HGAWATWGPWTPCSA-S------CHGGPHEPKETRSRKCSAPEPSQKPP-----GKPCPGLA---- 
TSR4-Properdin|     ---AGGWGPWGPVSPCPV-T------CGLGQ----TMEQRTCNHPVPQ--HG-----GPFCAGDA---- 
TSR5-Properdin|     ---DGEWDSWGEWSPCIR-RNMKSISCQEIP--GQQSRGRTCRGRK----FD-----GHRCAGQQ---- 
TSR6-Properdin|     ---KGSWSEWSTWGLCMP-P------CGPNP---TRARQRLCTPLLPKYPPT-----VSMVEGQGEKNV 
TSR1-C6|            --CFCDHYAWTQWTSCSK-T------CNSGT----QSRHRQIVVDKY---YQ-----ENFCEQICSK-- 
TSR2-C6|            ---NCLLGDFGPWSDCDP--------CIEK-----QSKVRSVLRPS---QFG-----GQPCTAPL---- 
TSR3-C6|            ---DGQWGCWSSWSTCDA-T---------YK----RSRTRECNNPAPQ--RG-----GKRCEGEK---- 
TSR1-C7|            ---NCQWDFYAPWSECNG--------CTKT-----QTRRRSVAVYG---QYG-----GQPCVGNA---- 
TSR2-C7|            ---DGGWSCWSSWSPCVQ-G---------K-----KTRSRECNNPPPS--GG-----GRSCVGET---- 
TSR1-C8alpha|     ---TCQLSNWSEWTDCFP- ------CQDK-----KYRHRSLLQPN---KFG-----GTICSGDI---- 
TSR2-C8alpha|       ---DGSWSCWSSWSVCRA-G---------I-----QERRRECDNPAPQ--NG-----GASCPGRK---- 
TSR1-C8beta|        ---DCELSSWSSWTTCDP--------CQKK-----RYRYAYLLQPS---QFH-----GEPCNFSD---- 
TSR1-C8beta|        ---DGKWNCWSNWSSCSG-R---------R-----KTRQRQCNNPPPQ--NG-----GSPCSGPA---- 
TSR1-C9|            ---DCRMSPWSEWSQCDP--------CLRQ-----MFRSRSIEVFG---QFN-----GKRCTDAV---- 
TSR1-TSP-1|        ---DDGWSPWSEWTSCST-S------CGNGI----QQRGRSCDSLN------------NRCEGSS---- 
TSR2-TSP-1|         ---DGGWSHWSPWSSCSV-T------CGDGV----ITRIRLCNSPSPQ--MN-----GKPCEGEA---- 
TSR3-TSP-1|         ---NGGWGPWSPWDICSV-T------CGGGV----QKRSRLCNNPTPQ--FG-----GKDCVGDV---- 
TSR1-ADAMTS13|      ---HGRWSSWGPRSPCSR-S------CGGGV----VTRRRQCNNPRPA--FG-----GRACVGAD---- 
TSR1-ADAMTS-L1|     ---DGLWDAWGPWSECSR-T------CGGGA----SYSLRRCLS-------------SKSCEGRN---- 
TSR1-Mindin|        ---DCEVSLWSSWGLCGGHC-- ---GRLGT----KSRTRYVRVQP----AN-----NGSPCPEL----
TSR1-F-SPONDIN|     ---TCIYSNWSPWSACSSST------CDKGK----RMRQRMLKAQL----DL-----S-VPCPDT---- 
TSR2-F-SPONDIN|     ---TCTMSEWITWSPCSI-S------CGMGM----RSRERYVKQFP----ED-----GSVCTLPT---- 
TSR3-F-SPONDIN|     ---SCLMTEWGEWDECSA-T------CGMGM----KKRHRMIKMNP----AD-----GSMCKAET---- 
TSR4-F-SPONDIN|     ---PCLLSPWSEWSDCSV-T------CGKGM----RTRQRMLKSLA----EL-----G-DCNEDL---- 








Figure 1. 12: Sequence alignment of C-mannosylated TSR domains from human 
proteins.  
The amino acid sequences of TSR domains from human proteins were aligned with Clustal 
Omega. Residues in yellow represent tryptophan residues in a WXXW motif. W in bold are 
known sites of C-mannosylation. Residues in red are conserved cysteine residues. Residues in 
grey represent the YXRXZ motif (where Y, Z = R, K or Q). 
 
Table 1. 2: TSR domains with empirical evidence of C-mannosylation.  
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1.5.2.1 - C-mannosylation of mindin 
Mindin (Spondin-2) is an extracellular matrix protein which belongs to the F-spondin protein 
family and has a variety of different functions [75-80]. Its primary function is to serve as a 
pathogen recognition molecule where it recognises LPS on bacterial cell surfaces and serves 
as an opsin for phagocytosis by macrophages [81]. Mice lacking mindin cannot clear pathogens 
and macrophages deficient in mindin show defective responses to microbial stimuli 
[81]. Mindin is composed of a TSR domain and a spondin domain, the spondin domain is 
known to bind to αMβ2 integrin on macrophage cell surfaces [69]. Currently, there is no 
information as to which of the two domains mediate the binding to LPS, or if they are both 
required for binding. Mindin is C-mannosylated on both W283 and W286 within the TSR domain 
(aa277-aa331) [69]. Full-length mindin produced in mammalian cells showed significant 
binding to LPS, but full-length mindin produced in bacterial cells, or the spondin domain alone, 
showed only weak binding to LPS [69]. This information suggests that C-mannosylation of the 
mindin TSR domain is important for LPS binding. 
	
1.5.2.2 - C-mannosylation of properdin 
Properdin is a glycoprotein that is a positive regulator of the alternative pathway of the 
complement system [82]. The complement system is an important part of the innate immune 
system that acts as an immediate first line defence against pathogens or foreign bodies [83]. 
Properdin is a highly C-mannosylated protein comprised of six TSR domains. Out of the 
seventeen-tryptophan residues in the six WXXW(XXW) motifs, fourteen tryptophan residues 
are C-mannosylated [65]. The impact of C-mannosylation on properdin expression and 
function remain unknown.  
 
1.5.2.3 - C-mannosylation of complement components 
The complement system acts as the first line of defence against microbial pathogens [83]. The 
formation of the membrane attack complex (MAC) and its subsequent binding to cell 
membranes of pathogens causes cell lysis and elimination of the pathogens [84]. Complement 
components C5b C6, C7, C8, and C9 form a tandem repeat polymer that forms the MAC of 
the innate immune system [84]. Complement component C6 has three TSR domains, C7 has 
two TSR domains, while C8α and C8β contain two TSR domains each and C9 contains only 
one TSR domain. Mass spectrometry studies by Hofsteenge et al. found that C6, C7, C8α, C8β 
and C9 were all C-mannosylated on multiple tryptophan residues [11]. C6 is modified on Trp8 
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and Trp11 located on TSR1, Trp69 which is not located on any TSR domain, and Trp547, Trp550 
and Trp553 located on TSR3 [11]. C7 is modified on Trp14 not located on any TSR domain and 
on Trp481, Trp484 and Trp487 located on TSR2. C8α is modified on Trp14 not located on any TSR 
domain, and on Trp512, Trp515 and Trp518 located on TSR2 [11]. C8β is modified on Trp16 and 
Trp19 on TSR1, and Trp497 and Trp500 located on TSR2 [11]. C9 is modified on Trp27 and Trp30 
on TSR1 [11]. A crystal structure of C8 has been solved and reveals electron density for these 
C2-α-D-mannosyl-tryptophans [66], which cluster together from both the C8a and C8b 
subunits.  
 
1.5.2.4 - C-mannosylation of ADAMTS13 
ADAMTS13 is a plasma metalloproteinase and a member of the ADAMTS family (a 
disintegrin-like and metalloproteinase with thrombospondin type 1 repeats) of proteins [85]. 
Its main function is regulating blood coagulation, where it cleaves Willebrand factor (VWF) 
multimers which attach platelets to endothelial cells thereby regulating platelet adhesion and 
aggregation [86]. It was shown by mass spectrometry that plasma-purified (endogenous) 
ADAMTS13 was C-mannosylated on Trp390 and Trp884 in TSR 1 and TSR4, respectively [87]. 
Another study, showed that the WXXW motif in TSR 1 of ADAMTS13 was important for its 
secretion and proteolytic activity by making alanine mutations of the first tryptophan residue 
[88]. This study, unlike other studies looking at mutants of the WXXW motif, did not make 
unfounded claims that C-mannosylation was responsible for the lack of secretion or activity in 
the WXXW mutant, though it does, once again, highlight the importance of the tryptophan 
ladder for protein folding and trafficking. 
 
 
1.5.3 - Other proteins classes with evidence of C-mannosylation 
 
1.5.3.1 - C-mannosylation of mucins 
Mucins comprise a family of large, complex and heavily glycosylated glycoproteins that are 
characterised by their ability to form gels. Their functions range from lubrication, formation of 
chemical barriers and cellular signalling and are implicated in lung diseases such as asthma, 
bronchitis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis [89] [90, 91]. 
MUC5AC and MUC5B are mucins that have been reported to be C-mannosylated based solely 
on lectin binding [92]. The cysteine-rich domains (CysDs) of MUC5AC and MUC5B possess 
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a WXXW motif and, when this domain was expressed in COS-7 cells, the protein could be 
captured by mannose-binding lectins (MBL). When the authors mutated the first tryptophan in 
the WXXW motif, the MBLs were not able to capture the domains, which was interpreted as 
the proteins no longer being C-mannosylated [92]. Immunofluorescence studies also suggested 
that mutation of the WXXW motif in mucin CysDs led to the protein being retained in the ER 
[92]. Expression of mucin CysDs in CHO-Lec35.1 cells, which have low Dol-P-Man levels, 
blocked secretion of the wild-type mucin CysD [92]. However, since Dol-P-Man is required 
for N-and O-glycosylation it is difficult to draw meaningful conclusions from this data. A 
recent study has also mutated the first tryptophan of the WXXW motif into an alanine in the 
MUC5B CysD and showed that this mutant could not be secreted, again, the authors 
extrapolated from this to erroneously conclude that C-mannosylation was essential for folding 
and trafficking of this mucin CysDs [93]. A continuing problem in the literature is the over 
interpretation of WXXW mutagenesis studies: removing a tryptophan that is important for a 
structural motif is not the same as preventing mannosylation of that motif [20]. On balance, 
claims that mucin CysDs are C-mannosylated remain contentious, as there has been no direct 
observation of a C-linked hexose. 
 
1.5.3.2 - C-mannosylation of hyaluronidases 
In humans there are five hyaluronidase homologues that break down hyaluronan (hyaluronic 
acid, HA), which is a non-sulphated glycosaminoglycan (GAG) comprised of alternating 
glucuronic acid and N-acetyl glucosamine [94]. Hyaluronan is found in the extracellular matrix, 
cartilage, epithelial, connective and neural tissues [94] and controls fluid homeostasis in these 
tissues [95]. Mass spectrometry experiments have demonstrated that Hyaluronidase 1 is C-
mannosylated [96]. The WXXW motif modified in hyaluronidase 1 is conserved in the other 
four human hyaluronidases, indicating that all of these enzymes are probably C-mannosylated.  
 
1.5.3.3 - C-mannosylation of lipoprotein lipase 
Mass spectrometry has recently revealed that lipoprotein lipase (LPL) is C-mannosylated on 
W417 when recombinantly expressed in HT1080 cells [97].  LPL is an enzyme that is involved 
in lipid transport and metabolism where it is responsible for the hydrolysis of core triglycerides 
in lipoproteins [98]. Mutation of this tryptophan to a phenylalanine residue resulted in a 
decrease in protein secretion and enzymatic activity, relative to the wild-type enzyme [97]. 
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Whether or not the W to F mutation, the loss of C-mannosylation, or both, are responsible for 
this decreased expression and activity remains to be determined.  
 
1.5.3.4 - C-mannosylation of myelin-associated glycoprotein (Siglec-4) 
Myelin-associated glycoprotein (MAG), also known as siglec-4, is a type-I transmembrane 
glycoprotein, lectin and signal transducer. Its main function is in glial-axonal interactions, but 
also has roles in inhibition of nerve regeneration [99] [100]. It recognises alpha 2,3-N-
acetylneuraminic on the terminal galactose of a gangliotetraose core [101]. X-ray crystal 
structures of recombinant MAG expressed in mammalian cells reveal a C2-α-D-mannosyl-
tryptophan on W22 [102], which was confirmed using mass spectrometry. This tryptophan is 
part of a WXXW motif that is not conserved in other siglecs. This glycosylation site is near the 
neuraminic acid binding site of siglec-4 and mutations of this residue actually increase the 
affinity of for neuraminic acid ligands. Thus, it may be that tryptophan mannosylation plays a 
role in negatively regulating the activity of siglec-4 (MAG) [102].  
 
1.5.3.5 - C-mannosylation of hypertrehalosaemic hormone 
Though the focus here has been on mammalian biology, tryptophan mannosylation is also 
prevalent in other metazoans. C-mannosylation has been identified in the stick insect Carausius 
morosus hypertrehalosaemic hormones, which are small neuropeptides that have a role in the 
regulation of the trehalose concentrations in insects [103]. This was contentious at the time 
because Drosophila melanogaster Schneider 2 cells do not demonstrate any C-
mannosyltransferase activity [71] [68]. The same is true for the Sf9 and Sf21 cells derived from 
Spodoptera frugiperda. It may be that these lab-adapted, immortalised cell lines simply do not 
express their C-mannosyltransferase. The hypertrehalosaemic hormone from Carausius 
morosus was shown to be C-mannosylated on Trp8 using NMR [104]. This complemented 
earlier mass spectrometry results demonstrating a hexose on one of the tryptophan residues of 
a similar peptide from a related species [105]. NMR diffusion measurements showed that the 
mannose reduced the hydrodynamics radius of this peptide as compared to the unmodified 
peptide and that the conformation of the modified peptide changed relative to the unmodified 
form, which was in equilibrium with higher-order aggregates [104]. This was the first and 





1.5.3.6 - C-mannosylation of Pvfp-1, a mussel adhesive protein 
An interesting case of C-mannosylation has been observed by mass spectrometry in the mussel 
Perna viridis with the Pvfp-1 protein, which is a mica-adhesive protein found with numerous 
C-mannosylated tryptophan residues [106]. Mussels contain multiple adhesive proteins that 
allow them to adhere to the rock substrates on which they grow. These adhesive proteins are 
dominated by the presence of 3,4-dihydroxyphenyl-L-alanine (Dopa), which is largely 
responsible for this adhesive property, as seen in Pvfp-5, a homologue of Pvfp-1 [107] [108]. 
In contrast to Pvfp-5 and other adhesive proteins, Pvfp-1 only has one Dopa amino acid in all 
of the protein but instead has 42 repeats of two decapeptides, ATPKPW1TAW2K and 
APPPAW1TAW2K in tandem [106]. Roughly 80% of this protein is composed of these two 
decapeptides repeats, and all tryptophan residues are modified by C-mannosylation [106]. 
While W1 was a simple C2-α-D-mannosyl-tryptophan, W2 was also hydroxylated at C7 too (C2-
α-D-mannosyl-7-hydroxy-tryptophan)  [106]. It has been hypothesized that the C2-α-D-
mannosyl-tryptophan is likely important for the ability of this peptide to bind aluminosilicates 
(e.g. mica)  [106]. In another study, work was conducted on what properties of the C2-α-D-
mannosyl-tryptophan in Pvfp-1 were causing this highly adhesive property [108]. They 
asserted that the π-cation interactions between the C2-α-D-mannosyl-tryptophan and lysine side 
chains provide a low desolvation penalty and that this facilitates conformational changes in the 
peptide at the surface of aluminosilicates and possibly explains why Pvfp-1 has such strong 
adhesive properties [108]. As such, C-mannosylated peptides may have applications in the 
development of new biocompatible materials and adhesives. 
	
1.5.4.7 - C-mannosylation of MP20 lens protein 
Mass spectrometry has provided evidence for C-mannosylation on the Bovine Lens fibre 
membrane intrinsic protein (lim2), or MP20 lens protein [109]. Lim2 is a member of the 
tetraspanin superfamily and is the second most abundant membrane protein in the mammalian 
eye lens fibre cells, which accounts for 99% of cell types in the lens [110]. Lim2 was identified 
as a ligand for Galectin-3, which is involved in cell-cell adhesion and cell-extracellular matrix 
interactions [110]. It is hypothesized that lim2 may play a role in the organisation of lens fibre 
cells in the lens of the eye [110]. However, the intriguing aspect of this protein is that it is C-
mannosylated on two non-canonical C-mannosylation sites: W42RYC and W61NAT [109]. The 
occupancy at W42 was higher than for W61 [109]. Humans have a homologue of lim2, which is 
90% identical to the bovine lim2 and these tryptophans are conserved (WRYC and WANT), 
and so it is quite likely that these non-canonical sites are mannosylated in humans too. Again, 
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this suggests that there are probably many examples in the human proteome of unexpected C-
mannosylation events. 
 
1.5.4.8 - C-mannosylation of viral proteins 
Ebola Virus soluble glycoprotein (sGP) was the first viral protein to be identified as C-
mannosylated. sGP was expressed in HEK293T cells and was found by mass spectrometry to 
be C-mannosylated on Trp288 within a WXXW motif [111]. W238F mutants of this 
glycoprotein had no defects in trafficking or processing. The functions of sGP are still not well 
understood; therefore, a full analysis of the impacts of C-mannosylation on sGP have not be 
explored.  sGP is not the only viral protein to have the WXXW motif. A RefSeq search returns 
over 2000 viral proteins with the WXXW motif [111]. Table 1.3 details viral proteins with a 
WXXW motif that are targeted to the secretory pathway and thus likely to be C-mannosylated. 
These proteins include examples from the Hepatitis B virus, Human immunodeficiency virus 
(HIV), Ebola Virus, Influenza A and C viruses, SARS coronavirus, Hepatitis C virus and 
Dengue virus type 1. Like the type I cytokine receptors and TSR domains, the WXXW motif 
of these proteins is accompanied with YXRXZ motif, suggests that these viral proteins may 
also possess a tryptophan ladder (Figure 1.13). Structural data for these regions of these 
glycoproteins is not presently available: it will be interesting to see if this prediction proves to 




Figure 1. 13: Alignment of the putative tryptophan ladders of viral glycoproteins. 
The amino acid sequences of the viral proteins were aligned using Clustal Omega. Residues in 
yellow indicate the tryptophan residues from the WXXW motif, and residues in grey indicate 







Table 1. 3: Viral proteins with the WXXW C-mannosylation consensus motif. 
 
 
1.6 - Discovery of the first C-mannosyltransferase 
The genetic basis of C-mannosylation was unknown until 2013, when the Bakker lab reported 
that dpy19 encoded a C-mannosyltransferase in Caenorhabditis elegans [68]. The rationale 
behind the discovery of the C. elegans C-mannosyltransferase was based on anticipated 
similarities between the enzymes that catalyse N-glycosylation and C-mannosylation [68]. 
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Oligosaccharyltransferase (OST), the enzyme responsible for N-glycosylation, is a multi-pass 
transmembrane domain protein with seven transmembrane helices (TMHs) that resides in the 
ER and utilises a sugar dolichol phosphate donor substrate [112]. Since C-mannosylation 
requires Dol-P-Man, a sugar dolichol phosphate donor substrate, it was reasoned that it might 
share some sequence similarities with OST. Based on this assumption, dpy19 in C. elegans was 
identified as a prime candidate. The name of this gene derives from DumPY-19 because 
mutations in this gene in C. elegans result in a shortened (dumpy) phenotype [113]. 
Heterologous expression of C. elegans DPY19 in Schneider 2 (S2) cells, which have no C-
mannosyltransferase activity, and isolation of the ER-rich microsomal fractions enabled an in 
vitro demonstration of dpy19-dependent C-mannosyltransferase activity by way of a radio 
assay [68]. Co-expression of TSR domains from C. elegans UNC5 and MIG-21 in these cells, 
followed by mass spectrometry on the purified proteins, enabled direct detection, localisation 
and quantification of the dpy19-dependent C-mannosylation [68]. When MIG-21 was 
expressed in the parental S2 cells lacking dpy19, it was not secreted, suggesting that C-
mannosylation is important for the folding and or secretion of MIG-21 [68].  
 
1.7 - Conservation and evolution of the dpy19 gene family. 
The first mention of the dpy19 gene in literature was in 2000 when it was discovered that the 
C. elegans dpy19 gene was essential in QL and QR neuroblast polarisation [113]. The term 
dpy19, or DumPY-19, was given to these mutants because this gene caused a Q neuroblast 
migration defect that resulted in a dumpy phenotype (short and stout) [113]. The dpy19 gene 
family encodes multi-pass integral membrane proteins and have undergone gene duplication 
and relocation events in both ancient and relatively recent times [114]. There are four dpy19 
homologues in mammals: dpy19l1, dpy19l2, dpy19l3 and dpy19l4. Phylogenetic analyses by 
Carson et al. have traced the evolution of these genes across species (Figure 1.14) [114]. The 
first duplication events of the ancestral dpy19 gene occurred before the divergence of the fish 
lineage, which gave rise to dpy19l1, dpy19l2 and dpy19l3 [114]. More recent duplication of 
dpy19l3 in mammals provided dpy19l4. Dpy19l1 is thought to have undergone ancient gene 
duplication in its segments of low copy repeats (LCR) and subsequent relocation to give 
dpy19l2 [114]. These gene duplications contribute to evolution by acting as molecular 
substrates for divergence [115], and the process continues to this day, with dpy19l1 and 
dpy19l2 undergoing even more recent gene duplication events leading to the creation of 







Figure 1. 14: Phylogenetic analysis of the dpy19 gene family.  
The neighbor-joining tree was created using the Jones-Taylor-Thornton matrix for amino acid 
evolution. Dpy19 refers to the C. elegans dpy19 gene. Dpy19l1-4 are the four human 






The number of dpy19 genes varies significantly across the tree of life (Figure 1.15). As 
mentioned, mammals have four functional dpy19 genes, while the Reptilia family only have 
three. Invertebrates, including nematodes (e.g. C. elegans), deuterostomes (e.g. C. intestinalis), 
and insects (e.g. Drosophila melanogaster) only have one dpy19 gene. The apicomplexans (e.g. 
Plasmodium and Toxoplasma spp.) also have only one dpy19 gene, though it was most likely 
acquired by horizontal gene transfer. Bacteria, fungi and plants do not possess a dpy19 
homologues (Figure 1.15). Clearly, the dpy19 gene, and thus tryptophan C-mannosylation, is 
an innovation of metazoans. It evolved at the same time as the TSR domain and underwent 
proliferation in vertebrates at around the same time as the evolution of type-I cytokine 





Figure 1. 15: Phylogenetic tree illustrating proliferation of the dpy19 genes.  
 
 
The dpy19 genes all encode proteins with similar structural topology. Each one is predicted to 
contain ≈10 transmembrane helices, though this number depends somewhat on the topology 
prediction algorithm used (Figure 1.16). The sequence similarity between Cedpy19 and the 
human homologues is not as well conserved as their overall topology. Hydropathy plots reveal 
three non-transmembrane regions that are assumed to be crucial for catalysis. These regions 
share far greater sequence similarity between proteins than the transmembrane regions. In all 
three of these non-membrane regions, human dpy19l3 and dpy19l1 have greater homology with 






Figure 1. 16: Hydropathy plots for Cedpy19 and the four human dpy19 homologues.  
Constructed using the TMHHM software package.  
 
1.8 - Mammalian C-mannosyltransferases are encoded by dpy19l1 and dpy19l3 
In 2015, dpy19l3, one of the four mammalian dpy19 homologues, was identified as a C-
mannosyltransferase that is active on R-spondin-1 (Rspo1) [71]. In 2017, the Bakker lab 
discovered that dpy19l1 was also a C-mannosyltransferase [74]. The activity of the gene 
products from individual dpy19 genes were examined in isolation through reintroduction to 
dpy19l1, dpy19l3 dpy19l4 triple knockout CHO cells (dpy19l2 is only expressed in the testes). 
Protein substrates, in this case the two TSR domains of mouse UNC5A, were expressed in 
these cell lines, isolated, and examined by mass spectrometry [74]. The tryptic peptides from 
TSR-1 (W1STW2TEW3SVC) and TSR2- (W1SPW2SKW3SAC) revealed that DPY19L1 had a 
higher propensity to modify W1 and W2, while DPY19L3 had a preference for modifying W3 
[74]. The authors concluded that the preferred peptide substrate for DPY19L1 is WXXW, 
whilst for DPY19L3 it is WXXC. Given that there is still overlaps in the activities of these 
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enzymes and numerous examples of non-canonical C-mannosylation sites, this conclusion is 
probably an over simplification. It is also important to keep in mind that this data was obtained 
from a heterologous system and a single protein substrate at unnatural enzyme and substrate 
concentrations. As such, it is important not to over-interpret these results but acknowledge that 
these two C-mannosyltransferases, and possibly others, have different and complimentary 
enzyme activities and as a consequence their biological roles are likely to be different. A brief 
discussion of the other mammalian dpy19 genes, which one might assume to be C-
mannosyltransferases, is warrant. 
 
Dpy19l2 is the most divergent of the dpy19 genes, is only expressed in the testes and lacks any 
C-mannosyltransferase activity. Mutations in dpy19l2 are the cause of globozoospermia: the 
main type of male infertility [116] [117] [118] [119].  DPY19L2 is localised to the inner nuclear 
membrane facing the acrosomal vesicle [120]. It most likely serves as a structural protein that 
links the acrosome to the nuclear envelope in spermatozoa. Without DPY19L2, the acrosome 
does not link to the nucleus, resulting in disrupted vesicular trafficking, lack of nuclear shaping 
and loss of unbound acrosome [120]. The localisation of DPY19L2, its sequence divergence 
and dearth of all C-mannosylation activity strongly suggest that this protein has evolved a 
different function altogether. 
 
All attempts to examine DPY19L4 for C-mannosyltransferase have provided negative results 
[74] [71]. The function of this ubiquitously-expressed protein remains unknown. It shares much 
closer homology with DPY19L1 and DPY19L3 than DPY19L2, so it may be that it is a C-
mannosyltransferase with a radically different substrate preference, or that it performs a 
different type of glycosylation. Either way, it remains a protein of great interest and proteomic 
studies on dpy19l4 knockout cells lines may be able to provide fresh insights into the role of 
this protein.  
 
1.9 - Apicomplexan C-mannosyltransferases 
Recent studies on CRISPR-Cas9-mediated genome-wide genetic knockout screens on 
Toxoplasma gondii, an Apicomplexan parasite, has revealed that a very severe fitness cost is 
incurred when its dpy19 homologue is disrupted [121]. Other work has shown that microneme 
protein 2 (MIC2), which is extremely important for parasite motility and host cell invasion, is 
C-mannosylated by the T. gondii parasite on several of its TSR domains [122] [123]. Thus, it 
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appears likely that the parasite’s DPY19 enzyme is important for the trafficking of MIC2 and 
possibly other parasite virulence factors, though this remains to be proven.  
 
In the malaria parasite, Swearingen et al. used mass spectrometry to show that 
thrombospondin-related adhesive protein (TRAP) from Plasmodium falciparum salivary gland 
sporozoites were C-mannosylated on multiple tryptophan residues [124]. Like MIC2, this 
protein plays an important role in motility and host cell (hepatocyte) invasion [125-127]. Hoppe 
et al. verified that TRAP was C-mannosylated by the P. falciparum DPY19 enzyme in a 
heterologous system using protein mass spectrometry [122]. This same system was used to 
demonstrate that the DPY19 enzymes from these parasites did not modify the WAKW peptide 
but did recognise the WAEWGEC peptide [122]. It remains unclear as to whether the peptide’s 
size, charge or sequence was the defining difference here, though it illustrates once again that 
the canonical WXXW C-mannosylation motif is an oversimplification that must evolve as we 
learn more about the diversity of the DPY19 enzymes.  
 
1.10 - Summary 
This chapter has highlighted the key advancements in the tryptophan C-mannosylation field 
since its discovery in 1994. For a long time, the field has taken an ad hoc approach to 
identifying this modification and sought to explore the role of the modification through 
imperfect mutagenesis experiments. The recent discovery of genes encoding C-
mannosyltransferases and a growing list of non-canonical C-mannosylation sites has changed 
the way we think about tryptophan C-mannosylation and provides a plethora of opportunities 
for the discovery of new glycobiology. This thesis outlines the experiments, results and 
conclusions I have made during my PhD to advance our understanding of this unusual protein 
modification.  
 
1.11 - Aims 
1. Create a simple expression system for the production of proteins with and without 
tryptophan C-mannosylation by engineering a C-mannosyltransferase into the yeast 
Pichia pastoris. 




3. Obtain insights into the mechanism of C-mannosylation by: 
a) Identifying conserved and functionally essential residues in the tryptophan C-
mannosyltransferases. 
b) Probing the substrate preference of tryptophan C-mannosyltransferases. 
4. Produce and validate monoclonal antibodies against C2-α-D-mannosyl-tryptophan to 
enable the simple identification of C-mannosylated proteins using immunochemistry 
techniques. 
5. Generation of chemical inhibitors of C-mannosylation for probing the function of C-
mannosylation in biological systems. 
6. Knockout of the mammalian C-mannosyltransferase genes, dpy19l1 and dpy19l3, in a 
human cell line, and probe these systems using surface proteomics to provide 



























Glycoengineering a tryptophan mannosylation pathway into Pichia pastoris 
 
2.1 - Introduction 
To study the impact of tryptophan C-mannosylation on protein fold and function we required 
a simple protein expression system to facilitate the production of samples with and without 
tryptophan mannosylation. The DPY19 C-mannosyltransferase enzymes utilise mannose-
phosphate-dolichol (Dol-P-Man) as a glycosyl donor. This molecule is only found in the 
eukaryotic ER membrane, which precluded the use of bacterial expression systems. Most 
metazoans have several homologues of DPY19 but simple eukaryotes like yeast have none 
(Table 2.1). Enzyme activity assays on yeast microsomes have confirmed their inability to 
perform tryptophan C-mannosylation [128]. Collectively, this suggested that we needed to 
either disrupt the multiple DPY19 genes in mammalian or insect cell lines or introduce DPY19 
genes into simple eukaryotes like yeast to obtain a common expression platform to make 
proteins with and without the modification. We elected to take the former approach and 
engineer the yeast Pichia pastoris because it is very simple to genetically manipulate, provides 
very stable cell lines, produces copious amounts of Dol-P-Man substrate for the DPY19 
enzymes, and is a high-yielding protein production platform. Furthermore, yeast is not 
accustomed to C-mannosylation and will not have machinery that recognise C2-α-D-mannosyl-
tryptophan such as lectins or chaperons that will help proteins fold. Therefore, any effects seen 
in proteins produced in the engineered yeast strain is due directly to the C2-α-D-mannosyl-













Table 2. 1: List of organisms with the DPY19 gene, enzyme activity and Dol-P-Man 
	
 
Our approach was to produce P. pastoris cell lines that constitutively express DPY19 
homologues (Table 2.2). We chose to use the pGAPz vector system for this because it provides 
constitutive expression of DPY19, under the powerful GAP promoter and protein would be 
expressing intracellularly and selectable using zeocin (Table 2.2). Various inducible expression 
constructs could then be integrated into these cell lines, and the parental cell line lacking 
DPY19, in order to produce proteins with and without tryptophan C-mannosylation. We chose 
the pPIC9k system for this because it provides inducible expression under the AOX1 promoter 
and provides selection using HIS4. This system provides secreted expression of target proteins 
and would mean that our reporter proteins can travel through the secretary pathway and come 
in contact with DPY19 (Table 2.2). The DPY19-expressing cell lines also provide a means to 
study the peptide substrate preferences and DPY19 mechanism in vitro. Such a simple protein 
production platform might also be useful in the biotechnology sector for the manufacture of 
vaccines with native glycosylation patterns, including those based on the Ebola virus soluble 
glycoprotein (EBOV sGP) [129] and the malaria parasite’s thrombospondin-related adhesive 
protein (TRAP), which is the antigen in a candidate vaccine for malaria [130]. Native EBOV 
sGP and TRAP are C-mannosylated and correct glycosylation is likely important for 
maximising vaccine efficacy and this will require engineering of C-mannosylation pathways 




Table 2. 2: Summary of the some of the commercial vector systems available for P. 
pastoris protein expression 
	
 
There is precedence for engineering yeast glycosylation pathways to provide biologics with 
native glycosylation. Most notably, this has been accomplished with the N- and O-
glycosylation pathways (Figure 2.1A, B). There are many N- and O-glycan structures, which 
can be complex, and the examples given below are not represented for all of the N- and O-
glycans that are seen in humans. P. pastoris is known to hypermannosylate N-glycans on 
proteins, and the enzyme responsible for this is the mannosyltransferase (OCH1) gene [131]. 
The first attempt to humanise the N-glycosylation pathway in P. pastoris was done in 2001 
when a 1,2-α-D-mannosidase was knocked into P. pastoris [132]. This enzyme trims the 1,2-
α-D-mannose that elongates the hypermannosylated N-glycan but this approach was only 85% 
efficient, giving heterogeneous N-glycans [132].  
 
Further work was done to produce proteins with human-like non-sialylated hybrid-type N-
linked oligosaccharide structure by knocking-out the OCH1 in the 1,2-α-D-mannosidase over 
expressing cell line along with the knock-in of both N-acetylglucosaminyltransferase I and 
beta-1,4-galactosyltransferase [133]. Meanwhile, another research group, at the same time, was 
able to produce recombinant proteins with human-like complex N-linked oligosaccharide 
structures [134]. This was done using the YJN201 strain of P. pastoris, which lacks OCH1 
activity, with knock-in of α-1,2-mannosidase, and β-1,2-N-acetylglucosaminyltransferase I 
(GnTI) and UDP-GlcNAc transporter [135]. They further modified the strain by knocking-in 
mannosidase II and β-1,2-N-acetylglucosaminyltransferase II (GnTII) and were able to produce 
proteins with N-GlcNAc2Man3GlcNAc2 complex human N-glycan [134]. In 2009 a nature 
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protocols paper was published for the production of different complex and hybrid N-glycans 
in P. pastoris using a technology called Glycoswitch [136]. The Glycoswitch technology takes 
advantage of using a step-wise introduction of different glycosidases and glycosyltransferases 
in different combinations to reach desired N-glycan structures [136].  
 
The next feat of engineering was to produce complex terminally sialylated N-glycan structures. 
This was challenging because the sialylation pathway, the final step in human N-glycosylation, 
does not exist in yeast [137]. Complex N-glycans with terminal sialylation are important for 
glycoproteins, although not for antibodies, because the sialic acid increases their half-life in 
the blood stream and their potency [137]. A strain of P. pastoris called GS.5 which produces 
terminally galactosylated biantennary glycans of the complex type 
Gal2GlcNAc2Man3GlcNAc2 was used for engineering the new strain [138]. Five different 
enzymes were knocked in to generate the new strain and recapitulate the entire sialylation 
pathway into yeast [137]. They were able to produce recombinant human erythropoietin (EPO) 
that was comparable to biologically active EPO produced in mammalian systems [137].  
 
Much like N-glycans in yeast, O-linked glycans are also hypermannosylated in yeast and have 
been subject to humanisation. Protein mannosyltransferases (PMT), of which there are 5 
homologues in P. pastoris, extend the chain of mannose residues on O-linked glycans and 
PMT1 and PMT2 have been knocked out in P. pastoris along with the use of PMT inhibitors 
greatly reduce the degree of hypermannosylation [139]. However, this approach alone does not 
completely remove the mannose residues, and often α-1,2-mannosidase and lysosomal 
mannosidase are knocked into these strains to remove the mannose residues or in vitro 
treatment of glycoproteins with recombinant mannosidases is performed [140] [141].  
 
An example of further humanising O-linked glycosylation in yeast is the engineering of glycans 
to containing Galβ1,3GalNAc1, which is a mucin type glycosylation, engineered in S. 
cerevisiae [142]. Four genes were introduced into the yeast as well as using PMT inhibitors to 
block endogenous O-linked hypermannosylation. Although this was not done in P. pastoris, it 
provides a proof-of-principle for it to be done in P. pastoris. Another example is the 
engineering of the α-dystroglycan O-linked glycosylation pathway into P. pastoris. An α-1,2-
mannosidase was introduced into the cell to trim the α-1,2-mannose chain, followed by the 
introduction of protein-O-linked-mannose β-1,2-N-acetylglucosaminyltransferase 1 which 
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capped the glycan with N-acetylglucosamine and then the sialylation pathway was introduced 
to add a sialic acid to the glycan [141]. 
	
	
Figure 2. 1: Humanisation of the N- and O-glycosylation pathways in yeast 
a) Humanisation of the N-glycosylation pathway in P. pastoris 
b) Humanisation of the O-glycosylation pathway in P. pastoris and S. cerevisiae  
 
With so much progress on the humanisation of P. pastoris N- and O-glycosylation pathways, 
it was now time to compliment these efforts by engineering a mammalian-like C-






2.2 - Results 
 
2.2.1 - Probing the suitability of P. pastoris as a host for C-mannosyltransferases 
We chose P. pastoris as a host for DPY19 enzymes because the yeast ER possesses a large 
reservoir of Dol-P-Man that is ordinarily utilised for the synthesis of high-mannose N-glycans, 
O-mannosylation and GPI anchor synthesis (Figure 2.2A) [143]. However, before introducing 
any DPY19 homologues in the yeast, we wanted to ensure that there were no obvious toxicity 
issues that could arise from C-mannosylation of essential yeast proteins passing through the 
secretory pathways. A BLASTp search revealed that 345 P. pastoris proteins possessed the 
WXXW consensus motif for C-mannosylation and that only 27 of these proteins pass through 
the secretory pathway (Figure 2.2B). None of these proteins were known to be essential and so 
we hypothesised that introduction of the DPY19 enzyme would not have any significant impact 
on the fitness of the yeast. 
	
	
Figure 2. 2: Engineering a glycosylation pathway into P. pastoris. 
a) Diagram illustrating the strategy for humanization of the yeast ER glycosylation 
pathway. Man: D-mannose; Glc: D-glucose; HK: hexokinase; MPI, phosphomannose 
isomerase; PMM2: phosphomannomutase; GMPPA/B: GDP-mannose 
	
	 60	
pyrophosphorylase (A/B); PGI: phosphoglucose isomerase; KPS: KDN-9-phosphate 
synthase; Man-6-P: mannose-6-phosphate; Fru-6-P: fructose-6- phosphate; Glc-6-P: 
glucose-6-phosphate; GDP-Man: GDP-mannose; Dol-P-Man: dolichol phosphate 
mannose; DPM1/2/3: Dol-P-Man synthase.  
b) Table of yeast proteins with the WXXW motif and that pass through the secretory 
pathway. 
 
2.2.2 - Engineering an active tryptophan C-mannosyltransferase in P. pastoris GS115 
We attempted to express three different tryptophan C-mannosyltransferases into P. pastoris 
GS115, including Caenorhabditis elegans DPY19 and the two human enzymes DPY19L1 and 
DPY19L3. In each case, genes encoding these enzymes with a C-terminal 3×FLAG tag were 
codon optimised for P. pastoris, synthesised and cloned into the pGAPZ (Invitrogen) vector 
under the strong constitutive glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter 
(Figure 2.3A). The plasmid was linearised within the GAP promoter using the AvrII restriction 
enzyme and the purified linear DNA electroporated into GS115 cells. Integrants were selected 
for using zeocin. Two dozen individual colonies from each transformation were cultured and 
used to prepare genomic DNA. PCR confirmed integration of the pGAPz-DPY19 cassettes into 
the GAP locus (Figure 3B). Western blot analyses using an antibody to the FLAG peptide 
revealed no evidence of FLAG-tagged peptides for the human DPY19L1 or DPY19L3 (Figure 
2.3C), despite having genomic integration verified through PCR (data not shown). However a 
strong band around 55 kDa in size was detected for cells harbouring C. elegans DPY19 (Figure 
2.3D). This band migrated significantly faster than expected for CeDPY19-FLAG3, which has 
a molecular weight of 83 kDa. Since the C-terminal FLAG-tag was detected by the antibody, 
the protein is either truncated at the N-terminus or, more likely, simply migrates faster-than-
usual by SDS-PAGE due to the high percentage of hydrophobic amino acids in this type-IV 
integral membrane protein [144]. Hydrophobic membrane proteins bind more SDS than 
globular proteins and so carry a higher charge to size ratio, resulting in faster migration through 
the acrylamide gel. This explanation is consistent with the considerable sample preparation 
optimisation that was needed for to prevent the DPY19 precipitating from sample buffer: lysis 
had to be performed in 10% SDS at 37 °C for 10 minutes immediately prior to running the 




To test if the CeDPY19 was localised to the microsomal compartments, yeast cells were 
fractionated into their subcellular components by ultracentrifugation and another western blot 
was performed on each fraction. The microsomal fractions, most likely the ER, contained 
active CeDPY19 (Figure 2.3E). To quantify the amount of CeDPY19 in the yeast, a titration 
was performed by western blot using maltose-binding protein (MBP) fused to the 3×FLAG as 
a standard (Figure 2.3F). Densitometry analysis indicated that there were around 4×105 copies 
of CeDPY19 per cell, which is an order of magnitude higher than for the 
oligosaccharyltransferase components OSTA and OSTB, which perform N-glycosylation 
within the ER. This very large number is of the same order of magnitude as for GAP, which 
was the promotor used for DPY19 in this system (Figure 2.3G) [145].  
 
Growth curves for the parental GS115 and the DPY19 cell lines demonstrated that there was 
no obvious fitness cost resulting from the overexpression of DPY19 (Figure 2.3H, I). An SDS-
PAGE for the supernatant of the GS115 and DPY19 strains grown in YPD and BMMY showed 
no obvious differences in protein secretion profiles (Figure 2.3J). Given the lack of an obvious 
phenotype upon introduction of DPY19, we did not investigate changes in the proteome or 





Figure 2. 3: Expression of tryptophan C-mannosyltransferases strain in P. pastoris 
GS115 
a) A cassette encoding DPY19 with a zeocin selectable marker was integrated into the P. 
pastoris genome by homologous recombination at the GAP promoter. 
b) Integration of the cassette encoding DPY19 was confirmed using PCR 
c) A representative western blot (α-FLAG)) of total lysates from the GS115, DPY19L1 
and DPY19L3 strains. 
d) A representative western blot (α-FLAG) of total lysate from the GS115 and DPY19 
strains. 
e) A representative western blot (α-FLAG) of sub-cellular fractions of cells from the 
GS115 and DPY19 strains. Total: total lysate; Soluble: cytosolic fraction; Microsome: 
microsomal fraction containing ER, Golgi and Mitochondria. 
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f) A representative western blot (α-FLAG) quantifying DPY19 copy number per cell 
using MBP-FLAG as a calibration standard. Densitometry was performed to estimate 
the copy number of DPY19 protein per cell.  
g) Table showing the copy number per cell of OSTA and OSTB, subunits making up the 
oligosaccharyltransferase, which perform N-glycosylation.  
h) Growth curve for GS115 demonstrating its exponential growth curve. OD600 
measurement were taken of GS115 (n=3) every 1 h for 15 h. An exponential growth 
curve was fit using Prism to obtain the rate constant k, from which doubling times were 
calculated.  
i) Growth curve for DPY19 demonstrating that there is no growth defect for cells 
harbouring DPY19. OD600 measurement were taken of DPY19 (n=3) every 1 h for 15 
h. An exponential growth curve was fit using Prism to obtain the rate constant k, from 
which doubling times were calculated.  
j) SDS-PAGE of yeast supernatants from GS115 and DPY19 strains grown in both YPD 
and BMMY media. SDS-PAGE gel is stained with Coomassie. 
 
2.2.3 – CeDPY19 in P. pastoris microsomes is catalytically competent  
An in vitro C-mannosylation radioassay was adapted for use with yeast microsomes to 
investigate if the recombinant CeDPY19 was active [14]. This radioassay utilises endogenous 
dolichol kinase and ATP to convert dolichol in the microsomal membranes to dolichol 
phosphate. Endogenous dolichol-phosphate-mannose synthase then utilises GDP to convert 
dolichol phosphate into Dol-P-Man. Use of GDP-[3H]-mannose in this assay results in the 
generation of radiolabelled Dol-P-[3H]-Man. This radiolabelled mannose is then transferred to 
tryptophan residues in the WXXW acceptor peptide. Purification of the peptide from the 
reaction mixture and scintillation counting enables one to detect tryptophan C-






Figure 2. 4: DPY19 is active in yeast and can transfer radiolabelled mannose onto 
acceptor peptides. 
a) Diagram showing the in vitro C-mannosylation reaction components and pathway. 
TBS; Tris-buffered saline; ATP: Adenosine triphosphate; ADP: Adenosine 
diphosphate; Dol: dolichol; Dol-P: dolichol phosphate; Dol-P-Man: dolichol phosphate 
mannose; GDP: guanosine diphosphate; GDP-Man: GDP-mannose.  
b) Synthetic WAKW acceptor tetrapeptide titration curve. Peptide concentrations of 1 mM 
(n=3), 0.5 mM (n=3), 0.05 mM (n=3) and 0.005 mM (n=3) were assayed. The signal to 
noise-ratio was measured for each concentration against reactions performed with 
GS115 (n=3).  
c) In vitro C-mannosylation assay using microsomes from the GS115 and DPY19 strains. 
All results are mean values ± SD. *** p<0.005. 
d) In vitro C-mannosylation assay using microsomes that were stored at -80 °C and at 4 
°C overnight. All results are mean values ± SD. 
e) In vitro C-mannosylation assay using Dol-P. Dol-P was at 200 µM. All results are mean 
values ± SD. 
f) In vitro C-mannosylation assay using Dol-P with different detergents. Dol-P was at 200 
µM. DDM: n-Dodecyl β-D-maltoside; OGT: octyl glucoside. All results are mean 
values ± SD. 
 
Microsome fractions containing DPY19 enzyme isolated from the DPY19 yeast strain showed 
significant activity as compared to the parental GS115 strain (Figure 2.4B). Omission of ATP 
did not dramatically impact mannosylation, suggesting that the dolichol phosphate 
concentration was not rate limiting for this coupled enzyme assay (Figure 2.4B). Omitting the 
acceptor peptide, the radiolabelled GDP-Man or microsomes from the experiment abrogated 
signal, as expected (Figure 2.4B). A titration of the acceptor peptide was performed to optimise 
the conditions of the DPY19 activity (Figure 2.4C). Optimal signal-to-noise was obtained for 
a peptide concentration between 50 and 500 µM. Higher concentrations increased the 
background signal and concentrations as low as 5 µM gave very little signal at all. To test the 
stability of DPY19 under different conditions, microsomes that were flash frozen at -80 °C or 
stored overnight at 4 °C were used in the assay. The results indicated that one freeze/thaw cycle 
or overnight storage at 4 °C was sufficient to inactivate the microsomes, which could be due 
to denaturation of DPY19 or one of the other enzymes involved in this coupled assay (Figure 
2.4D). We sought to the improve the signal-to-noise ratio of the assay and circumvent any 
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issues associated with the stability of dolichol kinase by the addition of dolichol-phosphate 
(Dol-P) to the reactions, as has been reported in mammalian systems [14]. However, we saw 
no improvement in signal from the assay or stability in microsome activity (Figure 2.4E) but 
did observe some precipitate form in these reactions. We assessed the impact of the detergents 
CHAPS, n-Dodecyl β-D-maltoside (DDM) and octyl glucoside (OGT) on the assay in the 
presence of Dol-P. While these detergents reduced visible precipitation, CHAPS and DDM did 
not significantly improve activity and OGT completely ablated activity (Figure 2.4F). Clearly, 
OGT may inhibit or denature DPY19 or other enzymes in the coupled assay. Collectively, the 
limited stability of enzyme activity in this microsomal assay coupled with the arduous process 
of preparing yeast microsomes dramatically diminished the utility of this assay.  
 
2.2.4 – Expression of C-mannosylated proteins in the engineered yeast strain 
Having established that CeDPY19 was active in yeast microsomes, the next step was to 
determine if the enzyme could commandeer intracellular Dol-P-Man to modify heterologous 
proteins passing through the yeast’s secretory pathway. To test this, a number of constructs 
encoding C-mannosylated proteins were prepared using the pPIC9k plasmid. This plasmid 
makes use of the strong inducible AOX1 promotor, which regulates the expression of alcohol 
oxidase 1 in P. pastoris to enable this methylotrophic yeast to utilise methanol and other 
alcohols as a source of carbon [146]. This is a very strong inducible promotor that is commonly 
used for recombinant protein expression in P. pastoris [147]. These plasmids were to be 
transformed into the GS115 parental P. pastoris strain and our engineered line that 
constitutively expresses CeDPY19. Integrants would then be selected for using histidine 
dropout media, since both of these cell lines have loss-of-function mutations in the his4 locus, 
which encodes histidinol dehydrogenase, and the pPIC9k plasmid contains a functional copy 
of this locus (Figure 2.5A).  
 
Genes encoding the ectodomain of human type-I cytokine receptors, human and C. elegans 
TSRs, the EBOV sGP and RNaseII were codon-optimised for P. pastoris, synthesized and 
cloned into the multiple cloning site of a pPIC9k plasmid that was modified to remove the 
STE13 protease site but retain the α factor pre/pro signal peptide [148, 149] (Figure 2.5B). The 
extracellular domain of the human type I cytokine receptors IL21R, EPOR and PLR were fused 
to a C-terminal hexahistidine tag and the human cytokine IL12B was fused to an N-terminal 
hexahistidine tag (Figure 2.5B). The TSR domains of human spondin-2 (mindin) and C. 
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elegans UNC5, as well as human RNaseII, were fused to an N-terminal FLAG, hexahistidine 
and SUMO tag as well as a C-terminal Strep-II tag (Figure 2.5B). EBOV sGP was fused to a 
C-terminal hexahistidine tag (Figure 2.5B). 
 
Clones for each construct in the GS115 and DPY19 strains were selected for growth on 
histidine dropout media and for their ability to grow on methanol. Integration of the expression 
construct was confirmed by PCR and individual clones were chosen for scale-up based on the 
results of small-scale protein test expressions for each clone. Protein was obtained in at least 
one of the yeast strains for all constructs except EBOV sGP. Protein production was scaled-up 
for the other seven constructs in both yeast strains. Briefly, scale-up involved growth of the 
yeast in BMGY media and induction in BMMY media, with supernatants being harvested after 
48 h (Figure 2.5C), concentrated and dialysed prior to immobilised metal ion affinity 
chromatography (IMAC), size exclusion chromatography (SEC) and ion exchange 









a) Integration of the pPIC9K cassette into the P. pastoris genome at the AOX1 promoter 
with his4 complementation.  
b) Construct design for reporter proteins produced in the GS115 and DPY19 strains. 
Cytokine receptors: IL21R, EPOR and PLR; TSRs: UNC5 and mindin. 







Figure 2. 6: Purification of reporter proteins produced in the GS115 and DPY19 strains. 
a) SDS-PAGE of reporter proteins purified from the GS115 and DPY19 strains. 3 µg of 
protein was combined with 4X SDS loading buffer and heated at 95 °C for 2 min and 
then loaded onto a SDS-PAGE gel.  
b) Size-exclusion chromatogram for IL21R-DPY19 using a s75 10/300 column.  
c) Size-exclusion chromatogram for UNC5-DPY19 using a s75 10/300 column.  
d) Size-exclusion chromatogram for EPOR-GS115 and EPOR-DPY19 using a s75 10/300 
column.  
e) Size-exclusion chromatogram for PLR-GS115 and PLR-DPY19 using a s75 10/300 
column.  
f) Size-exclusion chromatogram for IL12B-GS115 and IL12B-DPY19 using a s75 10/300 
column.  
g) Size-exclusion chromatogram for mindin-GS115 and mindin-DPY19 using a s75 
10/300 column.  
h) Size-exclusion chromatogram for RNaseII-GS115 and RNaseII-DPY19 using a s200 
10/300 column.  
 
A marked increase in protein expression yields was observed for many proteins in the yeast 
harbouring CeDPY19 relative to the parental GS115 strain. The C. elegans UNC5 TSR and 
human IL21R ectodomain only expressed in the presence of CeDPY19, providing excellent 
yields of 14 mg/L and 10 mg/L, respectively (Table 2.3): no protein was obtained from the 
GS115 strain (Table 2.3). This suggests that tryptophan C-mannosylation is required for the 
folding, trafficking and/or stability of these proteins. Similarly, a four-fold increase in protein 
production was observed for the human EPOR ectodomain and the mindin TSR in the presence 
of CeDPY19 (Table 2.3). For IL12B, there was a two-fold increase in protein secretion for 
protein produced in the CeDPY19 strain (4 mg/L) as compared to protein produced in the 
GS115 strain (2 mg/L) (Table 2.3). RNaseII also showed a two-fold increase in secretion for 
protein produced in the presence of CeDPY19 (Table 2.3). There was no difference in protein 
production observed for the human PLR ectodomain (Table 2.3). Unfortunately, EBOV sGP 
did not express in neither the GS115 or in the presence of CeDPY19 (Table 2.3). Perhaps this 
the protein construct can be optimised for the future production of this protein. Proteins 
produced in the DPY19 and GS115 strains appeared identical by SDS-PAGE (Figure 2.6A), 
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consistent with the fact that tryptophan mannosylation adds only 162 Da to the protein and this 
is just a small fraction of the protein’s molecular mass. 
 
Table 2. 3: Summary of proteins produced in the GS115 and DPY19 strains. 
	
	
2.2.5 – Analysis of recombinant protein glycosylation using mass spectrometry 
The proteins produced in yeast with and without CeDPY19 were analysed by mass 
spectrometry to assess the degree to which they were C-mannosylated. Each protein was 
proteolytically digested with an appropriate enzyme (Table 2.3) to generate a peptide spanning 
the WXXW consensus motif that could be analysed by LC-MS/MS. LC-MS and semi-
quantitation using extracted ion-counts (EIC) provided a means to approximate the relative 
abundance of each glycoform in the protein samples. Collision-induced dissociation (CID) and 
higher-energy collision dissociation (HCD) MS/MS methods were then used to sequence each 
peptide and localise the C-mannosylation sites.  
 
IL21R produced in the presence of CeDPY19 was digested with clostripain to provide the 
peptide 202AGPMPGSSYQGTWSEWSDPVIFQTQSEELKE232HHHHHH, which was 
observed in the unmodified, mono-hexosylated and di-hexosylated forms (Figure 2.7A). The 
mono-hexosylated peptide at RT = 30.53 min accounted for ≈23% of total peptide and HCD-
MS/MS localised the C-mannosylation site to W214, the first W of the WXXW motif (Figure 
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2.7B). The di-hexosylated peptide at RT = 29.42 min accounted for ≈76% of total peptide and 
HCD-MS/MS localised the C-mannosylation sites to W214 and W217 (Figure 2.7C). The 
unmodified peptide at RT = 31.65 min accounted for <1% of total peptide. No IL21R was 
obtained in the absence of CeDPY19 and so comparable analysis of protein lacking C-
mannosylation was not possible. 
	
	
Figure 2. 7: Interleukin 21 receptor (IL21R) is C-mannosylated on both Trp214 and 
Trp217.  
a) Extracted ion chromatograms of the observed glycoforms of the peptide of interest for 
IL21R produced in the DPY19 strain. Il21R was digested with clostripain. Green circle 
represents a mannose molecule. 
b) HCD MS/MS spectrum for singly C-mannosylated IL21R peptide 
c) HCD MS/MS spectrum for doubly C-mannosylated IL21R peptide. 
 
EPOR produced in the presence of CeDPY19 was reduced, alkylated and digested with 
LysArgiNase to produce a peptide 223RMAEPSFGGFWSAWSEPVSLLTPSDLD249 which 
was only observed in the unmodified and singly C-mannosylated form (Figure 2.8A, B). EPOR 
was C-mannosylated on Trp233 but is not modified on the second tryptophan residue and the 
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singly modified form accounts for ≈70% of total peptide while the unmodified form accounts 
for ≈30% of total peptide (Table 2.3). Similar analysis of EPOR produced in the absence of 
CeDPY19 showed no evidence of tryptophan mannosylation. Given that there was no change 
in secretion levels between PRLR produced in the GS115 strain and the presence of CeDPY19 
we opted to examine both of these samples using intact LC-MS. Figure 2.8C and 2.8D show 
that there is no major difference between the molecular weights of PRLR produced in the 
GS115 strain (27695 Da) and in the presence of CeDPY19 (27678 Da). We then decided to 
investigate the peptide fragmentation profile of PRLR produced in both strains using Lys-C 
and figure 2.8C and 2.8D show that both the samples produced identical fragmentation pattern 





Figure 2. 8: Erythropoietin receptor (EPOR) is singly modified on Trp233 and prolactin 
receptor (PRLR) is not C-mannosylated. 
a) HCD MS/MS spectrum for unmodified EPOR 
b) HCD MS/MS spectrum for singly modified EPOR 
c) Extracted ion chromatogram and (CID) MS/MS of PRLR produced in the GS115 strain 
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d) Extracted ion chromatogram and (CID) MS/MS of PRLR produced in the DPY19 strain 
 
 
IL12B produced in the presence of CeDPY19 was reduced, alkylated, and treated with Lys-C 
protease to provide the peptide of interest 309AQDRYYSSSWSEWASVPCS328, which was 
observed by LC-MS in the unmodified, mono-hexosylated and di-hexosylated forms (Figure 
2.9A). The unmodified peptide was observed at RT = 49.15 min and accounted for ≈3% of 
total peptide (Figure 2.9B). The mono-hexosylated peptide at RT = 43.96 min was only ≈ 4% 
abundance with C-mannosylation at W318 (Figure 2.9C). The majority of the peptide was in the 
di-hexosylated form at RT = 36.98 min with an abundance of ≈93% and C-mannosylation at 
W318 and W321 (Figure 2.9D). Similar analysis of IL12B produced in the absence of CeDPY19 
showed no evidence of tryptophan mannosylation. 
	
	
Figure 2. 9: Interleukin 12B (IL12B) is C-mannosylated predominantly on Trp318 and 
Trp321. 
a) Extracted ion chromatograms of the observed glycoforms of the peptide of interest for 
IL12B produced in the DPY19 strain. Il12B was digested with Lys-C protease. Green 
circle represents a mannose molecule. 
b) HCD MS/MS spectrum for unmodified IL12B peptide 
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c) HCD MS/MS spectrum for singly C-mannosylated IL12B peptide. 
d) HCD MS/MS spectrum for doubly C-mannosylated IL12B peptide. 
 
UNC5 produced in the presence of CeDPY19 was reduced, alkylated, and treated with trypsin 
to provide the peptide 83LDGGWSSWSDWSACSSSCHR292. LC-MS could scarcely detect the 
unmodified peptide at RT = 46.93 min and the singly modified peptide at RT = 41.49 min, with 
both accounting for <0.1% of the total peptide (Figure 2.10A). HCD-MS/MS was used to 
fragment the singly modified peptide to localise the site of glycosylation to W290 (Figure 
2.10B). The doubly modified peptide at RT = 36.30 min comprised ≈54% (Figure 2.10A) of 
total peptide and glycosylated on W287 and W290 (Figure 2.10C). The triply modified peptide 
at RT = 30.01 min accounted for ≈45% of total peptide (Figure 2.10A) and had C-
mannosylation at W287, W290 and W293 (Figure 2.10D). No UNC5 was obtained in the absence 
of CeDPY19 and so comparable analysis of protein lacking C-mannosylation was not possible. 
	
	
Figure 2. 10: UNC5 is C-mannosylated on Trp287, Trp290 and Trp293.  
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a) Extracted ion chromatograms of the observed glycoforms of the peptide of interest for 
UNC5 produced in the DPY19 strain. UNC5 was digested with trypsin. Green circle 
represents a mannose molecule. 
b) HCD MS/MS spectrum for singly C-mannosylated UNC5 peptide. 
c) HCD MS/MS spectrum for doubly C-mannosylated UNC5 peptide. 
d) HCD MS/MS spectrum for triply C-mannosylated UNC5 peptide. 
 
 
Mindin produced in the presence of CeDPY19 was reduced, alkylated and proteolysed using 
trypsin to provide the peptide EQIGGTS277DCEVSLWSSWGLCGGHCGR295, which LC-
MS/MS revealed to be present in the unmodified, mono- and di- hexosylated forms (Figure 
2.11A). The mono-hexosylated peptide at RT = 48.10 min accounted for ≈15% of total peptide 
count and C-mannosylation was localised to W283 (Figure 2.11B). The di-hexosylated tryptic 
peptide at RT = 41.79 min accounted for ≈84% of total peptide and C-mannosylation sites were 
localised to W283 and W286 (Figure 2.11C). The unmodified form of the peptide at RT = 52.54 
min accounted for <0.1% of total peptide. Similar analysis of mindin produced in the absence 
of CeDPY19 showed no evidence of tryptophan mannosylation. 
 
RNaseII produced in the presence of CeDPY19 was treated with Glu-C protease to provide the 
peptide NLYFQG28KPPQFTWAQWFE39, which LC-MS analysis revealed to be present as the 
unmodified, mono-hexosylated and di-hexosylated forms (Figure 2.12A). The majority of the 
peptide was observed in the mono-hexosylated form at RT = 68.49 min and accounted for 
≈99.8 % of the sample and was C-mannosylated on W34 (Figure 2.12B). The di-hexosylated 
form at RT = 62.23 min accounted for only ≈0.1% and C-mannosylation occurred at W34 and 






Figure 2. 11: Mindin is C-mannosylated on Trp283 and Trp286. 
a) Extracted ion chromatograms of the observed glycoforms of the peptide of interest for 
mindin produced in the DPY19 strain. Mindin was treated with trypsin. Green circle 
represents a mannose molecule. 
b) HCD MS/MS spectrum for singly C-mannosylated mindin peptide. 








Figure 2. 12: RNaseII is predominantly C-mannosylated on Trp34. 
a) Extracted ion chromatograms of the observed glycoforms of the peptide of interest for 
RNaseII produced in the DPY19 strain. RNaseII was digested with Glu-C protease. 
Green circle represents a mannose molecule. 
b) HCD MS/MS spectrum for singly C-mannosylated RNaseII peptide 
 
2.3 - Discussion 
 
There are over 500 proteins in the human proteome that contain the WXXW motif and pass 
the secretory pathway, making them potential substrates for tryptophan mannosylation [13]. 
Currently, just over 20 human proteins have been found with C-mannosyl-tryptophan though 
there is no doubt that this number will increase with the passage of time. The impact of this 
modification on protein fold and function remains unknown. In this chapter, a functional C-
mannosylation pathway has been engineered into the yeast P. pastoris to enable the study of 
DPY19 glycosyltransferases and the production of recombinant proteins with and without 
tryptophan mannosylation to probe the biological role(s) of this enigmatic protein modification.  
 
This work compliments on-going efforts to ‘humanise’ the glycosylation pathways of P. 
pastoris to provide a cheap and efficient protein production platform for the biopharmaceutical 
industry. Producing proteins with human-like glycosylation is critical to ensure the proper 
function of the protein, optimise stability and pharmacokinetics and minimise antigenicity 
[150]. Although yeast ordinarily hyper-mannosylate proteins, they can accommodate dramatic 
changes to their glycosylation pathways and are easy to genetically manipulate. P. pastoris 
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strains with humanised N-glycosylation already exist and have been used in the biotechnology 
industry [134, 136]. O-linked glycosylation has also been engineered in P. pastoris to produce 
proteins with human-like sialylated O-linked glycans [141]. The present work, while more 
modest in scope than these efforts, compliments N- and O-glycan engineering to provide 
human-like C-mannosylation in P. pastoris.  
 
How well the glycosylation patterns on the human proteins we have produced here emulate 
those of endogenous human proteins is difficult to assess because so few endogenous proteins 
have had their C-mannosylated examined. Indeed, RNaseII is the only protein isolated from 
human samples (urine) to be analysed for C-mannosylation: all other samples examined in the 
literature are recombinant proteins produced in human cell lines (e.g. HEK293). RNaseII 
purified from human urine is exclusively singly C-mannosylated. Our recombinant RNaseII 
expressed in the presence of CeDPY19 is 99.8% singly C-mannosylated [8]. While this is only 
a single data point, it is suggestive that this engineered system produces proteins with human-
like patterns of tryptophan C-mannosylation. 
 
Our protein expression data suggest that C-mannosylation aids in the proper folding and/or 
trafficking of some, but not all, proteins with a WXXW consensus motif. Previous efforts to 
probe the function of C-mannosylation involved mutating tryptophan residues in the WXXW 
motif to phenylalanine and alanine [21, 45, 57, 71]. The WXXW motif in many of these 
proteins forms π-cation tryptophan ladder motif, which involves the planar stacking 
arrangement of the guanidinium moiety of arginine over the centre of the aromatic ring of 
tryptophan to stabilise protein fold [19]. As such, it is difficult to interpret what these mutation 
studies say about tryptophan mannosylation. Nonetheless, such mutations in the WXXW motif 
of IL21R prevented the receptor from being trafficked to the cell surface [21], which mimics 
what we observe for IL21R in yeast lacking CeDPY19. Collectively this data implies that 
tryptophan C-mannosylation is important for the folding and/or trafficking of IL21R. Similar 
studies have been done for the thrombopoietin receptor (TPOR), common gamma chain, and 
Punctin-1: mutations in the tryptophan residues of the WXXW motif resulted in impaired 
trafficking to the cell surface [57] [63]. It would be interesting to see if our system could verify 





Interestingly, not all proteins with a WXXW are modified by C-mannosyltransferases, even 
when both are expressed at high levels, as was the case for the prolactin receptor (PRLR) in 
our yeast bearing CeDPY19. Both the parental GS115 and engineered yeast lines produced the 
same amount of unglycosylated protein, revealing that the WXXW consensus motif is 
necessary but not sufficient for tryptophan mannosylation. We rationalise this observation by 
postulating that the DPY19 enzyme only acts on unfolded or misfolded polypeptides in a co-
translational sense such that proteins that rapidly attain their native fold without the need for 
glycosylation will not be available for modification by the DPY19 enzyme.  
 
This simple examination of differences in protein expression levels helps to build the narrative 
that tryptophan C-mannosylation play a significant role in protein folding. The means to 
produce protein with and without the modification enables a more quantitative study of impacts 
on protein stability and function, which is addressed in the next chapter. 
 
The mass spectrometry data compiled here also begins to provide insights into the substrate 
preferences of the CeDPY19 enzyme. It has been established that the tryptophan 
mannosyltransferases preferentially modify the N-terminal Trp of the WXXW motif. Close 
examination of the data for UNC5 reveals that, of the three possible mannosylation sites in the 
WSSWSDW peptide, it is the second site that is preferentially modified, followed by the first 
site. Could it be then that the WSDW motif binds preferentially to CeDPY19 over the WSSW 
peptide? The substrate preferences and tolerances of the CeDPY19 enzyme is something that 
can be conveniently studied with the yeast system and will be addressed in later chapters. 
 
 
2.4 - Conclusions 
 
This chapter has described an engineered P. pastoris that enables the production of 
recombinant proteins with tryptophan C-mannosylation. This could be useful for the 
production of biologics like IL12B and vaccines against malaria or, with more optimisation, 
the Ebola virus. In at least one case, recombinant protein produced in this system had identical 
C-mannosylation to endogenous human samples. Protein expression data from this yeast 
system supported the idea that tryptophan mannosylation plays a role in protein folding and 
trafficking. Having the means to produce recombinant proteins with and without C-
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mannosylation now provides the means to examine this in great detail, explore the impact C-
mannosylation has on protein function and generate of antibody tools to detect the 
modification. This system also enables further study of the DPY19 enzyme by enabling the 
facile introduction of mutations to the enzyme or its substrates. All of the ideas are probed in 









Insights into the function of tryptophan C-mannosylation  
 
3.1 - Introduction 
 
Since the discovery of the first C2-α-D-mannosyl-tryptophan on RNaseII in 1994, the function 
of this unusual modification has remained elusive [8]. The reason for this is because the genetic 
identity of the enzyme that catalyses this reaction remained a mystery. This was until the 
discovery of the first C-mannosyltransferase gene, dpy19, in C. elegans in 2013 which paved 
the way for study of this modification [68]. Previous studies have sought to elucidate a role for 
tryptophan C-mannosylation through mutagenesis of the tryptophan residues in the WXXW 
consensus motif to phenylalanine and alanine [21, 57, 63, 71]. Mutagenesis of the C-
mannosylated WSEW motif in IL21R to FSEW perturbed protein trafficking, resulting in 
accumulation of the receptor in the ER and very little IL21R at the cell surface [21]. Similar 
results have been observed for IL2RG, TPOR, R-spondin and Punctin [21, 57, 63, 71]. It 
remains unclear as to whether or not these trafficking defects are a result of the amino acid 
substitutions, a loss of C-mannosylation, or both.  
In all of these proteins, the WXXW motif is involved in the formation of a tryptophan ladder 
motif, which is found in both the extracellular domains of type I cytokine receptors and TSR 
domains [17, 18]. Thus, it is likely that these Trp to Phe or Ala substitutions play a significant 
role in destabilising these proteins. This would mean that the lack of secretion of these proteins 
in these previous studies were not a result of a lack of C-mannosylation. Indeed, similar 
mutations on C-mannosylated proteins lacking a tryptophan ladder, such as lipoprotein lipase 
(LPL), actually resulted in an apparent reduction of LPL activity [97]. Though it should be 
noted that this data was collected on crude cell lysate without the determination of Michaelis-
Menten parameters, making it difficult to draw meaningful conclusions about the role of C-
mannosylation on LPL function. 
 
In Chapter 2 of this thesis, I took advantage of the discovery of the dpy19 gene and integrated 
it into P. pastoris. This enabled the production of proteins with and without the modification, 
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which provides an opportunity to examine the function of this modification on a number of 
proteins without any confounding mutagenesis. One of these proteins was the TSR domain of 
mindin.  
 
Mindin (Spondin-2) is an extracellular matrix protein belonging to the F-spondin protein family 
and with a variety of different functions (Figure 3.1A) [75-80]. Mindin contains a TSR domain 
and a spondin domain, where the spondin domain is known to bind to αMβ2 integrin on 
macrophage cell surfaces [69]. The primary function of mindin is to serve as a pathogen 
recognition molecule where it recognises LPS on bacterial cell surfaces and serves as an opsin 
for phagocytosis by macrophages [81]. There have been studies conducted to elucidate which 
domain of mindin binds to LPS and lipid A, but this has not been successful because the TSR 
domain could not be expressed. 
	
	
Figure 3. 1: Functions of Spondin-2 (mindin) in humans through its effects on different 
cells and organisms 
a) Diagram illustrating the myriad of roles that mindin plays for certain cell types.  





This Chapter examines the role of C-mannosylation on the stability and function of mindin and 
other proteins. 
3.2 - Results 
 
3.2.1 - C-mannosylation stabilises proteins to thermal denaturation 
 
In Chapter 2, we expressed a number of proteins in Pichia pastoris in the presence and absence 
of DPY19 to produce proteins with and without C-mannosylation, respectively. The yields of 
many proteins were higher when C-mannosylated: on average protein yields were 2-fold higher 
in the presence of DPY19. Interestingly, UNC5 and IL21R did not secrete at all without C-
mannosylation, suggesting that these proteins failed to fold or were unstable without the C2-α-
D-mannosyl-tryptophan. Differential scanning fluorimetry (DSF) provides a convenient means 
to examine the thermal stability of proteins [151]. DSF works by gradually heating proteins in 
the presence of a dye such as SYPRO orange, which fluoresces more strongly when it binds to 
hydrophobic amino acids that become solvent exposed upon denaturation (Figure 3.2A). 
RNaseII, IL12B and EPOR with and without C2-α-D-mannosyl-tryptophan were analysed by 
DSF. RNaseII, EPOR and IL12B with C2-α-D-mannosyl-tryptophan had a 2, 4, and 2- fold 
increase in their secretion, respectively, as compared to protein without C2-α-D-mannosyl-
tryptophan (Figure 3.2B). Tryptophan mannosylation increased the thermal stability of 
RNaseII by 2.2 ± 0.12 °C (Figure 3.2C, D), EPOR by 3.5 ± 0.1 °C, and IL12B by 5.0 ± 0.1 °C 






Figure 3. 2: C-mannosylation stabilises proteins and is required for the proper folding 
and secretion of target proteins. 
a) Diagram depicting the fold-state of protein undergoing thermal denaturation and 
binding of dye (blue stars) to hydrophobic residues buried in the protein structure. 
b) Table showing a summary of fold-increase in protein secretion for rRNaseII, rEPOR, 
rIL12B for protein produced with C2-α-D-mannosyl-tryptophan. 
c) Table showing a summary of the difference in melting temperature (Tm) of proteins 
with a C2-α-D-mannosyl-tryptophan as compare to protein without. Data is presented 
as mean ± standard deviation with triplicates.  
d) Thermal denaturation profiles for rRNaseII, rEPOR, rIL12B with and without C2-α-D-
mannosyl-tryptophan. The denaturation profiles are representations of the average of 
three replicates. 2 µg of rRNaseII, rEPOR, rIL12B was used in the assay. The data was 
trimmed to give a sigmoid and it was then normalised and a Boltzmann sigmoidal curve 






3.2.2 - C-Mannosylation does not impact RNaseII activity 
 
RNaseII is a protein with myriad functions, though its most important property is its RNase 
activity. Other functions include its ability to activate dendritic cells and serve as a 
chemoattractant for these cells, its anti-viral activity and its ability to activate toll-like receptor 
2 (TLR2) [152-156]. Tryptophan mannosylation may play a role in a number of these functions, 
though the simplest to assay for is the RNase activity. The RNase assay utilised here takes 
advantage of ethidium bromide’s fluorescence at 450 nm when bound to RNA [157]. I first 
titrated the RNA while keeping ethidium bromide concentration constant to find a RNA 
concentration range that gave a linear response (Figure 3.3A). When RNaseII hydrolyses these 
RNA molecules it disrupts binding of the ethidium bromide, resulting in a decay in florescence 
that can be used to determine enzyme kinetics (Figure 3.3B). Working within this RNA 
concentration range, I examined the kinetic activity of RNaseII with and without C-
mannosylation by keeping the enzyme concentration and ethidium bromide constant while 
titrating RNA concentrations from 0 to 60 µg/ml. In this concentration range, we do not see 
saturation of the enzyme with substrate in the Michaelis-Menten curves, which precludes us 
from determining kcat and KM values individually, only kcat/KM values. RNaseII-GS115, which 
lacked C2-α-D-mannosyl-tryptophan had a kcat/KM value of 2.3 ± 0.2 ml µg-1 s-1 (Figure 3.3C). 
RNaseII-DPY19, which possessed a single C2-α-D-mannosyl-tryptophan, had a kcat/KM value 
of 2.0 ± 0.3 ml µg-1 s-1 (Figure 3.3D). These values are within standard error of each other, 




Figure 3. 3: C-mannosylation stabilises secreted RNaseII but is not required for 
catalytic activity 
a) Dose-response curve for ethidium bromide (4 µM) with different concentrations of 
RNA (0-400 µg/ml). 
b) Decay of fluorescence once RNaseII-GS115 (green) and RNaseII-DPY19 (red) is 
added to ethidium bromide and RNA (black) over time.  
c) Michaelis-Menten plot for RNaseII-GS115 
d) Michaelis-Menten plot for RNaseII-DPY19 
 
3.2.3 - The TSR domain of Spondin-2 (mindin) mediates binding to LPS and this activity 
is influenced by tryptophan mannosylation 
Mindin (Spondin-2) is an extracellular matrix protein with several different functions [75-80]. 
Its primary function is to serve as a pathogen recognition molecule, where it recognises LPS 
on bacterial cell surfaces and serves as an opsin for phagocytosis by macrophages [81]. Mice 
lacking mindin cannot clear pathogens and macrophages deficient in mindin show defective 
responses to microbial stimuli [81]. Mindin is comprised of two domains, a spondin domain 
(31-221) and a TSR domain (277-331) in which W283 and W286 of the TSR domain are C-
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mannosylated (Figure 3.4A). Full-length mindin produced in mammalian cells shows 
significant binding to LPS, while just the spondin domain from mammalian cells or the full-
length mindin produced in bacterial cells has very little binding to LPS. Together, this suggests 
that the TSR domain of mindin and tryptophan mannosylation may be important for the LPS-
binding properties of mindin. 
The means to produce the TSR domain of mindin with and without C2-α-D-mannosyl-
tryptophan provided an opportunity to explore these questions. Attempts to examine the 
thermal stability of mindin with and without tryptophan mannosylation were thwarted by the 
inability of SYPRO orange to provide a meaningful thermal denaturation profile (data not 
shown). Some proteins are not amendable to DSF because they contain exposed hydrophobic 
residues that bind to SYPRO orange in both the folded and unfolded states, providing a 
saturated signal even before denaturation.  
To test the hypothesis that the TSR domain was binding to LPS and that C-mannosylation 
might play a role in this binding, we established an enzyme-linked immunosorbent assay 
(ELISA) for LPS binding. In this ELISA, 96-well plates were coated with the recombinant 
mindin TSR with and without C2-α-D-mannosyl-tryptophan, the production of which is 
outlined in Chapter 2, then blocked the plates with BSA, followed by incubation with LPS 
(Figure 3.4B). After washing, these wells were then probed with a mouse anti-LPS antibody 
followed by an anti-mouse IgG antibody conjugated to HRP and developed using a standard 
ELISA chromogenic reagent.  
 
Figure 3.4C shows that mindin TSR domains, with or without C2-α-D-mannosyl-tryptophan, 
are necessary and sufficient for LPS binding. We examined the use of BSA as a control for 
binding to LPS but we saw significant binding to LPS (Figure 3.4C). BSA is known to bind to 
LPS when BSA is coated on plates using high pH [158]. We therefore sought to optimise the 
negative control and explored the use of casein which does not bind LPS. To see if C-
mannosylation plays a role in the binding of mindin to LPS, the concentration of both mindin 
TSR samples were kept constant and the concentration of LPS was varied. Figure 3.4D shows 
that the mindin TSR without C2-α-D-mannosyl-tryptophan shows greater binding capacity to 
LPS than the sample with C2-α-D-mannosyl-tryptophan. Thus, it appears that C2-α-D-
mannosyl-tryptophan can reduce the affinity of LPS for the mindin TSR and thus regulate the 
activity of this protein. Questions as to which mannosylation site is most responsible for this 
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reduced binding and whether or not this glycosylation directly impedes LPS binding or acts 
through an allosteric mechanism remains to be explored. 
	
	
Figure 3. 4: The TSR domain of Spondin-2 (mindin) mediates binding to LPS and is 
required for phagocytosis and T-cell priming 
a) Schematic of the domain architecture of mindin. Red lines in the TSR domain of mindin 
denote the sites of C-mannosylation (W283 and W286). 
b) Flowchart showing how the mindin-LPS enzyme-linked immunosorbent assay 
(ELISA) was conducted. 
c) Mindin-LPS ELISA showing all appropriate controls. All data is in triplicates.  
d) Dose-response curve for mindin-LPS binding. X-axis is in log10 scale. 
 
 
3.3 - Discussion 
 
For the first time, we show that C-mannosylation directly stabilises proteins by engineering a 
system that allows the direct comparison of proteins with and without a C2-α-D-mannosyl-
tryptophan. Our results are not confounded by disruption of the tryptophan ladder through 
mutagenesis of the tryptophan residues and any effect we see is a direct consequence of the 
presence or absence of a C2-α-D-mannosyl-tryptophan. In chapter 2, we discovered that 
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proteins produced in the DPY19 strain with a C2-α-D-mannosyl-tryptophan had on average a 
2 to 5-fold increase in their secretion. For Il21R and UNC5 they would only be secreted when 
they were produced in the DPY19 strain with a C2-α-D-mannosyl-tryptophan. This promoted 
the hypothesis that C-mannosylation might have been playing a stabilising role thereby 
facilitating proper folding and trafficking to the cell surface to be secreted. Our differential 
scanning fluorimetry results in this chapter give unprecedented evidence that the C2-α-D-
mannosyl-tryptophan actually stabilises proteins such as RNaseII, EPOR and IL12B.  
 
Therapeutically, being able to modulate and control whether certain proteins go to the cells 
surface to conduct their function may be highly useful. For instance, IL6 is a driver for certain 
myeloproliferative disorders and the cancer is dependent on IL6 to proliferate and survive 
[159]. If C-mannosylation is needed for the IL6 receptor (IL6Rα) to be secreted to the cell 
surface, then an inhibitor that inhibits C-mannosylation could be beneficial for killing these 
cancers. Il7R is another example where it drives proliferation of T-cells and causes T-cell acute 
lymphoblastic leukaemia (T-ALL) [160]. Il21R is another protein where inhibiting it from 
travelling to the cell surface might be beneficial in rheumatoid arthritis where it is implicated 
in the progression of pathogenesis [161]. Another great example is UNC5C, which is a protein 
with two TSR domains which is involved with axon guidance, apoptosis and cell migration. A 
mutation in UNC5C has implicated it Alzheimer’s disease [162]. The mutation causes 
increased neuronal cell death and increase sensitivity to beta-amyloid peptide [162]. We have 
shown in chapter 2 that the C. elegans homologue of UNC5C does not secreted if it is not C-
mannosylated.  
 
A 19-amino acid miniature protein containing only a tryptophan ladder showed that tryptophan 
ladders stabilise proteins by -5.5 kcal/mol [20]. The tryptophan ladder is a structural element 
containing a WXXW motif that is characterised by π-cation interactions between two 
tryptophan residues and an arginine residue [17] [18]. Many C-mannosylated proteins such as 
type I cytokine receptors and thrombospondin type 1 repeats contain tryptophan ladders. An 
interesting study would be to produce this miniaturised protein with a C2-α-D-mannosyl-
tryptophan to investigate the role of C-mannosylation in tryptophan ladders. It could be that C-
mannosylation helps facilitate the stabilisation of tryptophan ladders and it would be interesting 





In light of the fact that C-mannosylation stabilises proteins, we wanted to further characterise 
the function of modification. We looked to the protein RNaseII (or Eosinophil-derived 
neurotoxin), where one of the functions of RNaseII is to be secreted from eosinophils, 
neutrophils and basophils into the blood stream and acts as an anti-microbial by targeting viral 
RNA. For RNaseII, we show that C-mannosylation stabilises the protein but has no effect on 
the enzymatic activity of RNaseII. Given that RNaseII may need a longer half-life in the blood 
stream in order for it to find and degrade viral RNA, the C2-α-D-mannosyl-tryptophan attached 
to the tryptophan residue is helping it achieve this longer half-life through a 
shielding/stabilising effect. RNaseA is very similar in amino acid sequence with RNaseII but 
does not have the WXXW motif. This protein is secreted from the pancreas and does not need 
to travel long distances to reach its targets and may be why it is not C-mannosylated.  
 
We have uncovered that the thrombospondin type I repeat (TSR) domain of mindin is 
responsible for binding to LPS which then leads to phagocytosis of bacterial pathogens [81]. 
Previous work around mindin’s role in binding to LPS could not shed light on which domain 
of mindin was causing this interaction because they could not express the TSR domain on its 
own. The spondin domain is known to bind to αMβ2 integrin on macrophage cell surfaces [69]. 
Unfortunately, there is no known structure of the TSR domain of mindin because it has not 
been recombinantly expressed before. A structure of the TSR domain of mindin with and 
without LPS bound would give insight into how this important process works on a molecular 
level. A possible mechanism of how this process works is that the spondin domain of mindin 
binds to macrophage cells surface via αMβ2 integrin, this leaves the TSR domain exposed. Once 
the TSR domain comes in contact with LPS on the cells surface of bacteria, it undergoes a 
conformational change upon binding to LPS and sends a downstream signal to macrophages 
that activates them for phagocytosis. Another question to ask is why there a need for the C2-α-
D-mannosyl-tryptophan on mindin if it negatively affects its ability to bind to LPS? Is it there 
as a control mechanism to finely tune the amount of LPS that mindin binds to? How does that 
benefit humans? Perhaps the C2-α-D-mannosyl-tryptophan’s role in stabilising mindin is more 
important than its role in LPS recognition? 
 
TSR domains are inherently difficult domains to recombinantly express because they are 
disulphide rich proteins. Most attempts at expression in E. coli have failed or have given very 
low expression levels making it impossible to crystallise these structures. With over 100 TSR 
domain containing proteins in the human proteome, only three of them have structures of which 
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only one has a crystal structure. Available in the PDB is an NMR solution structure of Spondin-
1 TSR domain (1SZL), a solution structure of a properdin TSR domain (1W0R), and a crystal 
structure of thrombospondin-1 TSR domain 2 and 3 (3R6B). There is also a NMR solution 
structure of Plasmodium TRAP TSR domain (2BBX), and a crystal structure of 
circumsporozoite protein TSR domain (3VDJ). We now have a system where we have 
engineered a crucial PM into that will allow the recombinant expression of many TSR domain 
containing proteins. For instance, brain-specific angiogenesis inhibitor 1 (BAI) is a protein that 
binds to phosphatidylserine on the cell surface of cells undergoing apoptosis for recognition by 
macrophages for phagocytosis [163]. BAI has five TSR domains and a GPS domain that 
anchors the protein onto the cell membrane. The TSR domains likely mediates binding to 
phosphatidylserine in a similar way that the TSR domain in mindin binds to LPS. Being able 
to express the TSR domains of BAI in our system to crystallise them with phosphatidylserine 
would allow us to understand how this fundamental process occurs. 
 
3.4 - Conclusions 
 
In conclusion, we have used our glycoengineered yeast strain to decipher the molecular and 
functional role of C-mannosylation by producing proteins with and without the modification. 
We have found that C-mannosylation plays a stabilising role in RNaseII, EPOR and IL12B. 
Our work found that C-mannosylation does not play a role in the RNase activity of RNaseII. 
Furthermore, we found that the TSR domain of mindin is responsible for its LPS binding 







Mutagenic study of the C. elegans C-mannosyltransferase DPY19 
 
 
4.1 - Introduction 
The DPY19 enzymes are unusual in their ability to form carbon-carbon bonds between proteins 
and sugars. Much remains unknown about this irreversible process, including the enzyme’s 
mechanism and which residues are involved in catalysis. Since the discovery of first C-
mannosyltransferase gene, dpy19 or DumPY-19, in C. elegans, very little has been said about 
how this enzyme might work. From a chemical standpoint, the unique carbon-carbon bond 
formation is very interesting.  
 
Dpy19 was initially discovered as a C-mannosyltransferase based on its perceived homology 
to bacterial OST and eukaryotic STTA/B, which are the enzymes responsible for N-
glycosylation [68]. The authors also concluded that since both N-glycosylation and C-
mannosylation use Dol-P-Man as a sugar donor substrate, that the C-mannosyltransferase must 
reside in the ER. However, it must be stressed that the DPY19 enzymes are still markedly 
different to the OST enzymes at a sequence level and in their predicted membrane topology 
[68].  
 
In silico analysis of human DPY19L3 using a number of different transmembrane prediction 
software packages has found that DPY19L3 most likely has 11 transmembrane helices [164], 
with the N-terminus projected into the ER lumen and the C-terminus projected into the 
cytoplasm. Two major non-transmembrane loops at residues 65 to 155 and 359 to 415 are 
predicted to project into the cytoplasm [164]. The other two major non-transmembrane loops 
from residue 437 to 466 and 499 to 523 are predicted to project into the ER lumen. Of course, 
structural studies are still needed to confirm these results. However, it is important to note that 
DPY19L3 is very different to the C. elegans DPY19 and these studies done on DPY19L3 may 
not inform us on how DPY19 works. 
 
Given that nothing is known about what features of the C-mannosyltransferases are important 
for catalysis, I decided to use the yeast system developed in Chapter 2 to perform some 
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mutagenesis studies to examine which conserved features are important for the catalytic 
activities of these unusual enzymes. 
 
4.2 - Results 
 
4.2.1 - The DPY19 family has several conserved amino acids among different phyla 
 
Multiple sequence alignments of diverse dpy19 homologues from organisms were used to 
identify residues that were conserved across the DPY19 family. For these alignments, the 
recently discovered human C-mannosyltransferases dpy19l1 and dpy19l3, along with dpy19 
homologues from organisms with only one dpy19 gene (Figure 4.1B) were used to improve the 
likelihood that only active C-mannosyltransferases were being compared. With this analysis, 
eight amino acid residues were identified, including: Y75, E102, E112, E118, H375, E579, 
R586, and Y591 (Figure 4.1B). The location of these residues is shown with respect to the 
predicted topology of C. elegans DPY19 in figure 4.1A. Seven out of eight of these residues 
lay in regions predicted to be in the ER lumen, and in two regions of non-transmembrane loops 





Figure 4. 1: The DPY19 gene family is highly conserved among different organisms 
a) Illustration of the predicted topology of the C. elegans DPY19 enzyme with annotation 
of conserved residues.  
b) Alignment and annotation of different DPY19 homologues from a wide range of 
organism highlighting the discovered conserved amino acid residues. 
 
4.2.2 - A key conserved residue amongst the DPY19 family is crucial for catalysis 
 
In order to explore the roles of these residues in catalysis, we made alanine or phenylalanine 
mutants of these conserved residues. Testing the activity of eight mutants using in vitro and 
cellular assays would be very time consuming. We therefore wanted to short-list mutants based 
on their in vitro activity, and take the mutants with decrease in activity and further test their 
activity in cells using IL12B as a reporter protein that can be examined using mass spectrometry 
for the extent of C-mannosylation (Figure 4.2A). Figure 4.2B shows that the cassette encoding 
these mutants have integrated into the P. pastoris genome. In Figure 4.2C, we can see the 
location of these residues and the transmembrane and non-transmembrane regions of DPY19.  
Figure 4.2D shows western blots of the DPY19 mutants, providing evidence that they are 
	
	 97	
expressed and are stable. This suggests that these residues probably do not play a vital structural 
role for the protein. The next task was to assess which of these residues were important for 
catalysis using the in vitro radioassay developed in Chapter 2. These assays revealed that the 
E102A, E112A, E118A, R586A and Y591A mutations had no significant impact on C-
mannosyltransferase activity (Figure 4.2E). However, the Y75F, H375A, and E579A mutations 
did result in a reduction in C-mannosyltransferase activity, suggesting that they may play a role 
in substrate recognition and/or catalysis (Figure 4.2F).  
 
 
Figure 4. 2: Short-listing DPY19 activity mutants 
a) Strategy for the identification of DPY19 mutants with a decrease in activity based on 
multiple sequence alignment identifying conserved residues. 
b)  Agarose gel of the polymerase chain reaction confirming integration at the 5’ flank, 
DPY19 gene, and 3’ flank for eight DPY19 mutants 
c) Schematic showing the location of the residues found the be conserved in DPY19 genes 




d) Western blots for the eight different DPY19 mutants. An anti-flag antibody was used 
for the western blots. 
e) In vitro C-mannosylation assay showing DPY19 mutants with a significant decrease in 
activity. All data is in triplicates. *** p-value <0.001 
f) In vitro C-mannosylation assay showing DPY19 mutants with no significant decrease 
in activity. All data is in triplicates. 
 
The activity of these mutants within the cell were then assessed by integrating a cassette 
encoding inducible IL12B, which is mannosylated on tryptophan and serves as a useful reporter 
protein that can be purified and analysed using tandem mass spectrometry (Figure 4.3A). No 
difference in the level of IL12B expression was observed in these three mutants (Figure 4.3B). 
Figure 4.3C shows the summary of the level of total C-mannosylation for IL12B produced in 
GS115, DPY19-WT, DPY19-Y75F, DPY19-H375A, and DPY19-E579A. There was a slight 
reduction in C-mannosylation in both the DPY19-Y75F and DPY19-H375A mutants 
indicating that these residues might play a minor role in substrate binding and/or catalysis 
(Figure 4.3C). However, for the DPY19-E579A mutant, there was a near-complete loss of C-
mannosyltransferase activity indicating that this residue is crucial for catalysis (Figure 4.3C). 
 
Upon close investigation of the different glycoforms of IL12B, we see differences in C-linked 
and O-linked glycosylation in these different DPY19 mutants.  For IL12B produced in DPY19-
WT, 92% of IL12B is doubly modified with C-mannosylation, with very little O-linked 
glycosylation (Figure 4.3E). For IL12B produced in DPY19-Y75F, we get 68% C-linked 
glycosylation (C-mannosylation) but we get an increase in triply modified (14%) (2 x C-linked, 
1 x O-linked) glycosylation (Figure 4.3F). For DPY19-H375A, we get a very similar 
glycosylation pattern as for DPY19-Y75F, but a slight increase in the singly glycosylated (C-
linked) glycoform (Figure 4.3G). However, for IL12B produced in the DPY19-E579A mutant 
we see a dramatic loss of C-linked (C-mannosylation) glycosylation (Figure 4.3H). 
Unmodified IL12B accounts for 65% of all of IL12B, 10% singly glycosylated O-linked 
glycosylation and 3% C- and O- linked glycosylation. We get 4% triply O-linked (3 x O-linked) 
glycosylation and 9% quad O-linked (4 x O-linked) glycosylation (Figure 4.3H). The severely 
diminished C-linked (C-mannosylation) glycosylation means that E579 is crucial for C-
mannosyltransferase activity of DPY19. Figure 4.3I shows a summary of the different 
glycoforms of IL12B produced in the various strains. IL12B-E579A has diminished singly and 
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doubly glycosylated states as compared to IL12B-WT, while IL12B-Y75F and IL12B-H375A 
have slight reductions in their doubly glycosylated glycoforms.  
	
	
Figure 4. 3: A key conserved residue amongst the DPY19 family is crucial for catalysis 
a) Strategy for conducting the cell-based assay for DPY19 mutant activity. 
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b) SDS-PAGE for DPY19-WT, DPY19-Y75F, DPY19-H375A and DPY19-E579A. 
c) Summary of the cell-based total C-mannosyltransferase activity on the three DPY19 
mutants. 
d) Extracted ion chromatogram for IL12B produced in the GS115 strain showing the 
different glycoforms. C-linked refers to C-mannosylation whereas O-linked refers to 
O-glycosylation. 
e) Extracted ion chromatogram for IL12B produced in the DPY19-WT strain showing the 
different glycoforms. C-linked refers to C-mannosylation whereas O-linked refers to 
O-glycosylation. 
f) Extracted ion chromatogram for IL12B produced in the DPY19-Y75F strain showing 
the different glycoforms. C-linked refers to C-mannosylation whereas O-linked refers 
to O-glycosylation. 
g) Extracted ion chromatogram for IL12B produced in the DPY19-H375A strain showing 
the different glycoforms. C-linked refers to C-mannosylation whereas O-linked refers 
to O-glycosylation. 
h) Extracted ion chromatogram for IL12B produced in the DPY19-E579A strain showing 
the different glycoforms. C-linked refers to C-mannosylation whereas O-linked refers 
to O-glycosylation. 
i) Summary of the different C-linked glycoforms for IL12B produced in the GS115, 
DPY19-WT, DPY19-Y75F, DPY19-H375A and DPY19-E579A strains. 
 
4.3 - Discussion 
 
The DPY19 family is a highly conserved protein family that has only recently been discovered, 
and of the four dpy19 homologues in human, there is only evidence for activity for two of them 
[71, 74]. It may be that these other two homologues are inactive or may have different 
substrates which have not been identified yet. Because of this, not very much is known about 
this family and there is no crystal structure showing what the enzyme looks like. Considering 
that DPY19 homologues possess 12-13 transmembrane helices, crystallising or even purifying 
these complex enzymes is very difficult. As demonstrated in chapter 2 of this thesis, the C. 
elegans DPY19 enzyme is unstable after 24h at 4 °C, and does not even survive a freeze thaw 
cycle, which makes it very difficult to purify and perform experiments on at an in vitro level. 
We were also not able to express the DPY19L1 and DPY19L3 human homologues of DPY19 
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in P. pastoris. Given that the C. elegans DPY19 is unstable due to temperature, it may be that 
DPY19L1 and DPY19L3 are also unstable proteins at temperatures of 30 °C, the temperature 
at which P. pastoris grows. It also may be that these proteins require specific chaperones to 
fold, which may only be found in specific higher eukaryotic organisms. 
 
The data in this chapter has shown that among the DPY19 protein family there are a number 
of conserved amino acid residues, of which one of them E579, is crucial for catalysis. This is 
a very interesting find because of the four DPY19 homologues in mammals, E579 is only found 
in DPY19L1-3, and is absent in DPY19L4. We know that DPY19L1 and DPY19L3 are active 
C-mannosyltransferases which might need this specific residue for their catalysis. DPY19L2 
and DPY19L4 are not active C-mannosyltransferases on the substrate proteins that they have 
been tested on [71] [74]. It is not clear why DPY19L2 has this residue given that all attempts 
to show its activity as a C-mannosyltransferase have failed thus far on the substrates tested, but 
this does not rule out that it may be active on other substrates. Perhaps there are other residues 
that are involved in catalysis. Perhaps these other residues are not conserved, because their 
importance lay in their properties and can be substituted by similar residues, for instance basic 
residues, acidic residues or charged residues.  
 
This might give some indication that for dpy19l4, it has evolutionarily diverged from the C-
mannosyltransferase function and is possibly providing a different function to C-
mannosylation. Considering that dpy19l4 does not contain the conserved E579 amino acid that 
is required for catalysis in the C. elegans dpy19, it may be that dpy19l4 has evolved to perform 
a different function, whether it is enzymatic or structural. It may still be a glycosyltransferase, 
but it may not be installing a mannose onto a tryptophan. It may be installing another 
carbohydrate molecule, such as a glucose, galactose or fucose onto another amino acid. It may 
be that this protein may have undergone mutations to change it into a structural protein, such 
as dpy19l2 [120]. It may be that it is a receptor, or may have even become a transporter.  
 
It is interesting how the homologues among the dpy19 gene family are so different at the 
sequence level as compared to each other. We know that an ancestral dpy19 gene gave rise to 
dpy19l1 and dpy19l3, and dpy191 gave rise to dpy19l2 in mammals and vertebrates and 
dpy19l3 gave rise to dpy19l4 [114]. However, the striking difference even among active C-
mannosyltransferases, dpy19l1 and dpy19l3, suggests that delineating their mechanism of C-
mannosylation may reveal that these two enzymes have different target proteins. Dpy19l3 and 
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dpy19l4 have only a 43% similarity supporting the idea that dpy19l4 still has function but its 
function is different to the other homologues.  
 
It would be interesting to mutate the E579 residue in mammalian DPY19L1 and DPY19L3, 
since they are both C-mannosyltransferases and investigate how this impacts their activity. We 
also provide some insight into the topology of the DPY19 family and show that most of the 
conserved residues are found in soluble non-transmembrane regions indicating that these 
regions might be where the active site of this enzyme lies. Ultimately, crystallising the C. 
elegans DPY19 protein and the mammalian DPY19L1 and DPY19L3 proteins would give us 
a complete picture of how this enzyme family works and delineate the intricate differences 
between DPY19L1 and DPY19L3.  
 
4.4 - Conclusions 
 
Our investigation into DPY19 through multiple sequence alignments led to the discovery of 
highly conserved amino acid residues among the DPY19 family. Mutants were made for each 
conserved amino acid for the C. elegans dpy19 gene and their activities were tested in vitro 

























Generation of antibodies against C2-α-D-mannosyl- tryptophan for the 
identification of C-mannosylated proteins 
 
5.1 - Introduction 
Since the discovery of C-mannosylation in 1994 on RNaseII from human urine, only 
approximately 30 other proteins have been demonstrated to possess this modification [8] and 
the tools for detecting the modification have remained unchanged. Mass spectrometry is the 
main method for detecting hexose-modified tryptophan and, while it provides valuable 
localisation and occupancy information, it is expensive, medium-to-low throughput, and 
cannot definitely assign the attached hexose as an α-D-mannoside. A simple way to overcome 
these limitations would be to generate monoclonal antibodies against C2-α-D-mannosyl-
tryptophan. These antibodies, together with modern immunochemistry methods, could be used 
to identify a large number of the C-mannosylated proteins predicted to exist within the 
proteome, to validate DPY19 knockout cell lines and to aid in the development of small 
molecule inhibitors of DPY19. While no monoclonal antibodies have been described to date, 
an affinity purified polyclonal serum against C2-α-D-mannosyl-tryptophan has been reported 
[165], though it is no longer available to the scientific community. This illustrates the feasibility 
and need for the generation of monoclonal antibodies to C2-α-D-mannosyl-tryptophan.  
 
In this chapter, I demonstrate how my engineered DPY19 yeast strain can be used to prepare a 
peptide bearing C2-α-D-mannosyl-tryptophan, and how this peptide was used to raise 
monoclonal antibodies that are specific for the modification. The selectivity of these antibodies 
was evaluated against a panel of C-mannosylated proteins using Western blots and their 
affinities for antigen were determined using SPR. Sequencing the complementarity-
determining regions (CDRs) of all monoclonal antibodies identified from two mice revealed 
immune-convergence for the recognition of C2-α-D-mannosyl-tryptophan. The Fab domain of 
one antibody was co-crystallised with the mannosylated peptide antigen and x-ray diffraction 
techniques provided molecular-level insights into the interactions between these mAbs and C2-
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α-D-mannosyl-tryptophan. Finally, these antibodies were used to provide evidence of new C-
mannosylated proteins in fetal calf serum, human serum and Toxoplasma gondii tachyzoites. 
 
5.2 - Results 
 
5.2.1 - Generation of a C-mannosylated antigen using the DPY19 yeast strain 
Synthesising C2-α-D-mannosyl-tryptophan and incorporating this glyco-amino acid into 
peptide antigens is a demanding process [166-168] and several attempts to emulate this 
chemistry in our laboratory have been unsuccessful. Initial attempts to raise antibodies against 
C2-α-D-mannosyl-tryptophan involved immunising mice with recombinant UNC5 produced in 
my yeast strain harbouring C. elegans DPY19, which had been shown by mass spectrometry 
to be extensively glycosylated (see Chapter 2). With three mannosylation sites, it was reasoned 
that UNC5 would provide a diverse array of epitopes and encourage an immune response to 
C2-α-D-mannosyl-tryptophan. However, the serum from these mice failed to demonstrate a 
strong antibody titre against UNC5, as determined by ELISA assays and Western blots. Clearly 
this small disulphide rich protein was not immunogenic enough for this experiment. 
 
An alternative strategy for antigen generation was adopted, which involved the proteolysis of 
recombinant protein from the DPY19 yeast strain, purification of the mannosylated peptide, 
and conjugation to an immunogenic carrier protein. To this end, the ectodomain of human 
IL21R produced in our DPY19 strain (see Chapter 2) was digested by clostripain 
(Endoproteinase-Arg-C) which cleaves the amide bond following arginine residues [169]. 
Clostripain cuts at nine sites in this IL21R construct to give a total of 10 fragments with 
molecular weights up to ≈8 kDa (Figure 5.1A). Our peptide of interest, 
AGPMPGSSYQGTWSEWSDPVIFQTQSEELKEHHHHHH, has two C2-α-D-mannosyl-
tryptophan residues and a C-terminal hexahistidine (His6) tag for purification using 
immobilized metal affinity chromatography (IMAC). The optimal conditions for clostripain 
digestion were determined to be 20 µg of clostripain per milligram of IL21R at 25°C for 2 h 
(Figure 5.1B). After digesting 40 mg of recombinant IL21R with clostripain, the peptide of 
interest was captured using IMAC (Figure 5.1B). This IMAC fraction contained a substantial 
number of impurities, therefore we decided to further purify the peptide using size exclusion 
chromatography (SEC). The SEC chromatogram gave us two major peaks. The first peak 
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eluted around 7.5 ml, which is where we would expect the void volume: this turned out to 
possess most of the impurities (Figure 5.1C), as determined by SDS-PAGE. The second major 
peak at 15 ml was predominantly the mannosylated peptide of interest and was about 80% 
pure. This sample was purified further by high-performance liquid chromatography (HPLC) 
(Figure 5.1D) on a C8 semi-prep column. The peptide of interest was eluted using a gradient 
of 5-100% acetonitrile and 0.1% trifluoroacetic acid (TFA) across 12 column volumes (30 ml) 
to give a peak at 18 to 20 min (Figure 5.1D). LC-MS/MS confirmed that this material was the 
peptide AGPMPGSSYQGTWSEWSDPVIFQTQSEELKEHHHHHH, and that the peptide 
contained zero, one and two C2-α-D-mannosyl-tryptophans (Figure 5.1E). The majority of the 
peptide (>76%) was doubly modified and about 23% was singly modified. An SDS-PAGE of 
this material provided further evidence of its purity (Figure 5.1F). 
 
This peptide, which possesses a lysine side chain amino group and an N-terminal amine, was 
activated with Traut’s reagent to install a sulfhydryl group. This was conjugated to maleimide-
activated keyhole limpet hemocyanin (KLH) and maleimide-activated bovine serum albumin 
(BSA) using the manufacturer’s protocols (Figure 5.1G). KLH is a carrier protein known to 
enhance the immunogenicity of molecules that are not generally immunogenic [170]. KLH is 
a very large macromolecular complex with many different epitopes and is xenogeneic to 
mammalian organisms, which significantly increases its immunogenic response [171]. The 
peptide-BSA conjugate was prepared for screening antibodies specific to the peptide but not 




Figure 5. 1: Generation of an immunogenic C-mannosylated antigen. 
a) Table listing the IL21R peptide fragments obtained from digestion with clostripain. 
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b) SDS-PAGE of fractions from the clostripain-digestion and IMAC purification of 
IL21R. The band at 10 kDa is the peptide of interest. 
c) SEC chromatogram showing the separation of peptides from ‘elution 3’ of Figure 5.1B. 
Peak A is the void volume and contains impure peptide aggregates. Peak B is the 
peptide of interest. 
d) HPLC chromatogram for purification of Peak B from Figure 5.1C. Mono-mannosylated 
peptide is the major peak and di-mannosylated peptide is the shoulder to the right of 
this peak. 
e) Extracted ion chromatogram (EIC) of fraction 34 and 35 from Figure 5.1D showing the 
relative abundance of peptide glycoforms. 
f) SDS-PAGE of the purified peptide.  
g) The peptide was activated with Traut’s reagent, conjugated to maleimide-activated 
KLH and BSA. The KLH conjugate was used to immunise mice with Freund’s 




5.2.2 – The peptide-KLH conjugate provides a strong immune response in mice  
Four mice were immunised with the peptide-KLH conjugate and Freund’s complete adjuvant. 
Each were given three boosters of peptide-KLH conjugate and Freund’s incomplete adjuvant 
over the course of three months. Serum was collected from these animals one week after the 
last booster and evaluated by ELISA using the BSA-conjugated peptide (Figure 5.2A): all 
animals demonstrated a high antibody titre against the peptide of interest. We then assessed the 
serum of these mice through Western blot against a panel of proteins with and without C2-α-
D-mannosyl-tryptophan (Figure 5.2B). We decided to use IL21R, UNC5 and IL12B with C2-
α-D-mannosyl-tryptophan and IL12B without C2-α-D-mannosyl-tryptophan. We were looking 
for mice with serum that reacted to proteins other than IL21R only in the presence of C2-α-D-
mannosyl-tryptophan. Mouse #1636 and #1637 gave us this exact result, with strong 
recognition of IL21R, and bands for IL12B with C2-α-D-mannosyl-tryptophan but not without 





Figure 5. 2: Some mice immunised with the peptide-KLH conjugate produce antibodies 
that only recognise C-mannosylated proteins  
a) ELISA titration results showing reactivity of immunised mouse serum to the peptide-
BSA conjugate (mouse ID#: 1630, 1631, 1636 and 1637). 
b) Western blot results for serum from mouse 1630, 1631, 1636, 1637 as well as a naïve 
balb/c control. The proteins IL21R, UNC5 and IL12B were produced in yeast with or 
without DPY19 to provide proteins with and without C2-α-D-mannosyl tryptophan. 
Serum was diluted to 1/1000 and secondary anti-mouse antibody was used at 1/10,000. 
 
 
5.2.3 –  Generation of mAbs that recognise C2-α-D-mannosyl-tryptophan 
Hybridomas were generated from mice #1630, #1636 and #1637 using the spleen fusion 
method (Figure 5.3A) [172-174]. After 2 weeks, hybridoma supernatants from these mice were 
screened by ELISA for their reactivity to the BSA-conjugated peptide, resulting in 48 hits 
(Figure 5.3B–D). Western blots were conducted on all of these hits using the same protein 
analytes as before. Five hybridomas produced antibodies that were able to recognise C2-α-D-
mannosyl-tryptophan in different proteins (IL21R and IL12B), 23 were specific for the IL21R 
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peptide, and 20 did not recognise any of the proteins (Figure 5.3E–G). Mouse #1637 yielded 
two clones (5G12 and 10E9) (Figure 5.3A) and mouse #1636 provided three clones (9E7, 6G4 
and 7G12) (Figure 5.3G). These five hybridoma clones underwent several rounds of serial sub-
cloning by limiting dilution and after each round, the supernatant from the sub-clones was 
assessed for reactivity to C2-α-D-mannosyl-tryptophan by Western blot. The final five 
hybridoma clones were used to produce 1 mg of pure antibodies using the protein-A affinity 





Figure 5. 3: Short-listing hybridomas that recognise C2-α-D-mannosyl tryptophan 
a) Illustration showing how hybridoma clones are produced.  
b) ELISA results for reactivity of the peptide-BSA conjugate to hybridoma clones from 
mouse 1630. Hybridoma supernatant was diluted 1/100 and tested against 100 ng of 
antigen-BSA conjugate. 
c) ELISA results for reactivity of the peptide-BSA conjugate to hybridoma clones from 
mouse 1636. Hybridoma supernatant was diluted 1/200 and tested against 100 ng of 
antigen-BSA conjugate 
d) ELISA results for reactivity of the peptide-BSA conjugate to hybridoma clones from 
mouse 1637. Hybridoma supernatant was diluted 1/200 and tested against 100 ng of 
antigen-BSA conjugate 
e) Western blot results for selected positive hybridoma clones from mouse #1637 using 
IL21R, UNC5 and IL12B with C2-α-D-mannosyl tryptophan and IL12B without C2-α-
D-mannosyl tryptophan. 100 ng of reporter proteins was used.  Supernatant was diluted 
to 1/50 and secondary anti-mouse antibody was used at 1/10,000. 
f) Western blot results for selected positive hybridoma clones from mouse #1630 using 
IL21R, UNC5 and IL12B with C2-α-D-mannosyl tryptophan and IL12B without C2-α-
D-mannosyl tryptophan. 100 ng of reporter proteins was used.  Supernatant was diluted 
to 1/50 and secondary anti-mouse antibody was used at 1/10,000. 
g) Western blot results for selected positive hybridoma clones from mouse #1636 using 
IL21R, UNC5 and IL12B with C2-α-D-mannosyl tryptophan and IL12B without C2-α-
D-mannosyl tryptophan. 100 ng of reporter proteins was used.  Supernatant was diluted 
to 1/50 and secondary anti-mouse antibody was used at 1/10,000. 
 
5.2.4 - Characterisation of five monoclonal antibodies that recognise C2-α-D-mannosyl-
tryptophan  
Two monoclonal antibodies from each mouse were screened using Western blots against a 
panel of reporter proteins produced with and without C-mannosylation in the DPY19 yeast 
strain in order to evaluate the selectivity of these reagents. Although all these reporter proteins 
have a WX1X2W motif, the amino acids X1 and X2 can vary markedly, as can the residues either 
side of this motif. The 5G12 mAb from mouse #1637 was absolutely specific for C-
mannosylated proteins. It had strong recognition for recombinant IL21R, IL12B and Rspo1 
(Figure 5.4A), which possess a Ser-Glu-Trp(Man) tripeptide in their amino acid sequence 
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(Figure 5.4C).  It had slighter weaker recognition for MTRAP and mindin: MTRAP has a Ser-
Glu-Trp(Man) tripeptide but has low C-mannosylation occupancy, while mindin has a Ser-Ser-
Trp(Man) tripeptide in its sequence (Figure 5.4A, C). There is also a very weak band for EPOR 
and UNC5: EPOR has a Ser-Ala-Trp(Man) tripeptide in its sequence, while UNC5 has Ser-
Asp-Trp(Man) tripeptide in its sequence (Figure 5.4A, C). For mouse #1636, mAb 7G12 was 
evaluated by Western blot and found to have strong recognition for IL21R, Rspo1 and MTRAP 
(Figure 5.4B). All of these proteins have a Ser-Glu-Trp(Man)-Ser tetrapeptide (Figure 5.4C). 
It also recognises IL12B, which has a Ser-Glu-Trp(Man)-Ala tetrapeptide (Figure 5.4B, C). 
Clearly both of these mAbs recognise proteins with C2-α-D-mannosyl-tryptophan, though 
neither could recognise the modification in all protein contexts. The mAbs from both mice had 
a strong preference for peptides containing the Ser-Glu-Trp(Man) motif (Figure 5.4C).  
 
	




a) Western blot of reporter proteins with and without C2-α-D-mannosyl tryptophan 
mapping out selectivity of 5G12 from mouse #1637. Proteins with a C2-α-D-mannosyl 
tryptophan include: IL21R, EPOR, IL12B, UNC5, mindin, Rspo1, MTRAP and 
SPATR. Proteins without C2-α-D-mannosyl tryptophan include: EPOR, IL12B, 
mindin, Rspo1, and MTRAP. 100 ng of each reporter proteins was used. Purified 5G12 
was diluted to 1/2000 and secondary anti-mouse antibody was used at 1/10,000. 
b) Western blot of reporter proteins with and without C2-α-D-mannosyl tryptophan 
mapping out selectivity of 7G12 from mouse #1636. Proteins with a C2-α-D-mannosyl 
tryptophan include: IL21R, EPOR, IL12B, UNC5, mindin, Rspo1, MTRAP and 
SPATR. Proteins without a C2-α-D-mannosyl tryptophan include: EPOR, IL12B, 
mindin, Rspo1, and MTRAP. 100 ng of each reporter proteins was used. Purified 7G12 
was diluted to 1/2000 and secondary anti-mouse antibody was used at 1/10,000. 
c) Table of reporter proteins along with the local amino acid sequence near the WXXW 
motif. Proteins highlighted in yellow are proteins with strong recognition by 5G12 and 
7G12. EW is highlighted in bold because it shows the common sequence that is 
recognised by the two antibodies. 
 
Next, surface plasmon resonance (SPR) was used to determine the binding affinities of each 
mAb for the AGPMPGSSYQGTWSEWSDPVIFQTQSEELKEHHHHHH peptide bearing 
two C2-α-D-mannosyl-tryptophans. The peptide, which possesses amino groups at the N-
terminus and on the lysine side chain, was immobilised to a carboxymethyl cellulose-coated 
SPR chip by EDC coupling. Each of the mAbs were flowed across the chip at a range of 
concentrations (500 nM to 7.8 nM) to provide sensorgram response curves that could be fit to 
a bivalent binding model. This provided association rates (kon) and dissociation rates (koff) for 
peptide binding to each mAb, which enabled calculation of the dissociation constants (KD) 
for each of the five mAbs. The mAbs 5G12 and 10E9 from mouse #1637, had dissociation 
constants (KD) of 42 and 58 nM, respectively (Figure 5.5A, E, F). These KD values were 5–
10 fold higher than mAbs 9E7, 6G4 and 7G12 from mouse #1636, which had KD values of 
3.2, 9.4, and 40 nM, respectively (Figure 5.5B-D, F). Differences in these KD values was 
mostly driven by variations in the koff rates, as all the mAbs had similar kon rates (Figure 
5.5F): both 5G12 and 10E9 had substantially greater koff rates than 9E7, 6G4 and 7G12. The 
mAbs with the slowest off rates were 9E7 and 6G4, making them the most appropriate for 
future applications in glycoprotein discovery through immunoprecipitation and affinity 




Figure 5. 5: SPR determination of mAb-peptide binding kinetics. 
a) Sensorgram of 5G12 mAb binding to C-mannosylated peptide.  
b) Sensorgram of 6G4 mAb binding to C-mannosylated peptide.  
c) Sensorgram of 7G12 mAb binding to C-mannosylated peptide.  
d) Sensorgram of 9E7 mAb binding to C-mannosylated peptide. 
e) Sensorgram of 10E9 mAb binding to C-mannosylated peptide. 





5.2.5 - Sequencing the mAbs that bind C2-α-D-mannosyl-tryptophan 
To gain some insights into how unique these antibodies might be, the sequence of the 
complementarity determining regions (CDRs) was determined using a commercial hybridoma 
sequencing service (Genscript). Antigen recognition is predominantly determined by the CDRs 
of both light and heavy chains of the IgG (Figure 5.6A). Remarkably, there was minimal 
diversity observed amongst the mAbs at a sequence level, even between those originating from 
different animals (Figure 5.6B-C). In the light chain region, all of the antibodies had identical 
amino acid sequences except for 7G12, which differed substantially in CDR1 (Figure 5.6B). 
For the heavy chain, most of the variability came from CDR3, and mAbs from mouse #1637 
had almost identical sequences, while mAbs from mouse #1636 had very similar sequences 
(Figure 5.6C). All of these mAbs appear to utilise a heavy chain derived from the IGKJ1*01 F 
allele, and four of the five possess a near identical light chain derived from the IGKV1-110*01 
F allele, while 7G12 utilised the similar IGKV3-12*01 F allele. Clearly, this combination of 
heavy and light chains provided an excellent scaffold for the development of high-affinity C2-
α-D-mannosyl-tryptophan antibodies. The most notable difference between mAbs from the two 
mice lay in CDR3 of the heavy chains. It is tempting to speculate that this particular sequence 
may be responsible for the substantially slower off-rates, and thus lower dissociation constants, 




Figure 5. 6: The CDR sequences of antibodies against C2-α-D-mannosyl tryptophan 
a) A cartoon illustrating the structure of a mouse IgG antibody. Variability in the CDRs 
of the heavy and light chains define what epitopes are recognised by the antibody. 
b) Sequence alignment of the light chain CDR regions of the five antibodies from mouse 
#1636 and #1637. 
c) Sequence alignment of the heavy chain CDR regions of the five antibodies from mouse 
#1636 and #1637. 
 
5.2.6 - Structural insights into antibody recognition of C2-α-D-mannosyl-tryptophan  
Intrigued by the immuno-convergence observed for these antibodies, structural studies were 
pursued in collaboration with Dr. Michael Jarva, to determine how these heavy and light chain 
combinations recognised C2-α-D-mannosyl-tryptophan. The most broadly-reactive mAb, 
5G12, was produced from hybridomas and purified using protein A-agarose on a 20-mg scale. 
This material was digested with papain to yield a Fab and Fc fragments. The Fab fragment was 
purified by passing the proteolysed mixture through a protein G column to capture the Fc 
fragment. The flow-through, which contained the Fab fragment, was further purified by SEC 
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and used in crystallisation trials with the purified IL21R glycopeptide AGPMP 
GSSYQGTWSEWSDPVIFQTQSEELKEHHHHHH bearing two C2-α-D-mannosyl-
tryptophans. An Fab-peptide crystal appeared after 42 days in a solution containing 10% (v/v) 
2-propanol, 20% (w/v) polyethylene glycol 4000, 0.1 M sodium HEPES, pH 7.5, with 150 nL 
Fab–peptide solution at a 1:1.2 molar ratio at 10 mg/ml (Figure 5.7A). The Fab-peptide complex 
was collected on a crystallographer’s loop and flash frozen with ammonium sulphate 
cryoprotectant. When shot with X-rays on the MX-2 beamline at the Australian Synchrotron, 
the crystal provided a diffraction dataset to 1.8 Å (Figure 5.7B). 
 
	
Figure 5. 7: The Fab-peptide complex protein crystal 
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a) Image of the 5G12 Fab-peptide crystal at day 42. The Fab–peptide crystal was grown 
over 42 days in sitting drops at 20°C by mixing 150 nl well solution containing 10% 
(v/v) 2-propanol, 20% (w/v) polyethylene glycol 4000, 0.1 M sodium HEPES, pH 7.5, 
with 150 nL Fab–peptide solution at a 1:1.2 molar ratio at 10 mg/mL. 
b) Representative X-ray diffraction pattern for the Fab-peptide complex protein crystal 
obtained on the MX-2 beamline at the Australian Synchrotron. 
 
From this diffraction dataset, the structure of the complex was solved in conjunction with Dr. 
Michael Jarva by molecular replacement using a search model created by removing the variable 
loops from an IgG2 Fab (PDB ID: 5MYK). The final structure was refined to a resolution of 1.6 
Å with a final Rwork/Rfree of 0.1892/0.2207 (Table 5.1).  
	





Cell	dimensions  	 	
a,	b,	c	(Å)	 43.23	89.89	59.32	


































This high-resolution structure captured the 5G12 Fab in complex with the mannosylated 
peptide. Positive electron density showed that it bound to a fragment of the peptide 
corresponding the TWSEWSDP residues (Figure 5.8A, B). We were able to assign positive 
electron density adjoined to the second tryptophan to a C-linked mannose in its 1C4 pyranose 
conformation. The CDR3 loops of the mAbs were largely responsible for the interactions 
between antibody and the mannose and effectively buried the sugar into the cleft of the 
antibody (Figure 5.8A, B). The C2-α-D-mannosyl-tryptophan makes the majority of the polar 
interactions with the Fab. The 4-OH of the mannose makes three hydrogen bonds to Asp50H, 
Asn59H, and Arg99H (Figure 5.8C, D). The 5-OH makes an additional three hydrogen bonds, 
with both the side chain and backbone amide of Arg101L, and a buried water, which in turn is 
bound to the backbone carbonyls of Ser96L and His98L (Figure 5.8C, D). Arg101L makes a 
contribution through a hydrogen bonds with the 6-OH of mannose (Figure 5.8C, D). The C2-
α-D-mannosyl-tryptophan is situated such that the aromatic sidechain of tryptophan lies is 
parallel with the side chain amide of Asn103H and is close enough to make formal pi-pi stacking 
interactions (Figure 5.8C, D). The backbone of the tryptophan make two additional hydrogen 
bonds: the carbonyl interacts with H31L and the amide with the carbonyl of Thr97L (Figure 
5.8C, D). The glutamate preceding the C2-α-D-mannosyl-tryptophan creates two notable 
hydrogen bonds with the sidechain of S32L and its backbone nitrogen (Figure 5.8C, D), 





Figure 5. 8: Structural insights into the Fab-peptide complex 
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a) Top down view of the binding epitope of the Fab showing heavy and light chains in 
complex with the peptide bearing C2-α-D-mannosyl tryptophan. The Fab is rendered as 
a surface model with the variable heavy chain in black (left side), and the variable light 
chain in grey (right side) with their CDR1-3 loops in cyan, orange, and yellow, 
respectively. 
b) The peptide bearing C2-α-D-mannosyl tryptophan is depicted using sticks with oxygen 
in an unbiased Fo-Fc density map at 4-sigma. Water is shown as a red sphere. 
c) Residues involved in the peptide binding site with the Fab CDRs colored as above but 
depicted as sticks. Only the S-E-W residues of the peptide are depicted for clarity. 
d) 90-degree rotation of the image in (c). 
 
 
5.2.7 - Evidence of novel C-mannosylated proteins in diverse organisms 
The 5G12 antibody, which could recognise C2-α-D-mannosyl tryptophan in the broadest 
peptide context, was used to provide evidence for the existence of C-mannosylated proteins in 
diverse organisms. Western blots with samples from fetal calf serum (FCS) (Bos taurus), 
human serum (Homo sapiens) and Toxoplasma gondii tachyzoite lysate were probed with 5G12 
and revealed several bands for each organism (Figure 5.9A-C). For FCS, there were three bands 
which corresponded molecular weights of 47, 55 and 100 kDa (Figure 5.9A). We saw similar 
bands in the human serum sample, with an additional band at 25 kDa (Figure 5.9B). These 
three common bands seen in both the FCS and human serum are quite likely proteins from the 
complement immune system. Properdin, C6, C7, C8 and C9 are known to be C-mannosylated 
and these are abundant in blood plasma [11, 65]. In the Toxoplasma gondii lysate (a generous 
gift from A/Prof. Chris Tonkin), several bands were observed but the most prominent was a 
protein of ca. 75 kDa. The most abundant protein in these parasites with a WXXW motif is 
Microneme protein 2 (MIC2). Fortuitously, a MIC2 knockout cell line was available in the lab 
of A/Prof Chris Tonkin and, when lysate from this parasite line was probed with 5G12 by 
Western blot, the strong band at 75 kDa significantly diminished (Figure 5.9C). MIC2 has since 
been identified as a protein with tryptophan mannosylation [123]. This data reveals that these 
antibodies have very little ‘background’ promiscuity and that they can be useful for identifying 
protein in complex samples.  The main limitation of these high quality, well-validated reagents 
is that they do require the Glu-Trp(Man) dipeptide for reliable detection, though fortunately 





Figure 5. 9: Western blots illustrating the presence of C2-α-D-mannosyl tryptophan on 
several proteins in diverse and complex biological samples. 
a) Western blot of fetal calf serum using the 5G12 antibody. 60 µg of total protein was 
used as measured by a Bradford protein assay. Purified 5G12 was used at a dilution of 
1/2000 in 3% skim milk in PBS. Secondary anti-mouse antibody was used at 1/10,000 
in 3% skim milk in PBS. 
b) Western blot of human sera using the 5G12 antibody. 60 µg of total protein was used 
as measured by a Bradford protein assay. Purified 5G12 was used at a dilution of 1/2000 
in 3% skim milk in PBS. Secondary anti-mouse antibody was used at 1/10,000 in 3% 
skim milk in PBS. 
c) Western blot of Toxoplasma gondii cell lysate using the 5G12 antibody. 30 µg of total 
protein was used as measured by a Bradford protein assay. Purified 5G12 was used at 
a dilution of 1/2000 in 3% skim milk in PBS. Secondary anti-mouse antibody was used 
at 1/10,000 in 3% skim milk in PBS. 
 
5.3 - Discussion 
 
The data presented here describes the first five monoclonal antibodies capable of recognising 
peptides bearing C2-α-D-mannosyl-tryptophan, the generation of which were enabled by the 
yeast strain engineered to express DPY19. The lack of tools in the field have hindered 
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investigations into the biological roles of C-mannosylation [8]. Previously, Ihara et al. 
described the generation of a polyclonal antibody against C2-α-D-mannosyl-tryptophan by 
immunising rabbits with chemically synthesised C2-α-D-mannosyl-tryptophan [165]. They 
used this polyclonal affinity-purified antibody to show that Zucker rats, an animal model for 
diabetes, had increased C-mannosylation in proteins as compared to lean rats. The functional 
reasons and consequences for this observation were never investigated further. However, some 
of the data presented in this paper are problematic. Western blots using this polyclonal antibody 
provided inconsistent results in RAW264.7 cells and even showed no significant changes 
between tissue homogenates from Zucker rats and lean rats. Given how little work was put into 
characterising this polyclonal antibody, these results must be interpreted carefully. The 
monoclonal antibodies developed here are much better characterised and could be useful for 
revisiting the role of C-mannosylation in diabetes.  
 
This raises the question of, “what other diseases is C-mannosylation involved in?” Considering 
that there are over 500 proteins with the consensus sequence for C-mannosylation and that 
these proteins are involved myriad cell-signalling pathways, it is likely that changes in C-
mannosylation are observed in many diseases. The same is probably true for the different stages 
of development. These antibodies provide us with the means to start tackling these questions. 
 
Sequencing these antibodies led to the interesting observation of immunoconvergence between 
the antibodies from mouse #1636 and mouse #1637. Of course, the adaptive humoral immune 
response mediated by B cells has accesses to the same repertoire of VDJ rearrangement in each 
mouse, but the size of this hypothetical repertoire is vast, which makes convergence on near-
identical solutions of interest [175]. At the sequence level, the only real difference for 5G12 
and 10E9, which are derived from the same mouse, is in the heavy chain CDR2 at position 53 
(L vs P). The noticeable differences in the kon and koff rates for ligand binding by these 
antibodies suggests that difference in the framework regions (FWR) may also be significant. 
Antibodies 6G4 and 9E7 from mouse #1636 are almost identical in the CDR regions. The heavy 
chain CDR1 at position 28 for 9E7 is P but in 6G4 it is T, however, if we look at the crystal 
structure of 5G12 we can tell that this site is not near the binding site and may not play a 
significant role in recognition of the ligand. A real difference between these two antibodies can 
be seen at position 101 in the light chain CDR3, where a R is present in 9E7 and a P is present 
in 6G4. If we look at the crystal structure of 5G12, the R at that position makes important 
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interactions between O5 and O6 of the mannose ring, which are not going to be present in 6G4 
and may explain its lower affinity relative to 9E7. 
 
The crystal structure of 5G12 Fab in complex with the peptide antigen illustrated the importance 
of the Glu-Trp(Man) dipeptide for binding. The structure reveals that the light and heavy chain 
CDR3 regions make most of the interactions with C2-α-D-mannosyl-tryptophan through 
extensive hydrogen bonding interactions. The mAb also makes considerable interactions 
through light chain CDR1 and heavy chain CDR2 with the peptide. The electron density 
observed for the mannose provides unambiguous assignment of a 1C4 pyranose conformation, 
which has not been possible in previous structures of polypeptides with C2-α-D-mannosyl-
tryptophan. This conformation is very different to that of alpha-linked O-mannosides and has 
previously been observed in solution by NMR [176]. It can be rationalised by the absence of 
an anomeric effect in the C-glycoside and the steric bulk of the indole moiety making an axial 
orientation in the usual 4C1 conformation unfavourable. Direct detection of stereochemistry 
and ring conformation is a major benefit of using an antibody over other techniques like mass 
spectrometry. 
 
The generation of monoclonal antibodies that recognise C2-α-D-mannosyl-tryptophan by 
Western blot will facilitate the study of C-mannosylation in various organisms. These 
antibodies can be used as a means to verify inhibition of C-mannosylation activity following 
the genetic knockout of the C-mannosyltransferase gene(s). We have knocked out DPY19L1 
and DPY19L3 in THP-1 cells, but these genes can certainly be knocked out in other human 
cell lines to better understand the implication of this modification in a wide variety of cellular 
settings (Chapter 7). Knockout mice of DPY19L1 and DPY19L3 have not been published yet 
and are viable, but that is the next logical step in characterisation of C-mannosylation in 
mammalian model. These antibodies could be used to verify these knockout mice. There are 
also many opportunities in these reagents in the microbiology field. Since the discovery of C-
mannosylation in the malaria parasite [124], there has been intense interest in exploring the 
role of the putative Plasmodium C-mannosyltransferase gene. This is also true for Toxoplasma 
gondii, although targeting this gene has proven to be difficult [121]. The key point is that these 
tools make it very easy to monitor changes in tryptophan mannosylation by Western blot. 
 
Beyond Western blots, the SPR kinetics of antigen binding to each antibody reveals that 6G4, 
7G12 and 9E7 may be useful for the affinity purification of mannosylated peptides, as they 
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have very low koff rates. Given that we have identified bands corresponding to C-mannosylated 
proteins in mammalian serum and Apicomplexan parasite lysate, immunoprecipitations on 
diverse samples (e.g. human cells, Toxoplasma gondii and Plasmodium falciparum) seem like 
a logical next step. For this type of protein modification work, there is always a compromise 
between antibody affinity and selectivity: ideally one wants high affinity and relaxed enough 
selectivity to recognise a modification in many contexts. It remains to be seen if these 
antibodies strike the right balance for this application.  
 
Further refinement of these antibodies for these applications could be achieved through 
mutagenesis. This could provide more general tools with greater affinity for their ligand. The 
5G12 antibody may be the best scaffold to build from because a crystal structure of the 
antibody-peptide complex is now available and because 5G12 recognises C2-α-D-mannosyl-
tryptophan in the broadest number of peptide contexts. This structure suggests that mutation of 
H31L and S32 L in the light chain CDR1 would perturb any interaction with the glutamate in 
the Glu-Trp(Man) motif. Targeting these positions will likely decrease the antibody’s affinity 
for Glu-Trp(Man) but could broaden or alter its specificity to Xxx-Trp(Man). Site directed 
mutagenesis at key sites of these antibodies is one way to refine these tools, the other approach 
could be to generate different peptides using the engineered yeast system and revisit antibody 
generation to develop complementary tools. The prevalence of the Glu-Trp(Man) motif grants 
the present tools ample opportunities for discovery: the development of complementary 
antibody tools is a goal to return to as the field matures. 
 
5.4 - Conclusion 
 
In this chapter, the DPY19 engineered yeast strain from Chapter 2 enabled the multi-milligram 
production of a peptide bearing C2-α-D-mannosyl-tryptophan. Conjugation of this peptide to 
KLH and delivery with Freund’s adjuvant provided a high antibody titre in mice, with some 
animals producing a C2-α-D-mannosyl-tryptophan-specific response. From these animals, five 
distinct monoclonal antibodies were obtained, each recognising slightly different glycopeptide 
sequences and with different binding kinetics. Sequencing data revealed that these antibodies 
were the result of immunoconvergence: different mice had utilised the same germline alleles 
to develop a C2-α-D-mannosyl-tryptophan-specific response. The structure of one of the Fab 
regions of one of these antibodies in complex with peptide antigen provided insights into how 
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these antibodies recognise C2-α-D-mannosyl-tryptophan. These antibodies were finally 
evaluated on more complex biological samples, including human and bovine serum samples 
and lysate from an Apicomplexan parasite. These experiments demonstrated that the antibodies 
experienced low promiscuity. As a result, the glycobiology field now has access to high-quality 
antibody tools for the detection of C2-α-D-mannosyl-tryptophan and, while these tools have 
some limitations, their shortcoming are well documented here. These antibodies have been 
crucial for the development of the first chemical inhibitors of C-mannosylation, described in 
Chapter 6 and are presently being used to identify new endogenously C-mannosylated proteins 
































6.1 - Introduction 
 
The discovery of C-mannosylation quickly led to the identification of the WXXW 
glycosylation consensus sequence (sequon) for this modification [13]. Glycosylation 
predominantly occurs on the first tryptophan, although it is not uncommon to see the 
modification on the second tryptophan. In the pursuing years, anomalies were found where C-
mannosylation was occurring on tryptophan residues that were not part of a WXXW motif. For 
example, TPOR was discovered to be C-mannosylated on Trp416 of a W416AAQ motif. 
Anomalous C-mannosylation was also observed in Bovine Lens fibre membrane intrinsic 
protein (lim2 or MP20) which does not have any WXXW motifs: instead C-mannosylation is 
observed on the W42RYC and W61NAT motifs [109]. These observations appear to suggest 
that C-mannosyltransferases are not absolutely specific to the WXXW motif. How 
promiscuous these enzymes are, and to what extent they recognise the general amino acids, X 
in the WXXW sequon, remain unknown. This is a question that could be addressed using my 
engineered yeast and the in vitro assay described in Chapter 2. 
 
An understanding of the substrate preferences of the DPY19 enzymes does not only tell us 
what proteins are being modified by DPY19, it can also inform the development of substrate-
mimicking inhibitors of these enzymes. Inhibitors of C-mannosylation will allow one to 
explore the function of C-mannosylation in different cell lines without having to genetically 
perturb the system. Such a tool could be very useful for defining the role of C-mannosylation 
in diverse systems.  
 
 




6.2.1 - Substrate preferences of the C. elegans C-mannosyltransferase 
 
When tryptic peptides of UNC5 containing the W1XXW2XXW3 motif were analysed by 
tandem mass spectrometry in Chapter 2, some intriguing observations were made (Figure 
6.1A). DPY19 was able to C-mannosylate all of the tryptophan residues in that peptide, but not 
to the same extent. The peptide was observed in the unmodified state, the singly, doubly and 
triply modified states. For the singly C-mannosylated peptide, instead of modifying the W1 
residue in the W1SSW2SDW3 peptide, it exclusively modified the W2 residue (Figure 6.1A). 
The only difference between glycosylating the W2 over the W1 is that there is an aspartic acid 
in the X2 position of the WXXW motif rather than a serine. 
 
This result raises the question of: does DPY19, or C-mannosyltransferases more broadly, have 
a preference for X1 and X2 of the WX1X2W motif? To test this question, we conducted a 
BLAST search for all secretory proteins from C. elegans and humans with a WX1X2W motif, 
which are putative DPY19 substrates. An amino acid frequency plot was constructed to 
illustrate that serine was most favored at X1 followed by threonine for both C. elegans and 
human proteins (Figure 6.1Bi-iii). From this information, we designed and synthesized a series 
of WXXW peptides that were abundant in the proteome and decided to evaluate the preference 
of DPY19 for these peptides.  
 
 




a) Extracted ion chromatogram for the UNC5 glycopeptide data showing different 
glycoforms. 
b) i. Web logo for WXXW motif in C. elegans. A total of 117 sequences used. 
ii. Web logo for the WXXW motif for human TSR domain containing proteins. A total 
of 220 amino acid sequences were used. 
iii. Web logo for the WXXW motif for human type I cytokine receptors. A total of 40 
amino acid sequences were used. 
 
The in vitro radioassay developed in Chapter 2 provide a means to test if any of these peptides 
were preferentially modified by DPY19. A range of WXXW peptide analogues were 
synthesized, though many were found to have very poor solubility in aqueous buffer (Figure 
6.2A). This led to an evaluation of the assay’s DMSO tolerance. Figure 6.2B shows the DMSO 
tolerance of the assay using the WAKW peptide. DMSO concentrations up to 1% are well 
tolerated without significant impact on enzyme activity. Since our bioinformatics sequence 
searches showed that WSEW was enriched in both the C. elegans proteome and the human 
type I cytokine receptors, we decided to compare this peptide with WAKW. At a high peptide 
concentration of 1 mM, DPY19 exhibited a slight preference for WAKW (100%) over WSEW 
(84%) (Figure 6.2C). At a peptide concentration of 50 µM, there was a significant difference 
in the preference of WAKW (100%) over WSEW (70%) (Figure 6.2C). This gave us some 
evidence that just because WSEW is enriched in the proteome, it does not mean that it is 
preferable for C-mannosylation.  
 
We wanted to also investigate the peptide WGGW because in chemical terms, it represents the 
simplest amino acid structures in between the two tryptophan residues. It would allow us to 
examine if an amino acid side chain is necessary for recognition. The WGGW peptide was not 
soluble at 1 mM, but at 50 µM DPY19 was active on the peptide and it had comparable activity 
to WSEW (70%) but less active as compared to WAKW (Figure 6.2C). We also wanted to 
investigate if different stereoisomers of tryptophan residues would be recognised by DPY19 
which would allow us work out a possible mechanism of how DPY19 engages with the 
substrate. We wanted to work out the mode of binding to substrate; does it bind to the first 
tryptophan and then proceeds to the second tryptophan? We synthesized wSEW (first 
tryptophan is D-tryptophan), WSEw (second tryptophan is D-tryptophan), and wSEw (both 
tryptophan residues are D-tryptophan). However, the peptides were relatively insoluble at 1 
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mM and even at 50 µM they were only slightly soluble. Therefore, we could not make any 
conclusion from our results on these peptides. 
 
Despite the establishment of the WXXW consensus sequence as the minimum requirement for 
C-mannosylation over two decades ago, we wanted to investigate if the second tryptophan 
residues in the WXXW motif is essential. We synthesized the peptides WSEF and WSEA and 
examined their activity against WAKW and WSEW. At a high peptide concentration of 1 mM, 
DPY19 exhibited the same preference for WSEW (84%) and WSEF (89%), with a significantly 
lower preference for WSEA (72%) (Figure 6.2C). At a peptide concentration of 50 µM, there 
was a considerably larger difference in the preference for WSEF (79%) over WSEA (46%) 
(Figure 6.2C). Interestingly, DPY19 can glycosylate WXXZ peptides where Z≠W when the 
peptide is at high concentration. 
 
We wanted to confirm this result by conducting a cell-based assay where we made two mutants 
of the WSEW motif in IL12B, WSEF and WSEY (Figure 6.2D). We then transformed the 
mutants in the DPY19 strain and expressed and purified the IL12B mutants and examine their 
glycosylation using mass spectrometry (Figure 6.2D). Figure 6.2E shows the extracted ion 
chromatogram and mass chromatogram for the WSEF mutant, where we see glycosylation of 
the first tryptophan residue, confirming our in vitro C-mannosylation assay result. The WSEY 
is also C-mannosylated, however to a lower extent (Figure 6.2F). The IL12B-WSEF mutant is 
71.8% glycosylated, which is significantly higher than the WSEY mutant at only 18.6%. This 
challenges the long-established notion that there must be a second tryptophan present in the 








Figure 6. 2: The second tryptophan residue in the WXXW motif is not essential for C-
mannosylation by DPY19  
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a) Chemical structures for the different WXXW peptide analogues used in the in vitro C-
mannosylation assay.  
b) Optimisation of the in vitro C-mannosylation assay for different concentrations of 
DMSO. 
c) In vitro C-mannosylation assay for the different WXXW peptide analogues. All data is 
in triplicates and the data is normalised relative to the WAKW, where WAKW is given 
100% activity and the other peptides are given a value based on their activity to 
WAKW. 
d) Strategy for the cell-based assay confirming C-mannosylation of IL12B when the 
second tryptophan residue in the WSEW motif is mutated to a F or Y. 
e) Extracted ion chromatogram and corresponding mass spectra for the 
AQDRYYSSSWSEFASVPCS peptide for the WSEF mutant. 
f) Extracted ion chromatogram and corresponding mass spectra for the 
AQDRYYSSSWSEYASVPCS peptide for the WSEY mutant. 
 
 
6.2.2 - Discovery of novel DPY19 peptide-mimetic inhibitors that inhibit C-mannosylation 
in a cell-based assay 
 
The discovery of an inhibitor will allow for the development of tools to probe DPY19 biology 
and assess the impacts of C-mannosylation on biological systems or organisms. Currently, the 
field of C-mannosylation is on a standstill because of the lack of tools to probe the biology of 
C-mannosylation, a chemical inhibitor would greatly advance the understanding of C-
mannosylation. If it is therapeutically beneficial to inhibit C-mannosylation for a particular 
disease in an organism, then this tool can then be further developed into a pharmaceutical drug 
in the future. The ability to create different substrate mimetics of the WXXW motif spurred an 
idea of creating a possible inhibitor of DPY19. Our unique system allows for the production of 
recombinant proteins with a C2-α-D-mannosyl-tryptophan. We have also produced antibodies 
against C2-α-D-mannosyl-tryptophan, which were introduced in chapter 5 of this thesis. The 
antibodies along with our engineered system will allow us to test possible inhibitors of DPY19 




Generally, when developing inhibitors of a protein target or pathway, there are three ways that 
are taken to carry out this process. The first one is the high throughput screen where thousands 
of compounds are assayed for activity against a protein target or cell line. The second is the 
fragment-based screen, where very small ‘fragment’ molecules are screened against a protein 
target and these fragments are ‘grown’ or ‘combined’ to yield a higher affinity inhibitor. The 
last is the rational based drug design approach, where the active site and substrate preferences 
of a protein target are used to guide the design of compounds that may bind the active site. 
With our growing knowledge of DPY19 substrate preferences, we reasoned that a rational 
inhibitor design approach could be fruitful for the development of the first DPY19 inhibitors.  
 
We know what the substrate for C-mannosylation is; a WXXW motif where the second 
tryptophan is important but not necessary. We also know that an α-D-mannose is attached to 
the C2 carbon of the indole ring of tryptophan. These two facts encouraged the design of 
substrate mimics that block the C2 carbon of the indole ring of tryptophan or that altered the 
sterics around or electronics at this position. We reasoned that these molecules would still bind 
to DPY19 but may not be ‘turned over’ by the enzyme. We chose four substrate mimics: the 
benzimidazolone compound (1), the 2-methyl-tryptophan compound (2), the 1-methyl-
tryptophan compound (3) and the benzimidazole compound (4) (Figure 6.3A). 
 
To assay these compounds, the yeast strain harbouring DPY19 and a reporter protein such as 
IL21R was grown for 24 hours, then protein expression was induced with or without the 
compounds. After 24 hours, the supernatant was harvested and probed for the presence of C-
mannosylated reporter protein via a western blot or ELISA using the antibodies against C2-α-
D-mannosyl-tryptophan (5G12) (Figure 6.3B). Before testing the substrate mimics, we first 
tested the substrate to verify that the peptide substrate itself would not act as apparent inhibitor 
through competition with the reporter protein. The WSSW substrate was tested in the cell based 
assay and the results indicate that it does not inhibit C-mannosylation (Figure 6.3D, E). We 
then tested the substrate mimic compounds at 1 mM using IL21R as a reporter protein and 
found that out of the four compounds, only compound 3 inhibited C-mannosylation.  
 
It was surprising that compound 3 inhibited DPY19 because, unlike the other compounds, the 
C2 carbon of the indole ring was not blocked. The implications of this inhibition on the DPY19 
enzyme mechanism are unclear. It could be that the steric bulk of the methyl group on the 
tryptophan nitrogen is sufficient for binding to the enzyme but blocks the subsequent reaction 
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or that deprotonation or electrophilic attack at the indole nitrogen is an important part of the 
enzyme’s mechanism. 
 
We then wanted to confirm that compound 3 was inhibiting C-mannosylation hence we tried 
mindin as another reporter protein. Mindin has a Flag-tag therefore we can probe with an anti-
Flag antibody to confirm if total cellular protein synthesis or translation is not being affected 
by compound 3 (Figure 6.3H). The results suggest that compound 3 is indeed inhibiting 
DPY19, and total protein synthesis or translation are likely not being inhibited because we can 
detect mindin with an anti-Flag antibody but cannot detect presence of C-mannosylation using 
the antibody against C2-α-D-mannosyl-tryptophan (Figure 6.3I). We do get a significant 
reduction in detection of mindin with the anti-Flag antibody but we must consider that there is 
a 4-fold increase in expression of mindin with a C2-α-D-mannosyl-tryptophan than without the 
modification as the results indicated in chapter 2 of this thesis. We also tried to examine what 
the minimum concentration of compound 3 was needed to achieve inhibition. We tried 2 µM 
and at this concentration there was no significant inhibition (Figure 6.3H, J). 
 
We then wanted to calculate the EC50 value for compound 3 because we wanted to design more 
drug-like and potent inhibitors of DPY19. We titrated the compound from 10 µM to 2000 µM 
in order to generate a saturation curve. The EC50 value for compound 3 was 350 µM (Figure 
6.3K). Although this value may be high, it represents a value that works in a cell- based assay 
and is a starting point for development of more potent inhibitors. This high value can also be 
attributed to the facts that yeast cells have a thick cell wall and it may be harder for compounds 
to enter the cell readily (Figure 6.3L). Yeast also have significantly more proteases than 
mammalian cells therefore the peptide substrate mimic inhibitor might be a target for 
degradation by peptidases and therefore might need a high concentration to achieve inhibition. 








Figure 6. 3: The use of substrate mimics for the development of novel chemical 
inhibitors of C-mannosylation. 
a) Chemical structure of the four peptide substrate mimics showing a change in the 
electronics of the indole ring of tryptophan. 
b) Schematics showing how the cell-based inhibitor assay works. Cells harbouring a 
reporter protein are cultured for 24 hours and then protein expression is induced with 
or without compounds. After 24 hours supernatant is harvested and an ELISA or 
western blot is conducted with an antibody against C2-α-D-mannosyl-tryptophan. 
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c) Chemical structure of the WSSW peptide substrate 
d) Western blot showing the cell-based inhibitor assay results for the WSSW peptide 
substrate using the 5G12 antibody (against C2-α-D-mannosyl-tryptophan) 
e) Quantification of the cell-based inhibitor assay results for the WSSW peptide substrate 
in 6.3C 
f) Quantification of the cell-based inhibitor assay results for the four peptide substrate 
mimics in 6.3G 
g) Western blot showing the cell-based inhibitor assay results for the four peptide substrate 
mimics in 6.3A using the 5G12 antibody (against C2-α-D-mannosyl-tryptophan) 
h) Western blot of the cell based assay for mindin showing induced and non-induced 
mindin using an anti-Flag antibody and 5G12 antibody (against C2-α-D-mannosyl-
tryptophan) 
i) Western blot showing the mindin cell-based inhibitor assay results for compound 3 at 
1 mM and 2 µM using anti-Flag antibody and the 5G12 antibody (against C2-α-D-
mannosyl-tryptophan) 
j) Quantification of the mindin cell-based inhibitor assay results for compound 3 in 6.3I 
k) ELISA results quantifying the EC50 of compound 3 using the 5G12 antibody (against 
C2-α-D-mannosyl-tryptophan) 
l) Illustration of a yeast cell highlighting the thick cell wall and enhanced secretion of 
peptidases. 
 
In order to change compound 3 from a tetrapeptide into a more drug-like molecule, we 
synthesized six second generation inhibitors of DPY19. We were focused on three regions of 
compound 3, the first one is the indole ring of the first tryptophan residue, the second consists 
of two serine amino acids, and the last tryptophan residue (Figure 6.4A). We wanted to explore 
whether changing the methyl group in the C1 position of the indole ring into other chemical 
groups would be more beneficial. We also wanted to simplify the sidechains of the two serine 
amino acids into either glycine (compound 5) or have a ‘linker’ chain such as the 5-
aminovaleric acid (compound 6) (Figure 6.4B). Compound 8 has a benzene group instead of 
the methyl group (Figure 6.4B). We also wanted to place a methyl group on the C1 position of 
the second tryptophan residue and examine if that would make the compound more potent 
(compound 7) (Figure 6.4B). Compound 9 has a 3-indolepropionic acid (IPA) moiety with a 
methyl group in the C1 carbon position, essentially eliminating the acetyl group. We also 
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wanted to investigate if there was a need for the second tryptophan residue to be present for 
recognition (compound 10) (Figure 6.4B).   
 
We then tested the six second generation compounds in our cell based assay and all of the 
compounds inhibited at 1 mM except for compound 5, with two glycine residues instead of 
serine residues. It was surprising that compound 6, with the 5-aminovaleric acid, inhibited 
because it means that the two amino acid residues are not need for recognition (Figure 6.4C). 
Compound 6 no longer makes the compound into a peptide, but a small molecule. It was not 
surprising that the second tryptophan molecule was not needed, as compound 10 gave 
inhibition (Figure 6.4F). Our previous data suggested we do not need the second tryptophan in 
order for the C-mannosylation to occur. We do not know if these 5 compounds will be more 
potent than compound 3, as we have not calculated the EC50 value for these compounds.   
 
	
Figure 6. 4: Design of second-generation inhibitors of C-mannosylation 
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a) Schematic illustrating the process of transforming compound 3 from a tetrapeptide to a 
more drug-like and more potent molecule. The circles represent regions that will be 
modified. 
b) Second generation inhibitors of DPY19 based on compound 3 
c) Western blot showing the cell-based inhibitor assay results for the six second generation 
peptide substrate mimics using the 5G12 antibody (against C2-α-D-mannosyl-
tryptophan) 
d) Quantification of the cell-based inhibitor assay results for compound 5 and 6 in 6.4C 
e) Quantification of the cell-based inhibitor assay results for compound 7 and 8 in 6.4C 
f) Quantification of the cell-based inhibitor assay results for compound 9 and 10 in 6.4C 
 
 
6.3 - Discussion 
 
Through our susbtrate preference studies, we have found that that there is a preference for X1 
and X2 in the WX1X2W motif. Our bioinformatics analysis found that WSEW was enriched in 
both the C. elegans genome and the human genome but this was not necessarily favourable for 
C-mannosylation. It was likely that those amino acids were playing a structural role for the 
protein. Our results indicated that WAKW is more favourably glycosylated than WSEW. This 
means that if we can figure out which amino acids are most favoured and least favoured for the 
X1 and X2 positions in the WX1X2W motif, we would be able to predict the level of C-
mannosylation. Of course, this would not be entirely accurate because protein folding dynamics 
must be accounted for as well as the level of C-mannosyltransferase present but this would 
allow for prediction of the level of C-mannosylation. There have not been any studies shedding 
any light on this topic, however, there was one study by Hilton et al that looked mutating the 
alanine residue in the WSAW motif of Erythropoietin receptor [59]. The authors mutated the 
alanine into a glutamic acid residue and found that it had a two-fold increase in cell surface 
expression. An experiment that we could have tried is comparing C-mannosylation of WSEW 
to WSAW peptides and examining if WSEW C-mannosylated to a higher extent than WSAW. 
If this was in fact that case, then this would explain why this mutant was able to go to the 
surface more efficiently because it was C-mannosylated to a higher extent and was more stable. 




Another intriguing result discovered in this chapter was that the second tryptophan residue in 
the WXXW motif is not essential for C-mannosylation to occur. For over two decades, it was 
thought that the second tryptophan was required for C-mannosylation. There has only been one 
account of this anomaly in literature when the thrombopoietin receptor was discovered to 
harbour a C2-α-D-mannosyl-tryptophan on a WSEF sequence motif [57]. This result has very 
wide implications, it opens up the number of proteins with potential C-mannosylation. It is 
very difficult to identify C-mannosylation on proteins unless these proteins are purified and are 
subject to mass spectrometry analysis. This would be a very cumbersome approach if one was 
trying to identify proteins with C-mannosylation that do not contain the non-canonical WXXW 
motif. An antibody recognising C2-α-D-mannosyl-tryptophan would be a much more efficient 
method for identifying these proteins, which we now have.  
 
A question that needs to be answered is what is the minimum requirement for C-
mannosylation? Is it sufficient to just have exposed tryptophan residues present for C-
mannosylation to occur? Are there any upstream or downstream motifs present that are 
recognised by C-mannosyltransferases in order for them to modify tryptophan residues? 
Perhaps other proteins are involved in recognising upstream or downstream motifs and in turn 
activate C-mannosyltransferases to C-mannosylate a protein. We could test this hypothesis by 
taking a protein that is not related to type I cytokine receptor and thrombospondin type I repeat 
domain containing proteins and place a WXXW motif sequence in that protein. If it gets C-
mannosylated than there might not be any other motifs for recognition.  
 
Another question to ask is why there are two active C-mannosyltransferases in vertebrates and 
mammals? Both DPY19L1 and DPY19L3 are active and when we align all four DPY19L 
homologues with the C. elegans DPY19 gene DPY19L1 is closer to DPY19 than DPY19L3. 
If the C. elegans DPY19 does not require a second tryptophan in order for it to modify the first 
tryptophan, then the reason there are two of these active genes in vertebrates and mammals is 
because they have different substrate preferences. It could be that DPY19L1 evolved to only 
recognise proteins with the WXXW motif and DPY19L3 evolved to recognise proteins with 
WXXZ. Evolutionarily, this would be a much more superior method to control which proteins 
are C-mannosylated and which proteins are not. You have two genes that carry out the same 
function but have selectively different on and off switches. If DPY19L3 is not present in a cell 
type and there is an abundance of proteins with WXXZ and if it would be a disadvantage if 
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these proteins were C-mannosylated in that cell type than there would not be any negative 
consequences for that cell type.  
 
The development of inhibitors of C-mannosylation will allow the study of C-mannosylation to 
be streamlined. The field of C-mannosylation was hampered by a lack of tools, but the addition 
of an inhibitor of C-mannosylation will allow the study of C-mannosylation in various cells 
and organisms. There are many TSR-domain containing proteins in Plasmodium falciparum 
and Toxoplasma gondii which have been shown to be C-mannosylated [123, 124]. These 
proteins are mainly secreted proteins involved in invasion and survival; therefore, it may be 
that a lack of C-mannosylation decreases or inhibits their secretion to the cell surface. Our 
inhibitor may be a new drug lead for treatment of Malaria and Toxoplasmosis because it may 
impair or kill the parasites. A genome-wide CRISPR screen in T. gondii identified that the 
putative C-mannosyltransferase gene was an essential gene and it was lethal when knocked-
out, further giving evidence that our inhibitor may be a drug lead for Toxoplasmosis [121] .  
 
6.4 - Conclusions 
 
Our structure activity relationship studies with different WXXW peptide substrates revealed 
that DPY19 indeed does have different affinities towards different substrates. We uncovered 
that the second tryptophan residues in the WXXW motif is not essential for C-mannosylation 
to occur. Furthermore, we have discovered the first peptide substrate mimic that inhibits 
DPY19 in a cell based assay. This chemical tool can now be used to probe the biology of C-














Insights into the impact of dpy19l1 and dpy19l3 on protein expression 
 
7.1 - Introduction 
The first gene to encode a C-mannosyltransferase, dpy19, was discovered in C. elegans in 2013 
[68]. The dpy19 gene family is highly conserved throughout the evolution of metazoans and 
has undergone substantial diversification [114]. The products of these genes are multi-pass 
integral membrane proteins and, while some have been functionally validated as C-
mannosyltransferases, others have no known function. In mammals, there are four dpy19 
homologues (dpy19l1–4), which have resulted from gene duplication events throughout 
evolution. The dpy19l1 and dpy19l3 genes resulted from duplication events from an archaic 
dpy19 ancestor, while dpy19l2 is the result of a more recent duplication of dpy19l1, and 
dpy19l4 is a more recent duplication of dpy19l3. Vertebrates from the reptilia class, only have 
three of the dpy19 homologues, which share features with the mammalian dpy19l1, dpy19l3 
and dpy19l4. Insects, such as Drosophila melanogaster, only have one dpy19 gene, as do the 
Apicomplexan parasites (Toxoplasma gondii, Plasmodium falciparum etc.), which likely 
acquired dpy19 through horizontal gene transfer. While it is clear that most of these genes 
encode C-mannosyltransferases, it is less obvious what their substrate preferences or biological 
roles are. 
 
A functional assignment of human dpy19l1 and dpy19l3 as C-mannosyltransferases has paved 
the way for an interrogation of the role of C-mannosylation in human cells [74]. The Bakker 
lab expressed the two TSR domains of recombinant mouse UNC5A in dpy19l1, dpy19l3, 
dpy19l4 triple knockout CHO cells complemented with a single dpy19 gene (dpy19l2 is only 
expressed in the testes). This allowed them to figure out which dpy19 genes encode functional 
C-mannosyltransferases. In addition to discovering that DPY19L1 and DPY19L3 are active C-
mannosyltransferases, they also found that they may have different protein substrate 
preferences. In the both the TSR1-W1STW2TEW3SVC and TSR2- W1SPW2SKW3SAC tryptic 
peptides, they found that DPY19L1 had a higher propensity to modify W1 and W2, while 
DPY19L3 had a higher chance of modifying W3. Although this is an interesting discovery, 
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these findings are limited to a single overexpressed protein in a heterologous system with an 
overexpressed enzyme.  
 
As yet, there have not been any studies examining the global effects of C-mannosylation on 
the expression levels of endogenous proteins. What happens to endogenous C-mannosylated 
proteins when the C-mannosyltransferase genes are knocked out or inactivated?  
 
In this chapter, the known human C-mannosyltransferases dpy19l1 and dpy19l3 were disrupted 
in a human cell line using CRISPR-Cas9 and comparative cell surface proteomics used to 
interrogate the effects of C-mannosylation on cell surface protein expression levels. Many 
proteins predicted to be C-mannosylated had severely reduced cell surface expression levels 
both the dpy19l1-/- and dpy19l3-/- cells as compared to the parental cell line. Some selectivity 
in protein substrates was also noted for DPY19L1 and DPY19L3. This simple series of 
experiments provides insights into the subtle difference in the biological roles of dpy19l1 and 
dpy19l3, lays the foundation for more extensive studies in other systems, and generates some 
interesting hypotheses surrounding possible roles for DPY19L1 and DPY19L3 in health, 
development and disease.  
 
 
7.2 - Results 
 
7.2.1 – Disrupting dpy19l1 and dpy19l3 in the human monocytic cell line THP-1 
To begin, a literature search was conducted to find an easy-to-culture human cell line that 
expressed many proteins with the WXXW C-mannosylation motif. Evidence was sought at the 
protein level, not only at the transcript level. THP-1 cells were quickly identified as an ideal 
human cell line to probe the roles of dpy19l1 and dpy19l3, since they expressed many type I 
cytokine receptors and thrombospondin type 1 repeats (Figure 7.1A), including: IL6Ra, IL7Ra, 
IL12R, IL21R, G-CSFR, GM-CSFR, UNC5C, UNC5B, RNaseII and IL12B [177-185]. 
 
To enable CRISPR-Cas9 disruption of the dpy19l1 and dpy19l3 loci, two guide RNAs were 
designed for each gene. For dpy19l3, both guides targeted exon 7 (Figure 7.1C). dsDNA 
encoding these guides were cloned into a lentiviral vector harbouring a GFP reporter and 
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transfected into THP-1 cells carrying an inducible Cas9-mCherry gene (Figure 7.1B). Cas9-
mCherry expression was induced using doxycycline and flow cytometry used to sort GFP and 
mCherry positive cells into 96-well plates (Figure 7.1D). These monoclonal cell lines were 
expanded, their gDNA isolated and Sanger sequencing used to determine if the dpy19l3 loci 
had been disrupted at the side targeted by the guide RNA. Eight out of the 10 clones had 
mutations resulting in truncation of the DPY19L3 protein, five of those clones were 
heterozygous for the mutation and three clones were homozygous (Figure 7.1E, F). Clone 1, 2, 





Figure 7. 1: Establishing dpy19l3-/- THP-1 cell lines. 
	
	 144	
a) Table showing list of proteins with a WXXW motif that are expressed in THP-1 cells 
with protein level evidence from literature.  
b) Diagram showing the strategy of how the CRISPR-Cas9 experiments were conducted. 
c) Schematic showing the gene architecture of dpy19l3 highlighting the introns (lines) and 
exons (solid bars). The guide RNAs for dpy19l3 targeted exon 7. 
d) Flow cytometry sorting of the doxycycline-induced polyclonal population harbouring 
guides against dpy19l3 showing the selection of mCherry and GFP populations. 
e) Summary of the sequencing results for 10 of the dpy19l3-/- clones, showing Indel 
generation and status of protein. 
f) Alignment of Sanger sequencing for dpy19l3-/- clones from above comparing the 
parental and mutant alleles. Segments highlighted in bold and red are the segments of 
DNA affects by the Indels. 
 
A similar approach was used to make dpy19l1-/- THP-1 cell lines, except the CRISPR-Cas9 
lentiviral vector had a CFP reporter protein instead of a GFP reporter, which would facilitate 
the later production of double-knockouts. For dpy19l1, two guide RNAs targeting exon 3 and 
exon 14 of the were chosen (Figure 7.2A). dsDNA encoding the two guide RNAs were cloned 
into a CRISPR vector containing the CFP reporter and transfected into THP-1 cells carrying 
an inducible copy Cas9-mCherry gene. After activation of Cas9 using doxycycline, we sorted 
single cells into 96-well plates using flow cytometry with CFP and mCherry gated filters 
(Figure 7.2B). Ten clones were expanded and subjected to Sanger sequencing. Eight of these 
had mutations resulting in truncation of DPY19L1. Out of the eight clones, three were 
heterozygous for mutation while five were homozygous null (Figure 7.2C). Clones 1, 3, and 5 






Figure 7. 2: Establishing dpy19l1-/- THP-1 cell lines. 
a) Schematic showing the gene architecture of dpy19l1-/-  highlighting the introns (lines) 
and exons (solid bars). The CRISPR-Cas9 guide RNAs were designed to target exons 
3 and 14. 
b) Flow cytometry sorting of the CRSIPR doxycycline-induced polyclonal population 
showing the selection of mCherry and CFP populations. 
c) Summary of the sequencing results for 10 of the dpy19l1-/- clones, showing indel 
generation and status of protein. 
d) Alignment of Sanger sequencing for dpy19l1-/- clones from above comparing the 
parental and mutant alleles. 
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To make the dpy19l1-/-, dpy19l3-/- THP-1 double knockout cell line, dpy19l3-/- clone 1 was 
transfected with the CRISPR cassette targeting exon 3 of dpy19l1-/- (Figure 7.3A). Cas9-
mCherry was activated using doxycycline and FACS used to clone cells into 96-well plates 
using the CFP and GFP gated filters (Figure 7.3B). These clones were expanded, genomic 
DNA isolated for 10 clones, PCR used to amplify the targeted region of dpy19l1 and this 
amplicon subjected to Sanger sequencing. Mutations resulting in protein truncation occurred 
in eight out of the 10 clones. Five of those clones were heterozygous mutations and three of 
the clones were homozygous null mutations (Figure 7.3C). Clones 7, 8 and 9 were used for 





Figure 7. 3: Establishing dpy19l1-/-, dpy19l3-/- THP-1 cell lines. 
a) Diagram showing the strategy of how the CRISPR-Cas9 experiments will be conducted 
and how clones for the double knockouts will be generated on the dpy19l3-/- clone 1 
background.  
b) Flow cytometry sorting of the CRISPR doxycycline-induced polyclonal population 
showing the selection of CFP and GFP populations. 
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c) Summary the sequencing results for 10 of the dpy19l1-/-, dpy19l3-/- clones, showing 
indel generation and status of protein. 
d) Alignment of Sanger sequencing for dpy19l1-/-, dpy19l3-/- clones from above comparing 
the parental and mutant alleles. 
 
 
7.2.2 - Loss of DPY19L1 and DPY19L3 alters cell surface protein expression. 
In the earlier chapters of this thesis, some proteins were observed to express better in P. pastoris 
and were more stable when modified by DPY19. Indeed, two to five-fold increases in protein 
expression levels were not uncommon. Some proteins, like UNC5 and IL21R, failed to express 
to any detectable level without this modification. As such, it was expected that loss of 
DPY19L1 and DPY19L3 in human cells would alter the expression profile of secreted and cell-
surface proteins with a WXXW motif, which are putative substrates for both of these enzymes. 
To investigate which proteins were impacted by loss of tryptophan mannosylation, comparative 
cell surface proteomics was to be conducted on parental, dpy19l1-/-, dpy19l3-/- and dpy19l1-/- / 
dpy19l3-/- THP-1 cell lines. The technique utilised here takes advantage of the fact that most 
cell surface proteins are glycosylated. These N- and O-glycans usually possess a terminal sialic 
acid that can be oxidised with sodium periodate to provide a reactive aldehyde functionality 
(Figure 7.4A). This aldehyde reacts selectively with amino-oxy biotin to covalently tag these 
glycoproteins with biotin. After biotinylation, cells were lysed and affinity purified using 
streptavidin immobilised on an agarose resin (Figure 7.4B). After extensive washing steps, 
these captured proteins are proteolytically digested into peptides, freeing them from the resin, 





Figure 7. 4: Strategy for biotin-labelling cell surface glycoproteins for affinity 
purification prior to proteomics. 
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a) Cartoon showing how the sialic acid on the N-glycans of proteins are oxidised with 
sodium periodate and then labelled with amino-oxy biotin prior to affinity purification. 
b) Cartoon showing the work-flow for the proposed cell surface proteomics. 
 
 
Cell surface proteomics experiments were performed on the THP-1 cells using three 
independent biological replicates. The samples were prepared by me and the data was collected 
and analysed by Dr. Jarrod Sandow (WEHI). Figure 7.5A shows a volcano plot comparing 
results obtained for dpy19l1-/- against the parental cell line, where the x-axis represents the log2 
fold change in expression and the y-axis represents the log10 confidence P-value. Proteins 
represented by blue and red dots are proteins that have a statistically significant change in 
abundance between the samples. Points in the right quadrant represent those proteins with 
decreased expression levels in the dpy19l1-/- cells, while those in the left quadrant had increased 
expression levels.  Figure 7.5B and C shows the same information for dpy19l3-/- and dpy19l1-
/- / dpy19l3-/- cells relative to the parental line, respectively. For all three knockout cell lines, 
many different proteins have been altered in expression level. However, many of these proteins 
do not have the WXXW motif, and are therefore not C-mannosylated. They most likely have 
shifted as a result of secondary effects to do with proteins that are C-mannosylated. This is also 
true for the proteins that have increased in cell surface expression. This may be a due to the 
fact that many proteins with a WXXW motif are cell surface receptor proteins capable of 





Figure 7. 5: Comparative cell surface proteomics for cells with disrupted dpy19l loci. 
a) Volcano plot comparing the cell surface proteome of parental and dpy19l1-/- THP-1 
cells. Fold-changes (log2) of relative protein expression (x axis) is plotted against the 
log10 p-value of the detection (y axis). Proteins significantly decreased in expression 
(right side) or increased in expression (left side) on the THP-1 cell surface are shown 
in blue (-,+) and red (--,++).  
b) Volcano plot comparing the cell surface proteome of parental and dpy19l3-/- THP-1 
cells. Fold-changes (log2) of relative protein expression (x axis) is plotted against the 
log10 p-value of the detection (y axis). Proteins significantly decreased in expression 
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(right side) or increased in expression (left side) on the THP-1 cell surface are shown 
in blue (-,+) and red (--,++).  
c) Volcano plot comparing the cell surface proteome of parental and dpy19l1-/- / dpy19l3-
/- THP-1 cells. Fold-changes (log2) of relative protein expression (x axis) is plotted 
against the log10 p-value of the detection (y axis). Proteins significantly decreased in 
expression (right side) or increased in expression (left side) on the THP-1 cell surface 
are shown in blue (-,+) and red (--,++).  
d) Heat map of proteins with a WXXW motif and significant decrease in cell surface 
expression. L1 = dpy19l1-/-, L3 = dpy19l3-/-, L3L1 = dpy19l1-/- / dpy19l3-/-.  
e) Pie chart showing the protein classification for the proteins in (d). 
f) Gene ontology analysis for proteins with a WXXW motif and significant decrease in 
cell surface expression in (d). 
 
 
To begin to make sense of this data, proteins that had a statistically significant decrease in cell 
surface expression and a WXXW motif were looked at in greater detail. Figure 7.5D shows a 
heat map for these proteins’ fold-change in relative abundance for each of the KO cell lines. 
This representation reveals some striking differences between DPY19L1 and DPY19L3: many 
proteins clearly require only DPY19L1 for surface expression, at least one requires DPY19L3 
but not DPY19L1, and others require both DPY19L1 and DPY19L3. Some noteworthy 
proteins include THSD7A and UNC5C. THSD7A, a protein of unknown function, has a ≈4-
fold decrease in dpy19l1-/- but no significant change in dpy19l3-/-. Even more striking is the 
netrin receptor UNC5C, which has a >28-fold decrease in dpy19l1-/-, while in in dpy19l3-/-  
there is at most a 3-fold reduction in UNC5C surface expression. This striking result suggests 
that DPY19L1 could play a profound role in netrin signalling.  
 
There are cases where the log2 fold change in DPY19L1 and DPY19L3 are similar if not the 
same. IGSF3, another protein of with poorly defined function, had a log2 fold-change of 2.58 
in dpy19l1-/-, 2.54 in dpy19l3-/-, and 2.28 in the double knockout, which translates to a 6-fold 
reduction in protein levels whenever any mannosyltransferase was removed. (Figure 7.5D). 
PLAUR (Plasminogen Activator, Urokinase Receptor) had a subtler interaction with the 
mannosyltransferases, with log2 fold change of 1.44 in dpy19l1-/-, 1.11 in dpy19l3-/-, and 1.32 
in the double knockout. Also of note was SLC6A8, a creatine transporter, where the log2 fold 
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change was 1.92 in dpy19l1-/-, 1.42 in dpy19l3-/-, and 1.5 in the double knockout cells (Figure 
7.5D).  
 
The best example of a protein being dependent on DPY19L3 but not DPY19L1 was IL7R (the 
interleukin 7 receptor), which was unchanged in dpy19l1-/- and decreased by 2–3-fold in 
dpy19l3-/- and the double knockout cell lines.  
 
All of the proteins that had reduced cell surface expression and a WXXW motif were analysed 
using functional pathway gene ontology software called PANTHER [26]. Figure 7.5E 
illustrates the breakdown of the proteins into their respective functional classifications. 
Surprisingly, there are as many transporters as there are receptors. No integral membrane 
transporters have yet been shown to be C-mannosylated, perhaps because no one has focussed 
on these proteins, which are harder to work with than the membrane proteins with a single 
transmembrane region. Some transporters that warrant further investigation for C-
mannosylation include the folate transporter, the solute carrier organic anion transporter family 
member 4A1 (SLCO4A1) and sodium- and chloride-dependent creatine transporter 1 
(SLC6A8). 
 
The functional pathways of all of these putative mannosyltransferase substrates were noted to 
interact with a diverse range of unrelated signalling pathways (Figure 7.5F). This likely 
explains why so many proteins without a WXXW motif change in abundance in the absence 
of DPY19L1 and DPY19L3.  
 
To expand the list of human proteins that are differentially regulated by C-
mannosyltransferases, the THP-1 monocytes were differentiated into macrophage-like cells. 
These macrophage-like cells express and secret different proteins to the monocytes [186]. An 
established method to differentiate THP-1 monocytic cells into macrophage-like cells makes 
use phorbol 12-myristate-13-acetate (PMA) (Figure 7.6A) [187]. Using a very high dose of 
PMA (>100 ng/ml) can induce enhanced secretion of TNF, a pro-inflammatory cytokine, 
making these cells more sensitive to pro-inflammatory stimuli [188]. Therefore, it is important 
to use lower concentrations of PMA that will not activate the macrophage-like cells. In this 
case, differentiation was accomplished using 10 ng/ml of PMA for 48 h, followed by a 24 h 
rest period without PMA, tryptic detachment of cells and subculture (Figure 7.6B) [188]. Due 
to time constraints, cell surface proteomics were only conducted on the double knockout and 
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parental cell lines. To preserve the surface proteins of these adherent cells (undifferentiated 
THP-1 cells are non-adherent) we used EDTA to detach cells rather than trypsin. 
	
	
Figure 7. 6: Comparative cell surface proteomics for double knockout and parental 
THP-1 macrophage-like cells. 
a) Work-flow for differentiation of THP-1 monocytic cells into macrophage-like cells 
using PMA. M1 and M2 macrophages can also be obtained from these cells. 
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b) Diagram illustrating the strategy for differentiating the parental and double knockout 
THP-1 cells into macrophage-like cells. 
c) Volcano plot comparing the cell surface proteome of parental and double knockout 
THP-1-derived macrophage-like cells. Fold-changes (log2) of relative protein 
expression (x axis) is plotted against the log10 p-value of the detection (y axis). Proteins 
significantly decreased in expression (right side) or increased in expression (left side) 
on the THP-1 cell surface are shown in blue (-,+) and red (--,++).  
d) Heat map of proteins with a WXXW motif and a significant decrease in cell surface 
expression in the double knockout THP-1-derived macrophage-like cells. 
e) Gene ontology analysis for proteins with the WXXW motif and a significant decrease 
in cell surface expression (d). 
f) Pie chart illustrating the protein classification for the proteins in (d). 
 
 
In the volcano plot in Figure 7.6C, the proteins with a negative log2 fold change (the left 
quadrant) are those that a decreased in the double knockout. The heat map in Figure 7.6D 
shows the proteins with a WXXW motif that have decreased in cell surface expression level. 
There are many proteins that have a decreased cell surface expression in these differentiated 
macrophage-like cells that were also observed in the monocytic form (Figure 7.6D). These 
include: IGSF3, THSD7A, UNC5B, DNAJC3, LDLR, L1CAM, and SLC6A8 (Figure 7.6D). 
This result provides improved confidence in the significance of this data. Notably, there is no 
expression of UNC5C in these macrophage-like cells, which was the most severely impacted 
protein in the monocytic form. Conversely, there are many proteins observed in the 
macrophage-like cells but not the monocytic cells that possess a WXXW and experience a 
decrease in cell surface expression. These include: lipoprotein lipase (-3.10, ≈8-fold decrease), 
polymeric immunoglobulin receptor (PIGR) (-2.70, ≈6-fold decrease), cathepsin B (-1.98, ≈4-
fold decrease), transmembrane glycoprotein NMB (GPNMB) (-1.97, ≈4-fold decrease), 
fibrocystin-L (-1.41, ≈2.5-fold decrease), prolyl endopeptidase (-1.38, ≈2.5-fold 
decrease), leucine-rich repeat-containing protein 25 (LRRC25) (-1.37, ≈2.5-fold decrease), 
protein dispatched homolog 1 (DISP1) (-1.37, ≈2.5-fold decrease), oncostatin-M specific 
receptor (OSMR) (-1.36, ≈2.5-fold decrease), Toll-like receptor 2 (TLR2) (-1.23, ≈2-fold 
decrease) and Plexin-B1 (-1.21, ≈2-fold decrease) (Figure 7.6D). The majority of these proteins 
are enzymes (61%) or membrane-bound signalling receptors (34%) (Figure 7.6F). This is quite 
different to that observed for the monocytic cells, where most of the proteins were receptors 
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and transporters. These proteins played roles in myriad pathways that were, once again, quite 
different to that observed in the monocytic cells (Figure 7.6E). 
 
 
7.2.3 - DPY19L1 and DPY19L3 impact the expression profiles of different proteins  
Having observed some differences in the way that DPY19L1 and DPY19L3 impact protein 
expression, the dpy19l1-/- and dpy19l3-/- data sets were compared directly to provide a more 
systematic assessment of the differences between these enzymes. Figure 7.7A is a volcano plot 
illustrating this information: proteins in the right quadrant (positive log2 fold-change) are less 
abundant in the dpy19l1-/- cells and proteins in the left quadrant (negative log2 fold-change) are 
less abundant in dpy19l3-/- cells. This clearly shows that a greater number of proteins are 
impacted by DPY19L1 than DPY19L3 (Figure 7.7A). This raises the question as to whether 
DPY19L1 is more active in cells, simply has a greater number of substrates than DPY19L3, or 




Figure 7. 7: A direct comparison of dpy19l1-/- and dpy19l3-/- THP-1 cells.  
a) Volcano plot comparing cell surface proteomic data for dpy19l1-/- and dpy19l3-/- cells. 
Fold-changes (log2) of relative protein expression (x axis) is plotted against the log10 p-
value of the detection (y axis). Proteins that have significantly changed in abundance 
are shown in blue (-,+) and red (--,++).  
b) Gene ontology analysis for proteins with a WXXW motif that show a selective and 
significant decrease in cell surface expression in dpy19l1-/- cells. 
c) Web logo for the 16 proteins identified to have a selective decrease in cells surface 
expression in the dpy19l1-/- cells.  
d) Table showing the identity of the proteins that are selectively perturbed by loss of 




A table of proteins that are impacted only by DPY19L1 or DPY19L3 is provided in Figure 
7.7D, along with the WXXW motif from this protein. DPY19L1 impacts the expression of four 
times more proteins in monocytes than DPY19L3. The expression of THSD7A, UNC5C, 
UNC5B, ACE, and DNAJC3 are most dramatically impacted by DPY19L1. For the DPY19L3, 
the most significant shift was for IL7R. A web logo was constructed for the WXXW sequences 
for proteins impacted by DPY19L1 (Figure 7.7C), though no significant consensus was 
observed that might explain the specificity of this enzyme for these proteins. There are reports 
that DPY19L3 actually recognises the WXXC motif, which may explain this observation [74]. 
It could also be that the stability of these proteins is differentially impacted by mannose on the 
first or last tryptophan of the WXXW motif and that the observed dependencies are a function 
of the different protein folds than the local sequence of the mannosylation consensus motif.  
 
The data presented in this chapter reveals that a loss of either DPY19L1 and DPY19L3 
significantly reduces the cell surface expression of many putatively C-mannosylated proteins. 
Whilst this proteomic data is intriguing and has facilitated the development of several 
hypotheses, these results must yet be validated using orthogonal techniques, such as FACS and 
western blots and microscopy. Attempts were made to do this for the most down-regulated 
proteins, UNC5B and UNC5C, but the commercial antibodies we obtained for these proteins 
failed to recognise anything. With suitable antibodies, microscopy would also be a useful 
technique for probing these putative protein trafficking defects. Quantitative PCR or RNAseq 
data would also be useful to show that the reduction in cell surface expression is not due to 
changes in transcription  
 
7.3 - Discussion 
 
C-mannosylation is proving to be a modification that is crucial for protein folding, stability 
and/or trafficking. In this chapter, disruption of C-mannosylation in human monocytic THP-1 
cells severely impeded the ability of many proteins to reach the cell surface. A similar result 
was observed in macrophage-like cells derived from these THP-1 cell lines. These results 
mirrored results in chapters 2 and 3 of this thesis, where expression of DPY19 in Pichia 
pastoris significantly improved the expression of proteins with a WXXW motif and proteins 




In terms of evolution, it is very interesting to consider why there are at least two functional C-
mannosyltransferases in mammals and vertebrates. With the exception of dpy19l2, all other 
dpy19 genes are expressed in all mammalian tissues, suggesting that there is not much variation 
in their tissue expression profiles. Generally, organisms which have one dpy19 gene tend to 
only have TSR domain containing proteins as substrates of C-mannosylation. While those with 
two or more C-mannosyltransferases have other C-mannosylated proteins, like the type-I 
cytokine receptors. Our data reveals that most of the proteins dependent on DPY19L1 
expression possess a TSR domain, while IL7R, the protein dependent on DPY19L3 expression, 
is a type-I cytokine receptor. Thus, it may be that the C-mannosyltransferases have diversified 
as their repertoire of substrates has expanded over time. Another complementary explanation 
for the diversification of dpy19 genes is that differential expression of DPY19L1 and DPY19L3 
provides an alternative means to control client protein expression levels.  
 
One interesting observation from this work in monocytic cells is that there were four times as 
many proteins dependent on DPY19L1 and there were for DPY19L3. It is hard to interpret the 
significance of this result, as we have no measure of the absolute number of proteins modified 
by each enzyme. Could it be that there is a greater number of protein substrates for DPY19L1 
as compared to DPY19L3? To what degree are these enzyme’s redundant? What are the true 
consensus motifs for each of these enzymes? These are all important questions that remain to 
be explored. It may be that DPY19L3 has evolved specifically to glycosylate non-canonical 
motifs, such as WXXC, and that it plays a more specialised role than DPY19L1 in 
glycosylating important subsets of proteins. In chapter 6 of this thesis, it was shown that the C. 
elegans DPY19 can C-mannosylate non-canonical WXXF/Y motifs, so there is precedence for 
this non-canonical activity. Shcherbakova et al. have reported that DPY19L3 specifically C-
mannosylated the W3 motif in the W1XXW2XXW3XXC sequence of UNC5A in CHO cells 
[74]. Loss of DPY19L3 and mannosylation of the WXXC motif did not impact UNC5A 
secretion. By contrast, loss of DPY19L1, which C-mannosylates W1 and W2, resulted in severe 
reduction of UNC5A secretion. Mannosylation of the first tryptophans in these proteins appears 
to be the most important for their stability. This may explain why the stability of more proteins 
are impacted by the loss of DPY19L1 than DPY19L3. Very little is known about the role of C-
mannosylation in protein kinesis, which covers events from protein transcription to protein 
secretion [189]. C-mannosylation stabilises proteins but what happens to these proteins in the 
absence of tryptophan mannosylation? Do they fail to fold in the ER and/or denature along the 
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protein trafficking pathway or at the cell surface? Are there chaperones that recognise C2-α-D-
mannosyl-tryptophan in a similar vain to calnexin and calreticulin in the ER [190-192]? 
Unfortunately, we cannot answer this question at this moment, but a good starting point would 
be to see where these proteins are ending up using a combination of immunofluorescence 
microscopy and molecular probes to inhibit the proteasome and ERAD.   
 
UNC5C is the protein that was most severely impacted by the loss of C-mannosylation by 
DPY19L1. UNC5C, along with UNC5A, B and D, has two TSR domains and is a receptor for 
netrin-1, which is involved in apoptosis, cell migration and axon guidance. Rare activating 
mutations in UNC5C results in increased neuronal cell death and increased sensitivity to 
cytotoxic molecules such as amyloid-beta [162]. UNC5C mutations are a genetic predictor for 
the late onset of Alzheimer’s disease. It is tempting to speculate that inhibition of DPY19L1 
may restrict trafficking of this death receptor to the cell surface and slow neuronal cell death 
in these patients. Further exploration of this concept in neuronal cell lines could yield new 
directions for the treatment of a subset of people with familial Alzheimer’s disease. 
 
Most of the other proteins that had significant reduction in cell surface expression are relative 
unknowns. Thrombospondin type I domain-containing protein 7A (THSD7A) is a cell surface 
protein that is involved in endothelial cell migration and cytoskeletal organisation [193]. When 
THSD7A was knocked out of oesophageal squamous cell carcinoma (ESCC) cells lines, 
reduced tumour cell invasion, migration and proliferation was observed [194]. Thus, it may be 
that inhibition of DPY19L1 could minimise the metastasis of some tumours. Immunoglobulin 
superfamily, member 3 (IGSF3) is another protein for which little is known. It is a 
transmembrane protein and is involved in neuronal morphogenesis [195]. Lastly, DnaJ 
homolog subfamily C member 3 (DNAJC3) is a chaperone protein involved in stress responses 
and an absence of this protein results in diabetes mellitus and multi-systemic 
neurodegeneration [196, 197], suggesting that inhibition of DPY19L1 could have deleterious 
side-effects.  
 
Lipoprotein lipase (LPL) is another interesting protein that had a significant reduction in cell 
surface expression in the DPY19L1-/- DPY19L3-/- double knockout macrophage-like cells. This 
protein had an 8-fold reduction in cell surface expression and it was recently discovered that 
this protein was C-mannosylated [97]. The authors of the paper mutated tryptophan residues 
of the WXXW motif and claimed that the loss of C-mannosylation of this protein causes 
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decreased secretion and enzymatic activity. However, mutating tryptophan residues in the 
WXXW motif could have confounding results because the mutations themselves can 
destabilise the protein or cause it to not fold properly. Therefore, it cannot be claimed that C-
mannosylation is essential on this data alone. The result in this chapter provide unambiguous 
evidence that a loss of C-mannosylation reduced LPL cell surface expression. Whether C-
mannosylation impacts the enzymatic activity of this protein remains to be seen.  
 
Another interesting protein with reduced cell surface expression is the Low-density lipoprotein 
receptor (LDLR), which cluster in clathrin-coated pits. The main role of this protein is to 
function as a receptor for Low-density lipoprotein (LDL), which is an important physiological 
process. This protein also acts as an entry point for the hepatitis C virus and other viruses into 
the liver [198],[199]. This is an important drug target for managing LDL levels and virus 
infections: DPY19 inhibition may bring a new dimension to LDLR drug discovery initiatives.  
 
There were various other proteins that had significant reduction in cell surface expression and 
both of these proteins have a role in cancer progression. L1CAM had both a reduction in the 
monocytes and macrophage-like cells. L1CAM is involved in cell migration and cell adhesion 
and is implicated in cancer metastasis, in particular melanoma invasion [200]. The reduction 
of cell surface expression of this protein will also reduce tumour metastasis. IL7R is the other 
interesting protein involved in cancer which had a decrease in cell surface expression when 
DPY19L3 was knocked out. Activating mutations in IL7R drive proliferation of T-cell acute 
lymphoblastic leukaemia (T-ALL) [160]. Inhibition of DPY19L3 could reduce the cell surface 
expression of this mutant IL7R and may slow the progression of T-ALL.  
 
To accompany these musings on the possible therapeutic roles of DPY19 inhibitors inferred 
from what’s known about the proteins identified by these proteomic experiments, it is worth 
considering the similarities and differences of DPY19L1 and DPY19L3. These enzymes share 
29% similarity at the amino acid sequence level but clearly recognise different peptide 
substrates. As such, the generation of selective inhibitors may be feasible, though appropriate 
small molecule scaffolds must first be identified. Whether DPY19 inhibition, selective or 
otherwise, is of benefit in any therapeutic context remains an open-ended question. Developing 





7.4 - Conclusions 
 
The powerful combination of CRISPR-Cas9 technology and comparative cell-surface 
proteomics has provided the least biased insights yet into how the human C-
mannosyltransferases DPY19L1 and DPY19L3 impact cell surface protein expression levels. 
The human monocytic cell line THP-1 was an ideal platform for these studies, as it is easily 
cultured and transfected, expresses a lot of putative C-mannosyltransferase substrate proteins, 
and can be easily differentiated into functionally distinct cell types. This data revealed that both 
DPY19L1 and DPY19L3 are important for the expression of a range of proteins, that they 
appear to be important to different subsets of proteins, and that more proteins require DPY19L1 
in this cell lineage than DPY19L3. The data also alludes to the presence of C-
mannosyltryptophan on a host of hitherto uninvestigated proteins, such as membrane 
transporters. Very large and significant decreases in the expression level of UNC5C and 
UNC5B mirror data presented in previous chapters for heterologous expression of UNC5. It is 
very likely that tryptophan mannosylation by DPY19L1 plays an important role in netrin 





















Materials and Methods 
 
8.1 - General procedures 
 
8.1.1 - PCR  
PCR reactions were carried out in 200 µl PCR tubes with a final reaction volume of 50 µl. 
Reactions contained 1 µl of template (≈1 ng/ml), 5 µl of each primer (5 µM), 14 µl dH2O and 
25 µl of Phusion polymer master mix (2x, ThermoFisher). Reactions were performed in a 
thermocycler (BioRad). then 10 µl DNA loading buffer (6x, NEB) was added to the reaction 
and the products purified on an agarose gel (0.5-1%) with SYBR safe DNA dye (Thermofisher) 
using electrophoresis (30 min, 90 V). DNA bands were visualised and excised using a blue 
light transilluminator. DNA was extracted from the agarose gel using the Wizard® SV Gel and 
PCR Clean-Up System (Promega). 
 
8.1.2 - Cloning 
Host plasmid vectors and dsDNA inserts were digested with the appropriate restriction 
enzymes (NEB) according to the manufacturer’s protocols. The plasmid vector was also treated 
with recombinant shrimp alkaline phosphatase (rSAP, NEB) according to the manufacturer’s 
protocols prior to purification by agarose gel electrophoresis (as described in 8.1.1.1). The 
digested dsDNA inserts were simply purified using the Wizard® SV Gel and PCR Clean-Up 
System (Promega). Ligation reaction were performed using a Quick Ligation kit (NEB) 
according to the manufacturer’s instructions. For transformation into bacterial cells, 2 µl of the 
ligation mixture was combined with 4 µl of KCM solution (5x) [201] and 14 µl of dH2O. 20 
µl of chemically competent TOP10 E. coli cells were added and the mixture was incubated on 
ice for 20 min followed by incubation at RT for 10 min. This 40 µl mixture was then plated 
onto LG agar plates with the appropriate antibiotic for the resistance marker used by the 
plasmid vector. Individual colonies were expanded, the plasmids isolated (Miniprep kit, 
Invitrogen) and Sanger sequencing (AGRF) performed to ensure that the plasmid possessed 




8.1.3 - Integration of vectors into Pichia pastoris 
pGAPZ and related plasmids (ThermoFisher) were integrated according to the manufacturer’s 
protocols. Briefly, 10 µg of plasmid linearized with AvrII was transformed into 100 µl of Pichia 
pastoris GS115 cells and plated onto YPDS (1% yeast extract, 2% peptone, 2% dextrose and 
1 M sorbitol) plates supplemented with 100 µg/µl zeocin. The plates were incubated in the dark 
at 30 °C for 4 days until colonies could be observed. Individual clones were re-plated onto 
YPDS + 100 µg/µl zeocin with a scoring grid. Zeocin-resistant clones were picked into 1 ml 
YPD (1% yeast extract, 2% peptone, 2% dextrose) media and cultured at 30 °C overnight. 
Genomic DNA was isolated (see 8.1.4) and PCR was used to confirm integration of the plasmid 
into the relevant locus. Clones that were validated by PCR were then analysed by Western blot 
(see 8.1.7) with an appropriate antibody to confirm expression of the integrated gene.  
pPIC9, pPIC9K and related plasmids (ThermoFisher) were integrated according to the 
manufacturer’s protocols. Briefly, 10 µg of plasmid linearized with SalI or SacI was 
transformed into 100 µl of Pichia pastoris cells and plated onto histidine drop-out media plates. 
The plates were incubated at 30 °C for 4 days until colonies could be observed. Individual 
clones were picked into 1 ml YPD (1% yeast extract, 2% peptone, 2% dextrose) media and 
cultured at 30 °C overnight. Genomic DNA was isolated (see 8.1.4) and PCR was used to 
confirm integration of the plasmid into the relevant locus. Clones that were validated by PCR 
were cultured on small scale and protein expression induced with methanol (as described in 
the manufacturer’s manual). Culture supernatants were evaluated by SDS-PAGE (see 8.1.6) 
and/or Western blot (see 8.1.7) with an appropriate antibody to confirm expression of the 
integrated gene. 
 
8.1.4 - Isolation of Pichia pastoris genomic DNA 
Yeast cell cultures were grown in YPD media (1 ml) at 30 °C and 220 rpm to an OD600 of 5.0. 
Cells were pelleted by centrifugation at 4 °C for 5 min at 1,500 × g. The cell pellet was washed 
twice with sterile H2O (10 ml) by resuspension and pelleting by centrifugation. The pellet was 
resuspended in 200 µl of buffer containing 10 mM NaPi @ pH 7.5, 1 M sorbitol, 10 mM EDTA, 
10 mM DTT. The suspension was then treated with 3 units of lyticase for 60 min at 37 °C to 
digest the yeast cell wall. 200 µl of 1% SDS was added and the samples carefully inverted 6 
times and incubated on ice for 5 min. 150 µl of 5 M potassium acetate @ pH 8.9 was added 
and the samples carefully inverted 6 times. The samples were then centrifuged at 10,000 × g 
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for 10 min at 4 °C. The supernatant was transferred to a fresh 1.5 ml microcentrifuge tube. 2 
volumes of 100% ethanol were added to the supernatant and the samples incubated for 15 min 
at RT. The samples were centrifuged at 10,000 × g for 20 min at 4 °C. The supernatant was 
discarded and the pellet was resuspended in 200 µl of TE buffer containing 10 mM Tris @ pH 
7.5, 1 mM EDTA. One volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added to 
the samples and the mixture vortexed vigorously before centrifugation at 16,000 × g for 5 min 
at RT. The upper aqueous phase was removed and placed in a fresh 1.5 ml microcentrifuge 
tube. 100 µl of 7.5 M NH4OAc was added and the sample mixed. 750 µl of 100% ethanol was 
added and the sample mixed. The sample was incubated at -80 °C for at least 1 h. Centrifugation 
at 4 °C for 30 min at 16,000 × g, followed by careful removal of the supernatant provided the 
gDNA pellet. This was washed with 150 µl of 70% ethanol. The DNA pellet was air-dried in 
a fume hood for 1 h. The gDNA pellet was resuspended in sterile H2O and stored at 4 °C. 
 
8.1.5 – Fractionation of yeast sub-cellular compartments 
Yeast cultures (100 ml) were grown in YPD to an OD600 of 2.0 then centrifuged at 1,500 × g 
for 5 min at 4 °C. The cell pellet was washed twice with filter-sterilised dH2O then resuspended 
in 2 ml of buffer containing 30 mM Tris-HC1 pH 7.5, 50 mM KC1, 5 mM MgCl2, 1 M sorbitol, 
10 mM DTT and 20% v/v glycerol. Thirty units of lyticase was added and the cells incubated 
at 37 °C for 60 min. Protease inhibitor cocktail (Roche cOmplete) was added to the mixture 
and the cells were lysed using a French press, with the mixture being passed through the 
pressure cell 8 times. The lysate was centrifuged at 3,000 × g for 5 min at 4 °C. The supernatant 
was then centrifuged three times at 16,000 × g for 10 min at 4 °C g to remove mitochondria 
and cell nuclei. This supernatant was then centrifuged at 90,000 × g for 1 h at 4 °C. The pellet 
containing the yeast’s microsomes was suspended in buffer containing 30 mM Tris-HC1 pH 
7.5, 50 mM KC1, 5 mM MgC12, 1 M sorbitol, 10 mM DTT and 20% v/v glycerol and stored 
at 4 °C for no longer than 24 h. 
 
8.1.6 - SDS-PAGE analysis 
Protein samples containing SDS loading buffer (ThermoFisher) were heated at 95 °C for 2 min, 
cooled and loaded onto a NuPAGE™ Novex™ 4-12% Bis-Tris protein gel (ThermoFisher). 
Electrophoresis was performed in a gel tank using NuPAGE™ MES SDS Running Buffer 
(ThermoFisher) according to the manufacturer’s instructions. Acrylamide gels were stained 
using a solution containing 0.2% Coomassie Brilliant Blue, 40% methanol, 10% acetic acid for 
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30 min at RT. De-staining was performed using a solution containing 10% methanol and 10% 
acetic acid for 4 h. 
 
8.1.7 - Immunoblotting (Western blots) 
Protein samples were subjected to SDS-PAGE as described in 8.1.6 but rather than being 
stained, proteins in the acrylamide gel were transferred to a nitrocellulose membrane using a 
mini blot module (ThermoFisher) according to the manufacturer’s protocols (60 min and 10 
V). The membrane was blocked with 4% skim milk in PBS for 60 min at RT. The membrane 
was washed with PBS + 0.1% tween 20, and probed with a primary antibody in PBS + 3% 
skim milk. The membrane was then washed with PBS + 0.1% tween 20 and probed with a 
secondary antibody conjugated to horse radish peroxidase (HRP) (ThermoFisher) for 60 min 
in PBS + 3% skim milk. The membrane was then washed with PBS + 0.1% tween 20, 
developed using the Immobilon Western Chemiluminescent HRP Substrate (Merck) and 
imaged using a ChemiDocTM Imaging System (BioRad).  
 
8.1.8 - Expression of proteins in Pichia pastoris using methanol induction 
A colony of the relevant protein-expressing yeast strain was used to inoculate 10 ml of YPD 
culture, which was grown for 24 h at 30 °C and 220 rpm. The 10-ml culture was used to 
inoculate 1 L of BMGY media (see Table 8.8) and this was cultured at 30 °C and 220 rpm until 
the OD600 reached 6.0 (≈24 h). The cells were gently pelleted by centrifugation at 1,500 × g for 
20 min at 4 °C, then resuspended in BMMY media (see Table 8.8) and cultured at 30 °C and 
220 rpm for 48 h, with an additional 0.25% v/v methanol being added after 24 h. The 
supernatant was harvested by centrifugation at 9,000 × g for 20 min at 4 °C. The supernatant 
was filtered (0.45 µm, Millipore), treated with a protease inhibitor cocktail (Roche cOmplete) 
and EDTA and NaN3 added to final concentrations of 2 mM and 0.02%, respectively. The 
supernatant was concentrated to 100 ml using an Amicon stirred cell (Millipore) and 
membranes with an 8 kDa NMWL. This concentrate was dialysed against twice against 2 L of 
50 mM Tris-HCl, 500 mM NaCl @ pH 7.5. After concentration and dialysis, this supernatant 
could be captured and purified by IMAC (see 8.1.9).  
 
8.1.9 - Immobilized metal affinity chromatography (IMAC) 
Immobilized metal affinity chromatography (IMAC) was performed using His GraviTrap 
TALON® columns (GE-Healthcare) according to the manufacturer’s protocol. Briefly, the 
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Talon column was washed once with dH2O then equilibrated into binding buffer (50 mM Tris-
HCl, 500 mM NaCl @ pH 7.5). The concentrated and dialysed supernatant (see 8.1.8) was 
applied to the column under gravity. The column was washed with one column-volume of 
binding buffer. Protein was eluted from the column using elution buffer (50 mM Tris-HCl, 500 
mM NaCl, 500 mM imidazole @ pH 7.5). The purity of fractions from this column were 
assessed by SDS-PAGE (see 8.1.6). Protein fractions with desired protein were pooled and 
further purified by SEC (see 8.1.10) and/or IEX (see 8.1.11).  
 
8.1.10 - Size exclusion chromatography (SEC) 
Protein samples were purified by SEC using either Superdex 75 increase 10/300 GL or 
Superdex 200 increase 10/300 GL columns (GE-Healthcare) on an FPLC system. Unless 
otherwise stated, the buffer containing 50 mM Tris-HCl, 150 mM NaCl @ pH 7.5 was used 
for these purifications. Protein fractions were assessed for purity using SDS-PAGE (see 8.1.6). 
 
8.1.11 - IEX 
Protein samples in low-salt buffer were purified by IEX using either MonoQ 10/100 GL or 
MonoS 10/100 GL columns (GE-Healthcare) on an FPLC system. The buffers species, pH and 
salt gradients used varied from protein to protein and are detailed elsewhere. Protein fractions 
were assessed for purity using SDS-PAGE (see 8.1.6). 
 
 
8.2 - Creating and studying Pichia pastoris strains harbouring DPY19 
 
8.2.1 – Integrating CeDPY19 into Pichia pastoris 
A synthetic gene encoding the Caenorhabditis elegans DPY19 (CeDPY19) protein with a C-
terminal 3× Flag-tag was codon optimised for Pichia pastoris (IDT) and cloned into pGAPZ. 
This vector was integrated into Pichia pastoris using the general procedure outlined in 8.1.3. 


































8.2.2 - Generation of CeDPY19 mutants 
Eight DPY19 mutants were made using the four primer PCR method. Primers for these 
reactions are provided in Table 8.1. PCR protocols are provided in 8.1.1. Mutant amplicons 
were cloned into pGAPZ using the EcoRI and NotI restriction sites. These vectors were 
integrated into Pichia pastoris using the general procedure outlined in 8.1.3. 
	
Figure 8. 1: List of primers for making DPY19 mutants 




























































































































































































































8.2.3 - Generation of IL12B mutants 
Two IL12B mutants were made using the four primer PCR method. Primers for these reactions 
are provided in Table 8.2. PCR protocols are provided in 8.1.1. Mutant amplicons were cloned 
into pPIC9K using the EcoRI and NotI restriction sites. These vectors were integrated into 
Pichia pastoris using the general procedure outlined in 8.1.3. 
 
Figure 8. 2: List of primers for making IL12B mutants 
Mutant Template Forward primer Reverse primer 
W300Y pGAPZ-DPY19 CTTTCATAATTGCGACTGGTTCC AATTCGCGGCCGCTCAGGAACAGGGCA 
CTGAGGCATATTCGGACCAGGAAGATG 
AATAG 





8.2.4 - Yeast growth curves 
A 5 ml YPD overnight culture (30 °C and 220 rpm) of Pichia pastoris GS115 with and without 
CeDPY19 was used to inoculated 100 ml of YPD. These 100-ml cultures were grown at 30 °C 
and 220 rpm, with the OD600 recorded every 60 min for 15 h. The data was plotted using Prism 
8 (GraphPad) and fitted to an exponential growth curve to obtain the growth exponent for each 
yeast strain. 
 
8.2.5 - In vitro C-mannosylation assay 
This assay was carried out in 1.5 ml microcentrifuge tubes with a final volume of 25 µl and 
contained 5 mM GDP-[3H] Man (120 KBq), 5 mM GDP-Man, 100 mM MOPS (pH 7.5), 0.1% 
saponin, 2 mM MnCl2, 2 mM MgCl2, 2 mM ATP, 1 mM synthetic peptide and 2 µl of 
membrane vesicles (see 8.1.5). The mixture was incubated in a shaker at 400 rpm at 28 °C for 
20 h. The reaction was stopped by adding 1 ml chloroform/methanol 3:2 (v/v) and 230 µl of 
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H2O. The samples were vortexed briefly and centrifuged at 3000 × g for 5 min. 400 µl of the 
aqueous (upper) layer containing the peptide was diluted into 4 ml of dH2O with 0.1% 
trifluoroacetic acid (TFA). This diluted aqueous solution was passed through a 200 mg C18 
Solid Phase Extraction Cartridge (SepPak, Waters) using a disposable plastic syringe. The solid 
phase cartridge was washed two times with 10 ml dH2O with 0.1% TFA. The labelled peptides 
were eluted with 4 ml of 100% methanol into a glass tube and the methanol evaporated. The 
residue was dissolved in 200 µl of methanol and 2 ml of scintillation solution (PerkinElmer) 
was added to the sample. This solution was transferred to counting tubes and beta-emission 
activity quantitated using a Microbeta scintillation counter (PerkinElmer).  
 
8.2.6 - Immunoblotting for CeDPY19 
Clones that had positive integration of CeDPY19 into the GS115 genome were grown in 1 ml 
of YPD media overnight at 30 °C at 220 rpm to an OD600 of 2.0. The culture was then 
centrifuged at 1500 × g for 10 min at 4 °C, cells were washed twice with sterile dH2O and the 
pellet was resuspended in 200 µl of buffer containing 10 mM NaPi @ pH 7.5, 1 M sorbitol, 10 
mM EDTA, 10 mM DTT. Cell walls were digested using 5 units of lyticase for 60 min at 37 
°C at 220 rpm to create spheroplasts. Protease inhibitor cocktail (Roche cOmplete) was added 
to the spheroplasts, which were then lysed using 200 µl of 10% SDS solution and 5 units of 
Benzonase® (Sigma) at 4 °C for 5 min with periodical inversion. 10 µl of 4x SDS loading buffer 
was added to 30 µl of this cell lysate and the mixture maintained at 37 °C for 10 min. It was 
crucial that these samples were not heated higher than this temperature, as this led to 
aggregation of the protein of interest. This sample was subjected to SDS-PAGE (see 8.1.6) and 
immunoblotting (see 8.1.7) using monoclonal ANTI-FLAG® M2 antibody (1/5000) (Sigma) 
as the primary antibody.  
 
8.2.7 - Production of MBP-FLAG3 
The dsDNA sequence below was manufactured (IDT) and cloned (see 8.1.2) into the 






This plasmid was transformed into chemically competent ‘NEB Express’ E. coli using the 
KCM method and plated onto LB-agar (100 µg/ml Amp) and incubated at 37 °C for 16 h. A 
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single colony was used to inoculate 10 ml of LB media containing 100 µg/ml Amp followed 
by incubation at 37 °C for 16 h. This culture was used to inoculate 1000 ml of “S-broth” (35 g 
tryptone, 20 g yeast extract, 5 g NaCl, pH 7.4) containing 100 µg/ml Amp, which was then 
incubated with shaking (250 rpm) at 37 °C until it reached an OD600 of 0.8. The culture was 
cooled to room temperature, IPTG added to a final concentration of 100 µM, and then incubated 
with shaking (200 rpm) at 18 °C for 19 h. The cells were harvested by centrifugation at 18,000 
× g for 20 min at 4°C. The cell pellet was resuspended in 40 ml of binding buffer (50 mM Tris, 
300 mM NaCl, 5 mM imidazole, pH 6.0) containing protease inhibitor cocktail (Roche 
cOmplete) and lysozyme (0.1 mg/ml) by nutating at 4°C for 30 min. Benzonase (1 µl) was 
added to the mixture then lysis was effected by sonication [10× (15 s on / 45 s off) at 45% 
amplitude]. The lysate was centrifuged at 18,000 × g for 20 min at 4°C and the supernatant 
collected. The supernatant was purified by IMAC (see 8.1.9) and SEC on a Sephacryl 200 
column (see 8.1.10). 
 
8.3 - Producing and characterising C-mannosylated proteins in yeast. 
 
8.3.1 - Reporter protein constructs 
DNA sequences encoding human IL21R (20-232 aa), EPOR (25-250 aa), PLR (25-234 aa) and 
IL12B with a hexahistidine tag, as well as sequences encoding human RNaseII, mindin 
(Spondin 2) TSR domain (277-331 aa) and C. elegans UNC5 TSR2 domain (274-326 aa) with 
a SUMO fusion partner and hexahistidine tag, were codon harmonised for Pichia pastoris 
(Table 8.3), synthesised (IDT), and cloned into pPIC9K using the NotI and XhoI restriction 
sites. Sanger sequencing-validated plasmids were integrated into P. pastoris strains (see 8.1.3). 
Proteins were expressed and purified described above (see 8.1.8-10). 
 
















































































































8.3.2 - Reduction and alkylation of protein samples for proteolysis 
Recombinant protein samples were mixed in buffer containing 2 M GnHCl, 5 mM DTT at 55 
°C for 30 min. Samples were cooled to RT and treated with 5 mM iodoacetamide for 30 min 
with the exclusion of light. The reaction was quenched by the addition of 10 mM DTT and 
incubated at RT for 5 min. Nine volumes of ice-cold ethanol was added to the samples, which 
were mixed well and incubated at -20 °C overnight. Samples were centrifuged for 15 min at 
13,000 × g at 4 0C. the supernatant was discarded and 1 ml of ice-cold ethanol was added to 
the pellet and incubated at -20 0C for 60 min. The samples were then centrifuged at 13,000 × g 
for 15 min at 4 °C. The supernatant was discarded and the protein pellet air-dried in a fume-
hood. 
 
8.3.3 - Proteolysis of proteins for mass spectrometry 
Reduced and alkylated samples (see 8.3.2) were resuspended in 40 mM NH4HCO3 buffer and 
treated with GluC (Promega) or trypsin (Promega) for 24 h (GluC) or 16 h (trypsin) at 37 °C. 
Peptides were captured using C18 stage tips [202, 203], eluted with buffer containing 0.1% 
formic acid and 80% MeCN, evaporated and stored at -20°C prior to analysis by LC-MS. 
 
8.3.4 - Identification of glycopeptides using reversed phase LC-MS, CID MS-MS and 
HCD MS-MS  
Purified peptides were re-suspended in Buffer A* (0.1% TFA, 2% MeCN) and subjected to 
analysis on either a Q-Exactive or Orbitrap Fusion™ Lumos™ Tribrid™ Mass Spectrometer 
(ThermoScientific). Q-Exactive analysed samples were separated using an in-house packaged 
25 cm, 75 µm inner diameter, 360 µm outer diameter, 1.7uµm 130 Å CSH C18 (Waters) reverse 
phase analytical column with an integrated HF etched nESI tip. Samples were loaded directly 
onto the column using an ACQUITY UPLC M-Class System (Waters) at 600 nl /min for 20 
min with Buffer A (0.1% FA, 2% MeCN) and eluted at 300 nl/min using a gradient altering 
the concentration of Buffer B (0.1% FA, 80% MeCN) from 2% to 32% B over 60 mins, then 
from 32% to 40% B in the next 10 min, then increased to 80% B over 8 min period, held at 
100% B for 2 min, and then dropped to 2% B for another 10 min. RP separated peptides were 
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infused into the Q-Exactive and data acquired using data dependent acquisition with one full 
precursor scan (resolution 70,000; 440-2000 m/z, AGC target of 1×106) followed by 10 data-
dependent HCD MS-MS events (resolution 35k AGC target of 2 × 105 with a maximum 
injection time of 150 ms, NCE stepping set to 20; 26; 32) with 60 s dynamic exclusion enabled. 
Fusion™ analysed samples were separated using a two-column chromatography set up 
comprising a PepMap100 C18 20 mm x 75 µm trap and a PepMap C18 500 mm x 75 µm 
analytical column (ThermoScientific). Samples were concentrated onto the trap column at 5 
µl/min for 5 min and infused into an Orbitrap Fusion™ Lumos™ Tribrid™ Mass Spectrometer 
at 300 nl/min via the analytical column using a Dionex Ultimate 3000 UPLC 
(ThermoScientific). 95 min gradients were run altering the buffer composition from 1% buffer 
B to 28% B over 60 min, then from 28% B to 40% B over 10 mins, then from 40% B to 100% 
B over 2 min, the composition was held at 100% B for 3 min, and then dropped to 3% B over 
5 mins and held at 3% B for another 15 min. The Lumos™ Mass Spectrometer was operated 
in a data-dependent mode automatically switching between the acquisition of a single Orbitrap 
MS scan (120,000 resolution) every 3 s and Orbitrap EThcD, Orbitrap HCD and ion trap CID 
scans for each selected precursor (maximum fill time 100 ms, AGC 1*105 and with a resolution 
of 30,000 for Orbitrap MS-MS scans). 
 
8.3.5 - Mass spectrometry data analysis 
Identification of proteins and C-glycosylated peptides was accomplished using MaxQuant 
(v1.5.3.1) [204]. Searches were performed against the predicted amino acid sequence of each 
protein with carbamidomethylation of cysteine set as a fixed modification. Searches were 
performed with trypsin cleavage or GluC specificity based on the digestion type allowing 2 
miss cleavage events and the variable modifications of oxidation of methionine, Hexose (W) 
(C6H10O5 addition to tryptophan) and acetylation of protein N-termini. The precursor mass 
tolerance was set to 20 parts-per-million (ppm) for the first search and 10 ppm for main search, 
with a maximum false discovery rate (FDR) of 1.0% set for protein and peptide identifications. 
The resulting outputs were processed within the Perseus (v1.4.0.6) [205] analysis environment 
to remove reverse matches and common proteins contaminates prior to further analysis. 
Glycopeptides identified were manually assessed according to the guidelines of Chen et al 
[206], annotated manually with the aid of Protein Prospector tool MS-Product 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct) and are provided 
within the supplementary figures. Occupation analysis was undertaken using extracted ion 
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chromatograms of identified peptide species. Extracted ion chromatograms of the 
monoisotopic peak, ±10ppm, of identified glycopeptides and unmodified peptides species were 
generated within Xcalibur (version 2.2, Thermo Scientific). Peaks were processed with a 15-
point Gaussian smooth and the area under the curve calculated. The resulting areas were used 
to compare peptide species with occupation rates provided as a percentage of the total ion 
current of compared species. 
 
8.3.6 - Differential scanning fluorimetry  
Differential scanning fluorimetry was performed in 0.1 ml strip tubes with a final reaction 
volume of 20 µl. Briefly, 1-3 µg of protein was mixed with buffer containing 50 mM Tris-HCl, 
150 mM NaCl @ pH 7.5 along with 1 µl of SYPRO™ Orange Protein Gel Stain (1:100 in 
DMSO). The tubes were then placed in a Rotor-Gene Q and samples were heated from 25 °C 
to 80 °C in 1 min intervals. The raw data was then processed by truncating the data set to centre 
on the sigmoidal melting curve. This data was normalised and a Boltzmann Sigmoidal curve 
was fitted to provide a calculated Tm value. All experiments were conducted in triplicate. 
 
8.3.7 - RNaseII activity assay 
The RNase activity assay was adopted and modified from Tripathy et al [157] for RNaseII. 
Briefly, the reaction was conducted in 1 ml disposable cuvettes with reaction volumes of 1000 
µl in buffer containing 50 mM Tris, 150 mM NaCl at pH 7.5 at 37 °C. RNA concentrations of 
60, 50, 40, 30, 20, 16, 8, and 4 µg/ml were incubated with 4 µM ethidium bromide for 30 min 
at RT. RNaseII-GS115 and RNaseII-DPY19 at 0.004 mg/ml was added to each sample and the 
decay of florescence emission at 600 nm was continuously monitored for 10 min at 30 °C. The 
sample was excited at 510 nm. The data from 0-60 s fit well to a linear regression model, with 
the slope providing the initial velocity of the enzyme under that condition. These initial rates, 
were plotted with respect to substrate concentration and fit with a Michaelis-Menten model 
using Prism 8 (GraphPad) to provide the kinetic parameters for the different glycoforms of 
RNaseII. 
 
8.3.8 - ELISA assay for LPS binding by mindin 
The ELISA assay for LPS binding by mindin was adapted and modified from He et al. [81]. 
Briefly, 100 µl of 10 µg/ml of casein, mindin-GS115 and mindin-DPY19 diluted in buffer 
containing 100 mM sodium bicarbonate at pH 9.6 were coated on Nunc-Immuno MicroWell 
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96-well plates (ThermoFisher) overnight at 4 °C. Wells were washed four times with PBS + 
0.2% tween-20, blocked with 100 µL PBS + 3% BSA at RT for 1 h, then washed four times 
with PBS + 0.2% tween-20. 100 µl of LPS was incubated in wells at concentrations of 300 
µg/ml, 100 µg/ml, 10 µg/ml, 1 µg/ml, 100 ng/ml and 0 ng/ml at RT for 1 h. These wells were 
then washed four times with PBS + 0.2% tween-20 and probed using 20 µL of 1 µg/ml (in 
PBS+ 3%BSA) of anti-LPS antibody (Biomatik) at RT for 2 h. Four washes with PBS + 0.2% 
tween-20 came next, followed by incubation with 20 µL of 1 µg/ml (in PBS+ 3%BSA) goat 
anti-mouse IgG-HRP conjugate (ThermoFisher) at RT for 1 h. The wells were then washed 
four times with PBS + 0.2% tween-20, then 100 µl of 1 mg/ml OPD (o-Phenylenediamine 
dihydrochloride) (ThermoFisher) developing reagent was incubated in wells for 20 min. The 
reaction was stopped with sulfuric acid and absorbance was measured at 490 nm. Absorbance 
data was plotted using Prism 8 (GraphPad). 
 
8.4 – Mammalian cell culture, cell line generation and cell surface proteomics. 
 
8.4.1 - THP-1 cell culture 
THP-1 cells were maintained in Roswell Park Memorial Institute (RPMI 1640) medium 
supplemented with 10% fetal calf serum and 100 µg/ml penicillin- streptomycin at 37 °C with 
5% CO2. Cells were sub-cultured in fresh media regularly to maintain cell viability and 
numbers. 
 
8.4.2 - HEK293T cell culture 
HEK293T cells were maintained in DMEM media supplemented with 10% fetal calf serum 
and 100 µg/ml penicillin- streptomycin until 90% confluency and split 1:5 to 1:10 at 37 °C 
with 5% CO2 to maintain cell viability and numbers. 
 
8.4.3 - Lentivirus production/transfection for CRISPR-Cas9 experiments 
The day before transfection, 3 x 106 HEK293T cells were seeded into a 10-cm dish in DMEM 
media supplemented with 10% fetal calf serum and 100 µg/ml penicillin- streptomycin and 
incubated at 37 °C with 5% CO2 overnight. On the day of transfection, the transfection mix 
was prepared by adding 4 µg of CRISPR guide RNA vector, 2 µg PMDL vector, 1 µg of pRSV-
Rev vector, 1 µg VSVG vector, 24 µl Fugene 6 and 300 µl optimum media and incubated for 
	
	 178	
20 min at RT. The media for the cells was replaced with fresh media and transfection mix was 
added to the cells dropwise and they were incubated at 37 °C overnight. The next day, the 
media was removed from the cells and 6 ml of fresh media was added to the cells and incubated 
overnight at 32 °C. Target cells for transfection with lentivirus were seeded at 100,000 cells 
per well in a 6-well plate. The next day, the lentivirus was harvested and filtered using a 0.45 
µM filter and 6 µl of polybrene was added to the virus. Spin transfection was initiated by adding 
3 ml of lentivirus and cells were centrifuged at 3000 × g for 60 min at 32 °C. the cells were 
then incubated at 37 °C for 4 h and the media was then replaced and then incubated at 37 °C 
overnight. After 24 h, the media for the infected cells was changed and cells were split in 
transferred into a T25 flask. The cells were allowed to rest for 48-72 hours and viability was 
assessed. Cas9 was then induced using doxycycline (50 mg/ml; diluted to 1/10,000) for 4 days. 
After doxycycline treatment, cells were allowed to rest for 4 days with two media changes. 
Cells were then sorted using FACS gated for mCherry (Cas9) and GFP/CFP (guide RNA) into 
96-well plates in 100 µl of fresh media. After 10 days, the cells were transferred into 24-well 
plates with 300 µl of media. After the cells were confluent, 16 clones were selected for genomic 
DNA extraction (see 8.4.5), PCR amplification and sequencing (see 8.4.6).  
 
8.4.5 - Isolation of genomic DNA from THP-1 cells 
Five million cells were centrifuged at 250 × g for 5 min. Genomic DNA was isolated from the 
cell pellet using the PureLink® Genomic DNA Mini Kit (ThermoFisher) according to the 
manufacturer’s instructions. gDNA was stored at 4 °C. 
 
8.4.6 - PCR amplification and sequencing of CRISPR’d genomic DNA 
PCR reactions were carried out in 200 µl PCR tubes with a final reaction volume of 50 µl 
containing 1 µl of genomic DNA, 5 µl of each primer (5 µM stock, Table 7.4), 14 µl dH2O and 
25 µl of GoTAQ (Promega). Reactions were performed in a thermocycler (BioRad), 10 µl of 
6x DNA loading dye was added, and the sample subjected to electrophoresis (30 min at 90 V) 
on a 1% agarose gel containing SYBR safe DNA dye. Bands corresponding to the PCR product 
were excised and the DNA extracted from the agarose gel using the Wizard® SV Gel and PCR 
Clean-Up System (Promega). These amplicons were subjected to Sanger sequencing (AGRF) 





Figure 8. 4: Sequencing primers for CRISPR of dpy19l1 and dpy19l3 
Gene Product size (bp) Forward primer Reverse primer 









8.4.7 - Sample preparation for cell surface proteomics 
Cells were harvested at 250 × g for 5 min at 4 °C and washed twice with ice-cold PBS (pH 
7.4). The sialic acid residues of cell surface proteins were oxidised and biotinylated with 1 mM 
sodium meta-periodate (ThermoFisher), 200 µM amino-oxy-biotin (Biotium) and 10 mM 
aniline (Sigma) in PBS at pH 6.7 for 1 h at 4 °C, with cells at a concentration of 2x107 cells/ml. 
The oxidation and labelling reaction was quenched by the addition of 1 mM glycerol. Cells 
were washed three times with PBS at pH 7.4, then harvested by centrifugation at 400 × g for 5 
min at 4 °C. The cell pellet was resuspended in lysis buffer containing 1% Triton X-100, 
150mM NaCl, protease inhibitor cocktail (Roche, cOmplete), 10 mM Tris-HCl, pH 7.6 and 
lysed for 60 min at 4 °C. Nuclei were removed by centrifugation at 2800 × g for 10 min at 4 
°C, then 16,000 × g for 10 min at 4 °C. The lysate was incubated with 50 µl of high-affinity 
streptavidin-agarose for 1 h 4 °C. The agarose beads were washed twice with lysis buffer, 
followed by washing three times with PBS + 0.5% (w/v) SDS. 100 mM DTT in 200 µl PBS + 
0.5% SDS was added to the beads and incubated for 20 min at RT. The beads were then washed 
with UC buffer (6 M urea, 100 mM Tris-HCl, pH 8.5) 10 times. 50 mM iodoacetamide in 100 
µl of UC buffer was added to the beads and they were incubated for 20 min at RT in the dark. 
The beads were then washed 10 times with UC buffer, followed by washing with PBS four 
times and dH2O three times. Proteins were digested on-bead with 2 µg Trypsin Gold in 100µl 
50 mM NH4HCO3 for 16 h. The samples were centrifugation at 1000 × g for 1 min and the 
supernatant containing the peptides of interest collected for mass spectrometry analysis 
(performed by Dr. Jarod Sandow at WEHI). 
 
8.4.8 - PMA differentiation 
1.5 ×106 cells were seeded into 100 mm dish containing 5 ml of RPMI 1640 media 
supplemented with 10% fetal calf serum and 100 µg/ml penicillin-streptomycin. PMA was 
added to a final concentration of 10 ng/ml and the cells were incubated at 37 °C with 5% CO2 
for 48 h. These cells were then washed once with PBS and 5 ml of the same media was added 
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to the cells, which were incubated at 37 °C with 5% CO2 for an additional 24 h. These adherent 
cells were then washed three times with PBS, trypsinised to detach cells, and then re-seeded 
into a fresh 100 mm dish containing 5 ml of the same media. Once these cells had reached 
satisfactory confluence they were harvested using EDTA-mediated detachment and prepared 
for cell surface proteomics (see 8.4.8). 
 
8.5 – Antibody generation and characterisation. 
 
8.5.1 - Proteolysis and purification of IL21R 
Before the proteolysis of IL21R, clostripain required activation for 1 h at RT. The clostripain 
activation reaction included 100 µg of clostripain in 10 mM Tris-HCl buffer with 2.5 mM DTT 
and 1 mM CaCl2. The proteolysis reaction included 5 mg of IL21R, 10 mM Tris-HCl buffer 
with 2.5 mM DTT, 1 mM CaCl2 and the addition of the entire clostripain activation reaction. 
After 2 h of digestion at 37 °C, protease inhibitor cocktail (Roche cOmplete) was added to the 
reaction and the sample was stored on ice before IMAC purification. The C-mannosylated 
peptide of interest was then purified with IMAC using a 1 ml HisTrap HP column (GE-
Healthcare). The HisTrap HP column was equilibrated with binding buffer (50 mM Tris-HCl, 
500 mM NaCl @ pH 7.5) and the proteolysis reaction applied to the column. The column was 
then washed with binding buffer for a total of 10 column volumes then eluted using elution 
buffer (50 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole @ pH 7.5). Protein fractions were 
assessed via SDS-PAGE for the peptide of interest. The fraction containing the peptide of 
interest was further purified by SEC using a Superdex 75 increase 10/300 GL column (GE-
Healthcare) equilibrated with 50 mM Tris-HCl, 150 mM NaCl @ pH 7.5. The eluted protein 
fractions were assessed by SDS-PAGE and the fractions containing the peptide of interested 
were pooled and purified further using high performance liquid chromatography (HPLC). 
HPLC was performed on a C8 semi-prep column equilibrated with buffer A (95% H2O, 5% 
MeCN and 0.1% TFA), the sample loaded and then eluted with a gradient from 5-100% of 
buffer B (100% MeCN and 0.1% TFA) across 12 column volumes (30 mL). Fractions were 
analysed using LC-MS to identify the peptide and assess its purity. Fractions containing pure 




8.5.2 - Conjugation of peptide to maleimide activated KLH and BSA 
The purified C-mannosylated peptide was dissolved in buffer (50 mM NaPi, 150 mM NaCl, 5 
mM EDTA, at pH 8) and Traut’s reagent added (final concentration 700 µM) followed by 
incubation for 1 h at 22 °C. This thiolated peptide was rapidly purified using a PD MiniTrap 
G-10 desalting column (GE-Healthcare) into conjugation buffer (100 mM NaPi, 150 mM NaCl, 
5 mM EDTA, pH 7.2). For conjugation to KLH, 600 µg of maleimide-activated KLH was 
combined with 400 µg of the desalted thiolated peptide in conjugation buffer and the sample 
incubated at 22 °C for 2 h. Reduced glutathione was added (final concentration 150 µM) and 
incubated for 20 min at 22 °C to quench the reaction. The sample was then desalted into 
DMPBS using a Zeba spin column (ThermoFisher). For conjugation to BSA, 400 µg 
maleimide-activated BSA was added to 300 µg of the desalted thiolated peptide in conjugation 
buffer and the sample incubated at 22 °C for 2 h. Cysteine was added (final concentration 200 
µM) and incubated for 20 min at 22 °C to quench the reaction. The sample was desalted into 
storage buffer (80 mM NaPi, 900 mM NaCl, 100 mM sorbitol) using a Zeba spin column 
(ThermoFisher).   
 
8.5.3 - Antigen immunisation schedule for mice 
At day 0, four mice were immunised with 45 µg of peptide-KLH conjugate with Freund’s 
complete adjuvant. At day 28, the mice were boosted with 45 µg of peptide-KLH conjugate 
with Freund’s incomplete adjuvant. This was repeated at day 56. At day 68, the mice were bled 
and serum antibody titres against peptide-BSA conjugate assessed using ELISA and western 
blot. The mice were boosted with 15 µg of peptide-KLH conjugate for a pre-fusion boost at 
day 84. At day 88 the spleens were harvested for hybridoma generation, which was performed 
by the WEHI monoclonal antibody facility using established protocols [172, 207, 208] 
 
8.5.4 - SPR 
Surface plasmon resonance experiments were performed on a Biacore 4000 using a CM5 
sensor chip (GE-Healthcare). Peptide was immobilised onto the CMC surface using EDC 
coupling. Antibodies were flown over the surface at the concentrations described in Chapter 5. 




8.5.5 - Papain digestion of IgG to generate Fab domains 
Fab fragments were generated through papain digestion of the 5G12 monoclonal antibody. 
Papain (Sigma) was prepared at 4 mg/mL in 100 mM potassium phosphate buffer, pH 6.1 and 
was activated by the addition of 2.5 mM EDTA, and 5 mM DTT. The activated papain was 
diluted to 0.05 mg/mL with 100 mM KPi buffer, pH 6.1, to ablate the effect of the reducing 
agent on the monoclonal antibody. Monoclonal antibody was prepared at 2 mg/mL in 100 mM 
potassium phosphate buffer, pH 6.1, and the enzymatic digestion was initiated by mixing equal 
parts monoclonal antibody with activated papain. The enzymatic digestion was carried out for 
60 min at 37 °C. The reaction was halted by the addition of 1/10th the volume of 3 M Tris-HCl, 
pH 8.5, and freshly prepared iodoacetamide to 30 mM. To remove Fc domains and undigested 
monoclonal antibody, the digest was passed through a column of protein G immobilised on 
agarose (ThermoFisher). The flow-through and wash fractions were collected and analysed by 
SDS-PAGE. The protein G flow-through contained near-pure Fab. This was further purified by 
SEC (Superdex 200 HiLoad 16/600, GE Healthcare – see 8.1.10) pre-equilibrated in 25 mM 
Tris-HCl, 150 mM NaCl, pH 7.4. The Fab eluted as a single peak and its purity was assessed 
by SDS-PAGE before pooling relevant fractions. A 10kDa NMWL centricon filter (Millipore) 
was used to concentrate the purified Fab to 15 mg/mL as determined by A280. 
 
8.5.6 - Crystallization of the Fab–peptide complex and structure determination 
The Fab–peptide crystal was grown over 42 days in sitting drops at 20 °C by mixing 150 nL 
well solution containing 10% (v/v) 2-propanol, 20% (w/v) polyethylene glycol 4000, 0.1 M 
sodium HEPES, pH 7.5, with 150 nL Fab–peptide solution at a 1:1.2 molar ratio at 10 mg/mL. 
The crystal was flash frozen in mother liquor using liquid nitrogen, and data was collected at 
the Australian Synchrotron (MX2 beamline) and processed using XDS [209]. The structure 
was solved by molecular replacement using PHASER [210] using a search model created by 
removing the variable loops from a IGG2 FAB (PDB ID: 5MYK) [211]. The final model was 
built in Coot [212] and refined with Phenix [213] to a resolution of 2.00 Å. Data collection and 
refinement statistics are summarized in Table 6.1. The Rwork and Rfree after the final refinement 
was 0.2507 and 0.2651 respectively. The coordinates have not yet been deposited in the Protein 





8.6 - Materials  
 
Figure 8. 5: List of antibodies  
Reagent Source Identifier 
Monoclonal ANTI-FLAG® M2 antibody Sigma F1804 
Lipopolysaccharide (LPS) Monoclonal 
Antibody 
Biomatik CAU29364 
Goat anti-Mouse IgG (H+L) Secondary 
Antibody, HRP 
ThermoFisher 62-6520 
Anti-GAPDH antibody  Sigma G9545 
Goat Anti-Rabbit IgG H&L (HRP)  Abcam ab6721 
 
Figure 8. 6: List of enzymes  
Reagent Source Identifier 
Quick Ligase New England Biolabs (NEB) M2200S 
NotI-HF New England Biolabs (NEB) R3189S 
BamHI-HF New England Biolabs (NEB) R3136S 
EcoRI-HF New England Biolabs (NEB) R3101S 
XhoI New England Biolabs (NEB) R0146S 
SalI-HF New England Biolabs (NEB) R3138S 
AvRII-HF New England Biolabs (NEB) R0174S 
Trypsin Gold, Mass Spectrometry Grade Promega V5280 
Lyticase Sigma L2524 
Clostripain (Endoproteinase-Arg-C) Worthington LS001643 
Recombinant shrimp alkaline phosphatase 
(rSAP) 
New England Biolabs (NEB) M0371S 
 
Figure 8. 7: List of reagents 
Reagent Source Identifier 
Phorbol 12-myristate 13-acetate (PMA) Sigma P1585 
FuGENE® HD Transfection Reagent Promega E2311 
Polybrene  Sigma  107689  
Propidium iodide  Sigma  81845  
Bovine Serum Albumin Sigma A2058 
OPD (o-phenylenediamine dihydrochloride) ThermoFisher 34005 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail Roche 11836170001 
Immobilon Western Chemiluminescent HRP Substrate Merck WBKLS0500 
Sep-Pak C18 Plus Short Cartridge Waters WAT020515 
Nitrocellulose Membrane, 0.45 µm ThermoFisher 88018 
Dulbecco's phosphate-buffered saline (DPBS) ThermoFisher 14190250 
GeneRuler 1 kb Plus DNA Ladder ThermoFisher SM1331 
Yeast Extract Sigma  92144 
Peptone from casein (Tryptone) Merck  107213 
Yeast Nitrogen Base Without Amino Acids Sigma Y0626 
SYPRO™ Orange Protein Gel Stain ThermoFisher S6650 
Ribonucleic acid from torula yeast Sigma R6625 
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Sodium meta-periodate  ThermoFisher 20504 
Amino-oxy-biotin  Biotium 90113 
Streptavidin−Agarose Sigma S1638 
Dolichol-Phosphate Avanti Custom  
Guanosine 5′-diphospho-D-mannose sodium salt Sigma G5131 
Tritiated GDP-Mannose ARC ART 0440 
Emulsifier-Safe PerkinElmer 6013389 
WAKW, WSEW, WSEA, WSEF, wSEW, WSEw, wSEw, 
WGGW synthetic peptides 
 Mimotopes Custom 
 
 
Figure 8. 8: Composition of media 
Media Composition 
RPMI (Thermofisher, A1049101) 
1x Penicillin-Streptomycin solution  
Dulbecco’s Modified Eagle’s (DME) 
medium  
DMEM powder (Gibco/Thermo, Cat#31600083) 40 mM 
NaHCO3 1x Penicillin-Streptomycin solution (Sigma, 
Cat#P0781)  
FACs buffer (KDS-BSS, 2-3% FBS)  
 
150 mM NaCl 
3.7 mM KCl 
2.5 mM CaCl2 
1.2 mM MgSO4  
1.2 mM KH2PO4  
0.8 mM K2HPO4  
7.4 mM HEPES NaOH  
Phosphate buffered saline (PBS) pH 
7.3  
20 mM Na2HPO4  
4.5 mM NaH2PO4  
150 mM NaCl  
10X YNB (13.4% yeast nitrogen base 
with ammonium sulfate without amino  
acids)  
 
134 g of yeast nitrogen base (YNB) 
Make to 1L with MilliQ water and filter. 
500X B (0.02% Biotin)  20 mg biotin in 100 mL of water and filter sterilize.  
 
10X D (20% Dextrose)  
 
200 g of D-glucose in 1,000 mL of water 
 
10X M (5% methanol) 
 
5 mL of methanol in 95 mL of water 
10X GY (10% glycerol)  
 
100 mL of glycerol in 900 mL of water 
Yeast Extract Peptone Dextrose 
Medium (YPD) 
 
1% yeast extract  
2% peptone  
2% dextrose (glucose)  
YPD-zeocin plates  1% yeast extract  
2% peptone  
2% dextrose (glucose)  
2% agar 
100ug/ml zeocin 
Minimal Dextrose plates (MD) 
 
1.34% YNB  
4 × 10-5 % biotin  




Minimal Methanol plates (MM) 
 
1.34% YNB  
4 × 10-5 % biotin  
0.5% methanol  
2% agar 
Buffered Glycerol-complex Medium 
(BMGY) 
 
1% yeast extract  
2% peptone  
100 mM potassium phosphate, pH 6.0  
1.34% YNB  
4 × 10-5 % biotin  
1% glycerol 
Buffered Methanol-complex Medium 
(BMMY) 
 
1% yeast extract  
2% peptone  
100 mM potassium phosphate, pH 6.0  
1.34% YNB  
4 × 10-5 % biotin  




Figure 8. 9: List of buffer compositions 
Buffer Composition 
1% Triton X-100 lysis buffer  Triton X-100  
20 mM Tris-HCl, pH 7.5 
150 mM NaCl  
2 mM EDTA  
1 Protease Inhibitor Cocktail tablet (Roche)  
RIPA lysis buffer  
 
25 mM Tris-HCl, pH 7.5 
150 mM NaCl 
2 mM EDTA 
1% v/v Triton X-100 
1% w/v sodium dodecyl sulfate 0.1% w/v SDS  
1 Protease Inhibitor Cocktail tablet (Roche) 
4x Sample reducing buffer  
 
250 mM Tris–HCl, pH 6.8 
40% glycerol 
8% SDS 
0.2% bromophenol blue 
200 mM DTT 
4x Sample non-reducing buffer  
 
250 mM Tris–HCl, pH 6.8 
40% glycerol 
8% SDS 
0.2% bromophenol blue 
Tris-buffered saline (TBS)  
 
20 mM Tris-HCl  
150 mM NaCl  
pH 7.5  
IMAC dialysis buffer 50 mM Tris-HCl  
150 mM NaCl  
pH 7.5  
IMAC wash buffer 50 mM Tris-HCl  
150 mM NaCl  
5 mM Imidazole 
pH 7.5  
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IMAC elution buffer 50 mM Tris-HCl  
150 mM NaCl 
500 mM Imidazole  
pH 7.5  
MonoQ binding buffer 50 mM Tris-HCl  
pH 7.5 
MonoQ elution buffer 50 mM Tris-HCl  
500 mM NaCl 
pH 7.5 
Yeast cracking buffer 30 mM Tris-HC1, pH 7.5 
50 mM KC1 
5 mM MgC12 
1 M sorbitol 
10 mM DTT 
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